| Apparent efficacy of food-based calcium supplementation in preventing rickets in Bangladesh 2008 · 250 mg Ca · Children aged 1–5 years without rickets and in the upper decile of plasma alkaline phosphatase activity in a rickets-endemic area of Bangladesh | 250 mg | 390 days | — |
| Calcium supplementation during pregnancy for reducing pregnancy induced hypertension 1995 · 120 mg calcium group · Healthy primipara pregnant women | 120 mg | — | — |
| Calcium supplementation during pregnancy for reducing pregnancy induced hypertension 1995 · 240 mg calcium group · Healthy primipara pregnant women | 240 mg | — | — |
| Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial 2019 · Calcium group · Parous women intending to become pregnant, with a previous pregnancy complicated by pre-eclampsia or eclampsia | 500 mg | — | 678 |
| Effect of the Dietary Approaches to Stop Hypertension (DASH) diet on the development of preeclampsia and metabolic outcomes in pregnant women with pre-existing diabetes mellitus: a randomised, controlled, single-blind trial 2023 · Standard diet group (SDG) · Pregnant women aged 18 years or older with pre-existing type 1 or type 2 diabetes mellitus | 500 mg | 127 days | 47 |
| Effect of the Dietary Approaches to Stop Hypertension (DASH) diet on the development of preeclampsia and metabolic outcomes in pregnant women with pre-existing diabetes mellitus: a randomised, controlled, single-blind trial 2023 · Adapted DASH diet group (DDG) · Pregnant women aged 18 years or older with pre-existing type 1 or type 2 diabetes mellitus | 500 mg | 125 days | 40 |
| The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial 2022 · Control group · Adults aged 20–80 undergoing elective lumbar spinal fusion for spinal stenosis or degenerative spondylolisthesis | 600 mg | 90 days | 13 |
| Apparent efficacy of food-based calcium supplementation in preventing rickets in Bangladesh 2008 · 50 mg Ca · Children aged 1–5 years without rickets and in the upper decile of plasma alkaline phosphatase activity in a rickets-endemic area of Bangladesh | 50 mg | 390 days | — |
| Apparent efficacy of food-based calcium supplementation in preventing rickets in Bangladesh 2008 · 500 mg Ca · Children aged 1–5 years without rickets and in the upper decile of plasma alkaline phosphatase activity in a rickets-endemic area of Bangladesh | 500 mg | 390 days | — |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Control group with prevalent vertebral fractures · Men with primary or secondary osteoporosis and prevalent vertebral fractures | 500 mg | 2 years | — |
| Does increased sunlight exposure work as a strategy to improve vitamin D status in the elderly: a cluster randomised controlled trial 2012 · UV+ (increased sunlight exposure with calcium supplementation) · Frail aged-care residents aged 70 years or older | 600 mg | 1 year | — |
| Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy 2024 · Tanzania trial, 500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation | 500 mg | — | — |
| [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes] 1993 · 50 IU Salcatonin plus calcium · Women aged 68–72 with moderate osteoporosis and low distal-forearm bone mineral content | 500 mg | 2 years | — |
| [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes] 1993 · 100 IU Salcatonin plus calcium · Women aged 68–72 with moderate osteoporosis and low distal-forearm bone mineral content | 500 mg | 2 years | — |
| [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes] 1993 · 200 IU Salcatonin plus calcium · Women aged 68–72 with moderate osteoporosis and low distal-forearm bone mineral content | 500 mg | 2 years | — |
| [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes] 1993 · Placebo Salcatonin plus calcium · Women aged 68–72 with moderate osteoporosis and low distal-forearm bone mineral content | 500 mg | 2 years | — |
| The effect of prepubertal calcium carbonate supplementation on the age of peak height velocity in Gambian adolescents 2012 · calcium group · Gambian boys and girls aged 8.3–11.99 years at enrollment, with low calcium intakes and poor childhood growth | 143 mg | 55 weeks | 80 |
| Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study 2014 · CFB group · Men and women aged 35 to 65 years with self-reported knee discomfort lasting more than 4 weeks | 220 mg | 2 weeks | 30 |
| Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial 2002 · Alendronate group · Women aged 55–81 with osteoporosis | 500 mg | 1569 days | 1,841 |
| Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial 2002 · Placebo group · Women aged 55–81 with osteoporosis | 500 mg | 1569 days | 1,817 |
| A predictive model for knee joint replacement in older women 2013 · calcium intervention group · Women aged over 70 years from the Western Australian general population | 1.2 g | 5 years | 747 |
| Calcium supplementation to prevent hypertensive disorders of pregnancy 1991 · calcium group · Nulliparous pregnant women in the 20th week of gestation | 2 g | — | 593 |
| Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial 2008 · calcium group · Adults aged 27–80 with a previously removed large-bowel adenoma; generally healthy men and women | 1.2 g | 4 years | 464 |
| Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial 2019 · calcium alone · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months | 1.2 g | 5 years | 419 |
| Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group 2000 · calcium group · Patients with a history of colorectal adenomas | 2 g | 3 years | 176 |
| Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers 1997 · calcium treatment group · Pregnant teenagers younger than 17.5 years, nulliparous, with first prenatal visit before 20 weeks' gestation | 2 g | — | 125 |
| Calcium supplementation and prevention of pregnancy induced hypertension 1996 · calcium group · healthy nulliparous pregnant women | 2 g | — | 103 |
| The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial 1998 · Calcium-only group · Postmenopausal women with osteoporosis and spine BMD T-score less than -2.5 | 1 g | 4 years | 100 |
| Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions 2011 · calcium carbonate arm · Adults with resected stage 0, I, or II colorectal cancer | 1.8 g | 5 years | 95 |
| The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial 2020 · Calcium with placebo · Overweight subfertile women with PCOS undergoing ovulation induction | 2.5 g | — | 93 |
| Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial 2003 · Cal-group · Elderly women aged 63–99 years in long-stay geriatric care | 1.2 g | 12 weeks | 60 |
| Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial 1995 · Placebo group · Postmenopausal patients with osteoporosis | 800 mg | 4 years | 56 |
| Correcting calcium nutritional deficiency prevents spine fractures in elderly women 1996 · Calcium, prevalent-fracture group · Women over age 60 with prevalent spine fractures and self-selected calcium intake below 1 g/day | 1.2 g | 1571 days | 53 |
| Calcium supplementation in pre-eclampsia 2001 · study group · Pregnant primigravidae with uncomplicated normotensive pregnancies, enrolled before 20 weeks' gestation | 2 g | — | 50 |
| Comparison of Limestone and Ground Fish for Treatment of Nutritional Rickets in Children in Nigeria 2015 · Ground fish group · Nigerian children with active calcium-deficiency rickets; median age 35 months (range 6–151 months) | 952 mg | 24 weeks | 44 |
| Comparison of Limestone and Ground Fish for Treatment of Nutritional Rickets in Children in Nigeria 2015 · Limestone group · Nigerian children with active calcium-deficiency rickets; median age 35 months (range 6–151 months) | 920 mg | 24 weeks | 44 |
| Prevention of preeclampsia by linoleic acid and calcium supplementation: a randomized controlled trial 1998 · experimental group · Primigravidas in the third trimester of pregnancy with risk factors for preeclampsia | 600 mg | — | 43 |
| Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? 2006 · Calcium alone · Institutionalized women aged 65–97 | 1.2 g | 90 days | 31 |
| Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients 1994 · Calcium · Angiotensin-sensitive nulliparous women with positive roll-over tests during pregnancy | 2 g | — | 29 |
| Supplementary calcium in prevention of pre-eclampsia 2001 · calcium group · Pregnant Iranian women at high risk of pre-eclampsia, between 28 and 32 weeks of pregnancy | 2 g | — | 15 |
| Calcium supplementation in nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth: an Australian randomized trial. FRACOG and the ACT Study Group 1999 · calcium · Nulliparous women with singleton pregnancies, starting before 24 weeks’ gestation | 1.8 g | — | — |
| Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate 1999 · Group C · Women with established postmenopausal osteoporosis; mean age 64.0 years | 1 g | 3 years | — |
| A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children 1999 · calcium group · Nigerian children with nutritional rickets; median age 46 months | 1 g | 24 weeks | — |
| Calcium supplements and colorectal adenomas. Polyp Prevention Study Group 1999 · calcium · Patients with a recent history of colorectal adenomas | 3 g | 4 years | — |
| Varying role of vitamin D deficiency in the etiology of rickets in young children vs. adolescents in northern India 2003 · Calcium alone · Children with rickets and adolescents with rickets/osteomalacia | 1 g | 90 days | — |
| Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture 2004 · group A (AAA Ca) · Elderly inpatients with osteoporosis | 900 mg | 540 days | — |
| Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture 2004 · group B (CaCO(3)) · Elderly inpatients with osteoporosis | 900 mg | 540 days | — |
| Effect of calcium supplementation on the risk of large bowel polyps 2004 · calcium treatment · Patients with a recent colorectal adenoma | 1.2 g | 4 years | — |
| Risk of prostate cancer in a randomized clinical trial of calcium supplementation 2005 · calcium-treated group · Men enrolled in a colorectal adenoma chemoprevention trial; age and other health details not stated | 1.2 g | 4 years | — |
| World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women 2006 · calcium group · Nulliparous, normotensive pregnant women recruited before gestational week 20 from populations with dietary calcium intake below 600 mg/day | 1.5 g | — | — |
| Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women 2006 · calcium group · Women older than 70 years, recruited from the population; mean age 75 years | 1.2 g | 5 years | — |
| Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial 2007 · calcium group · Adults with a previous colorectal adenoma | 1.2 g | 4 years | — |
| Treatment of postmenopausal osteoporosis with calcitriol or calcium 1992 · supplemental calcium · Postmenopausal women with osteoporosis and one or more vertebral compression fractures | 1 g | 3 years | — |
| Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial 2007 · Ca-only · Healthy postmenopausal women aged over 55 years | 1.4 g | 4 years | — |
| Blood pressure dynamics during pregnancy and spontaneous preterm birth 2007 · calcium supplement group · Normotensive nulliparous pregnant women with low dietary calcium intake (<600 mg/day), enrolled before 20 weeks of gestation | 1.5 g | — | — |
| Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women 2008 · control group · Community-dwelling women aged 70–90 with serum 25-hydroxyvitamin D below 24.0 ng/mL and a history of falling in the previous year | 1 g | 1 year | — |
| Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia 1991 · Gastric-coated calcium carbonate · 21 patients undergoing chronic haemodialysis with chronic renal failure | 3.1 g | — | — |
| Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia 1991 · Enteric-coated calcium carbonate · 21 patients undergoing chronic haemodialysis with chronic renal failure | 3.6 g | — | — |
| Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up 2011 · calcium supplementation group · Women aged 75.1 ± 2.7 years at baseline, recruited from the general population | 1.2 g | 5 years | — |
| Low-dose calcitriol versus calcium in established postmenopausal osteoporosis 1990 · calcium supplementation · Women under 80 with at least 3 years of postmenopausal osteoporosis | 1 g | 3 years | — |
| Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial 2013 · calcium-containing phosphate binder group (all patients received calcium carbonate) · Adults with incident hemodialysis | 2 g | 2 years | — |
| Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial 2017 · Calcium · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment | 1.2 g | 1376 days | — |
| Body mass index, calcium supplementation and risk of colorectal adenomas 2019 · CPPS calcium carbonate · People with a recently removed colorectal adenoma; sex and age range not specified | 1.2 g | 191 weeks | — |
| Body mass index, calcium supplementation and risk of colorectal adenomas 2019 · VCPPS calcium carbonate · People with a recently removed colorectal adenoma; sex and age range not specified | 1.2 g | 1303 days | — |
| Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial 2020 · Calcium carbonate · Men and women aged 45–75 recently diagnosed with a colorectal adenoma | 1.2 g | 5 years | — |
| Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial 2023 · Calcium · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants | 1.2 g | 5 years | — |
| Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy 2024 · India trial, 500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation | 500 mg | — | — |
| Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy 2024 · Tanzania trial, 1500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation | 1.5 g | — | — |
| Calcium supplementation during pregnancy for reducing pregnancy induced hypertension 1995 · 1 g calcium group · Healthy primipara pregnant women | 1 g | — | — |
| Calcium supplementation during pregnancy for reducing pregnancy induced hypertension 1995 · 2 g calcium group · Healthy primipara pregnant women | 2 g | — | — |
| Correcting calcium nutritional deficiency prevents spine fractures in elderly women 1996 · Calcium, no-prevalent-fracture group · Women over age 60 without prevalent fractures and self-selected calcium intake below 1 g/day | 1.2 g | 1571 days | — |
| Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group 1999 · calcium carbonate group · Adults with a recent history of colorectal adenomas; mean age 61 years, 72% men | 3 g | — | — |
| Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children 2012 · regular calcium content (RC) · Healthy children aged 1 to 6 years in low-socioeconomic communities of Jakarta, Indonesia | 440 mg | 26 weeks | 126 |
| Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years 2013 · regular calcium (RC) group · Healthy Indonesian children aged 1–6 years in low-socioeconomic urban communities of Jakarta | 440 mg | 26 weeks | 126 |
| Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years 2013 · low calcium (LC) · Healthy Indonesian children aged 1–6 years in low-socioeconomic urban communities of Jakarta | 50 mg | 26 weeks | 124 |
| Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial 2024 · calcium group · Chinese individuals with prediabetes; age and sex not specified | 500 mg | 24 weeks | 51 |
| An examination of the impact of unmelted, melted, and deconstructed cheese on lipid metabolism: a 6-week randomised trial 2024 · Equivalent components (deconstructed form) · Overweight adults aged 50 years or older | 500 mg | 6 weeks | 51 |
| Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial 2018 · Placebo group with calcium · Indonesian older women with handgrip strength ≤22 kg | 500 mg | 90 days | 48 |
| [Clinical study on primary osteoporosis treated with spreading moxibustion for warming yang and activating blood circulation] 2014 · calcium tablet group · People with primary osteoporosis; age and sex not reported | 600 mg | 12 weeks | 30 |
| [Clinical study on primary osteoporosis treated with spreading moxibustion for warming yang and activating blood circulation] 2014 · spreading moxibustion group (with calcium tablet treatment) · People with primary osteoporosis; age and sex not reported | 600 mg | 12 weeks | 30 |
| Effect of a dairy- and calcium-rich diet on weight loss and appetite during energy restriction in overweight and obese adults: a randomized trial 2013 · DAIRY/CA · Men and women aged 20–60 years with BMI 27–37 kg/m² and metabolic syndrome | 350 mg | 12 weeks | 26 |
| Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers 1994 · Rectal salmon calcitonin group · Postmenopausal women with established osteoporosis, due to forearm fracture or low bone mass | 500 mg | 1 year | 25 |
| Optimal Dose of Calcium for Treatment of Nutritional Rickets: A Randomized Controlled Trial 2016 · 500 mg group · Nigerian children with radiographically confirmed nutritional rickets; age and sex not stated | 500 mg | 24 weeks | 21 |
| Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers 1994 · Nasal salmon calcitonin group · Postmenopausal women with established osteoporosis, due to forearm fracture or low bone mass | 500 mg | 1 year | 17 |
| Effects of 3 diets with various calcium contents on 24-h energy expenditure, fat oxidation, and adipose tissue message RNA expression of lipid metabolism-related proteins 2005 · low calcium, low dairy (low/low) · Healthy, nonobese men; age 28 ± 2 years | 349 mg | 7 days | 12 |
| Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control 2002 · Lower dose gum · Subjects experiencing heartburn after a standardized provocative meal; age and sex not reported | 600 mg | 1 day | — |
| Effect of short-term high dietary calcium intake on 24-h energy expenditure, fat oxidation, and fecal fat excretion 2005 · LC/NP · Adults; sex and age not stated; no condition stated | 500 mg | 7 days | — |
| Effects of calcium and dairy on body composition and weight loss in African-American adults 2005 · Low-calcium/low-dairy diet, weight-maintenance trial · Obese African-American adults | 500 mg | 24 weeks | — |
| Effects of calcium and dairy on body composition and weight loss in African-American adults 2005 · Low-calcium/low-dairy diet, weight-loss trial · Obese African-American adults assigned to caloric restriction | 500 mg | 24 weeks | — |
| Calcium supplementation for 2 years improves bone mineral accretion and lean body mass in Chinese adolescents 2010 · 63 mg/d group · Healthy Chinese adolescents aged 12–15 years, male and female | 63 mg | 2 years | — |
| Calcium supplementation for 2 years improves bone mineral accretion and lean body mass in Chinese adolescents 2010 · 354 mg/d group · Healthy Chinese adolescents aged 12–15 years, male and female | 354 mg | 2 years | — |
| Comparison of the efficacy of calcium versus acetaminophen on reduction of orthodontic pain 2012 · Group 1 calcium · Female patients aged 14–19 with orthodontic treatment pain | 500 mg | 60 days | — |
| Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial 2024 · placebo group (calcium lactate co-supplementation) · pre-frail older adults | 500 mg | 12 weeks | — |
| Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen 2006 · once-weekly treatment group · Japanese patients with involutional osteoporosis | 200 mg | 48 weeks | 249 |
| Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen 2006 · once-daily treatment group · Japanese patients with involutional osteoporosis | 200 mg | 48 weeks | 247 |
| Physical activity modifies the effect of calcium supplements on bone loss in perimenopausal and postmenopausal women: subgroup analysis of a randomized controlled trial 2019 · 250 mg calcium group · Healthy women aged 50–75 years, perimenopausal or postmenopausal | 250 mg | 2 years | 150 |
| A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial 2002 · Etidronate group · Japanese patients with involutional osteoporosis | 200 mg | 48 weeks | 106 |
| A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial 2002 · Risedronate group · Japanese patients with involutional osteoporosis | 200 mg | 48 weeks | 101 |
| Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis 1994 · Placebo group with supplemental calcium · Postmenopausal Japanese women with osteoporosis; mean age 71.9 years | 300 mg | 1 year | 40 |
| Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation 1997 · placebo group · Patients with hemiplegia after stroke; mean duration of illness 4.8 years; age and sex not reported | 300 mg | 26 weeks | 34 |
| Premenopausal overweight women do not lose bone during moderate weight loss with adequate or higher calcium intake 2007 · WL NLCa group · Overweight, healthy premenopausal women aged 24–49 undergoing weight loss | 200 mg | 26 weeks | — |
| Premenopausal overweight women do not lose bone during moderate weight loss with adequate or higher calcium intake 2007 · WM NLCa group · Overweight, healthy premenopausal women aged 24–49 assigned to weight maintenance | 200 mg | 26 weeks | — |
| Effects of supplementation with multivitamin and mineral on blood pressure and C-reactive protein in obese Chinese women with increased cardiovascular disease risk 2009 · calcium · Obese Chinese women aged 18–55 years with increased cardiovascular disease risk, including hypertension, hyperglycemia or hyperlipemia | 162 mg | 26 weeks | — |
| Bone mineral density in postmenopausal Chinese women treated with calcium fortification in soymilk and cow's milk 2012 · milk with 250 mg calcium daily · Postmenopausal Chinese women aged 45–65 without osteoporosis | 250 mg | 548 days | — |
| Bone mineral density in postmenopausal Chinese women treated with calcium fortification in soymilk and cow's milk 2012 · soymilk with 250 mg calcium daily · Postmenopausal Chinese women aged 45–65 without osteoporosis | 250 mg | 548 days | — |
| Effect of low-dose calcium supplements on bone loss in perimenopausal and postmenopausal Asian women: a randomized controlled trial 2012 · 250 mg calcium group · Japanese women aged 50–75 years who were perimenopausal or postmenopausal | 250 mg | 2 years | — |
| Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements 2011 · CaD group · Postmenopausal women aged 50–79 years | 1 g | 7 years | 18,176 |
| Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study 2013 · Calcium plus vitamin D (CaD) group · Postmenopausal women aged 50–79 years | 1 g | 7 years | 18,176 |
| A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast 2021 · calcium plus vitamin D · Postmenopausal women aged 50–79 years at enrollment | 1 g | 2592 days | 18,176 |
| Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation 2017 · active treatment · older women; median age 63 years | 1 g | 7 years | 18,141 |
| Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative 2015 · intervention group · Postmenopausal women aged 50–79 years, free of heart failure at baseline, with and without pre-existing cardiovascular risk conditions | 1 g | 2577 days | 18,023 |
| Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study 2004 · Calcium and Vitamin D Program · Community-dwelling residents aged 66 years and older | 1 g | 3 years | 4,957 |
| Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial 2017 · vitamin D3 + calcium group · Healthy postmenopausal women aged 55 years or older | 1.5 g | 1461 days | 1,156 |
| Zoledronic acid and clinical fractures and mortality after hip fracture 2007 · zoledronic acid group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture | 1 g | 1826 days | 1,065 |
| Zoledronic acid and clinical fractures and mortality after hip fracture 2007 · placebo group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture | 1 g | 1826 days | 1,062 |
| Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study 2015 · supplement group — women · Women aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China | 324 mg | 6 years | 927 |
| Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study 2015 · supplement group — men · Men aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China | 324 mg | 6 years | 726 |
| Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial 2020 · intervention · Patients with confirmed benign paroxysmal positional vertigo (BPPV); supplementation was given when serum vitamin D was below 20 ng/mL | 1 g | 1 year | 518 |
| Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial 2019 · calcium and vitamin D · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months | 1.2 g | 5 years | 421 |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 200-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 1 g | 5 years | 287 |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · Placebo group · Postmenopausal women with established osteoporosis | 1 g | 5 years | 270 |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Risedronate group · Men with primary or secondary osteoporosis | 1 g | 2 years | 158 |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Placebo (Ca-D group) · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 2 years | 146 |
| The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial 1998 · MFP plus calcium group · Postmenopausal women with osteoporosis and spine BMD T-score less than -2.5 | 1 g | 4 years | 100 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women | 800 mg | 1 year | 99 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women | 800 mg | 1 year | 98 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · P-A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 72 years, predominantly women | 800 mg | 1 year | 98 |
| Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients 2021 · P-NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 70 years, predominantly women | 800 mg | 1 year | 97 |
| The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial 2020 · Vitamin D with calcium · Overweight subfertile women with PCOS undergoing ovulation induction | 2.5 g | — | 93 |
| Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery 2018 · Control group · Adults undergoing total or completion thyroidectomy with at least one well-perfused parathyroid gland identified by indocyanine green angiography; men and women; thyroid disease requiring surgery | 2 g | 15 days | 73 |
| Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial 2023 · Perioperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy | 4.5 g | 17 days | 68 |
| Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial 2023 · Postoperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy | 4.5 g | 2 weeks | 66 |
| Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial 2003 · Cal+D-group · Elderly women aged 63–99 years in long-stay geriatric care | 1.2 g | 12 weeks | 62 |
| Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study 2020 · experiment group · Men and women aged 80–93 years with osteopenia living independently | 600 mg | 548 days | 62 |
| Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study 2020 · control group · Men and women aged 80–93 years with osteopenia living independently | 600 mg | 548 days | 61 |
| Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial 1995 · Slow-release sodium fluoride group · Postmenopausal patients with osteoporosis | 800 mg | 4 years | 54 |
| Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial 1994 · slow-release sodium fluoride group · Women with postmenopausal osteoporosis | 800 mg | 913 days | 54 |
| Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection 2009 · Group A · Patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection; age and sex not specified | 3 g | — | 49 |
| Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy 2006 · oral calcium/vitamin D group · patients who underwent total thyroidectomy; age and sex not specified | 3 g | 2 weeks | 45 |
| Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial 2021 · Control group · Patients undergoing total thyroidectomy; age and sex not reported | 4.5 g | — | 44 |
| [Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia] 2014 · VD group · Men with idiopathic oligoasthenozoospermia | 600 mg | 90 days | 43 |
| Evaluation of efficacy of oral calcium phosphate as an adjunct to standard-of-care regular phototherapy in cases of neonatal jaundice: a hospital-based double-blind, randomised, placebo-controlled trial 2024 · intervention group · Neonates with neonatal jaundice requiring phototherapy, including term and preterm infants | 75 mg/kg | — | 40 |
| Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial 2021 · Intervention group · Patients undergoing total thyroidectomy; age and sex not reported | 4.5 g | — | 38 |
| Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? 2006 · Vitamin D plus calcium · Institutionalized women aged 65–97 | 1.2 g | 90 days | 33 |
| Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis 2012 · Cholecalciferol group · Postmenopausal women with osteoporosis | 1 g | 7 days | 30 |
| Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis 2012 · Placebo group with shared supplementation · Postmenopausal women with osteoporosis | 1 g | 7 days | 30 |
| Calcium plus vitamin D supplementation affects pregnancy outcomes in gestational diabetes: randomized, double-blind, placebo-controlled trial 2016 · Ca+vitamin D group · Pregnant women with gestational diabetes mellitus (GDM) in Arak, Iran | 1 g | 6 weeks | 30 |
| Calcium plus linoleic acid therapy for pregnancy-induced hypertension 2005 · calcium-CLA study group · Pregnant healthy primigravidas younger than 19 years or older than 35 years, with a family history of pre-eclampsia and diastolic notch; at high risk of pregnancy-induced hypertension | 600 mg | — | 24 |
| Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial 2014 · treatment group · Pregnant women with chronic hypertension and abnormal uterine artery Doppler findings, enrolled at 20–27 weeks of gestation | 2 g | — | 23 |
| The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial 2022 · Experimental group · Adults aged 20–80 undergoing elective lumbar spinal fusion for spinal stenosis or degenerative spondylolisthesis | 600 mg | 90 days | 21 |
| Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate 1999 · Group A · Women with established postmenopausal osteoporosis; mean age 64.0 years | 1 g | 3 years | — |
| Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate 1999 · Group B · Women with established postmenopausal osteoporosis; mean age 64.0 years | 1 g | 3 years | — |
| A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children 1999 · combination-therapy group · Nigerian children with nutritional rickets; median age 46 months | 1 g | 24 weeks | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · risedronate 2.5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 1 g | 2 years | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · risedronate 5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 1 g | 3 years | — |
| Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 · placebo group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis | 1 g | 3 years | — |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 100-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 1 g | 5 years | — |
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group 2000 · 400-IU salmon calcitonin group · Postmenopausal women with established osteoporosis | 1 g | 5 years | — |
| Varying role of vitamin D deficiency in the etiology of rickets in young children vs. adolescents in northern India 2003 · Calcium with vitamin D · Children with rickets and adolescents with rickets/osteomalacia | 1 g | 23 weeks | — |
| The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial 2005 · risedronate group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency | 1.2 g | 548 days | — |
| The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial 2005 · control group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency | 1.2 g | 548 days | — |
| Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial 2005 · Vitamin D supplementation group · Older residents of residential care, mean age 83.4 years, with serum 25-hydroxyvitamin D levels of 25–90 nmol/L | 600 mg | 2 years | — |
| Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial 2006 · cholecalciferol-calcium · Ambulatory, community-dwelling men and women aged 65 years or older | 500 mg | 3 years | — |
| Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial 2007 · PTH group · Postmenopausal women with osteoporosis and low bone mineral density at the hip or lumbar spine | 700 mg | 548 days | — |
| Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial 2007 · Ca + D · Healthy postmenopausal women aged over 55 years | 1.4 g | 4 years | — |
| Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial 2008 · calcium plus vitamin-D supplementation · Women in the Women's Health Initiative; age and specific health conditions are not stated in the abstract | 1 g | — | — |
| Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women 2008 · ergocalciferol group · Community-dwelling women aged 70–90 with serum 25-hydroxyvitamin D below 24.0 ng/mL and a history of falling in the previous year | 1 g | 1 year | — |
| Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women 2008 · vitamin D3 plus calcium · Community-dwelling, healthy ambulatory men and women aged 65 years or older | 500 mg | 3 years | — |
| Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits 2008 · calcium and vitamin D group · female Navy recruits undergoing basic training | 2 g | 8 weeks | — |
| Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals 2009 · calcium plus vitamin D · Community-dwelling women and men, mean age 77 years, with serum 25-hydroxyvitamin D below 78 nmol/l | 1 g | 1 year | — |
| Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study 2009 · Control group without previous vertebral fractures · Men with primary or secondary osteoporosis without previous vertebral fractures | 1.2 g | 2 years | — |
| Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial 2009 · CaD supplementation · Postmenopausal women aged 51–82 years | 1 g | 2557 days | — |
| Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial 2011 · CaD (calcium plus vitamin D) · Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative calcium/vitamin D trial | 1 g | 7 years | — |
| Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set 2011 · Calcium and vitamin D (CaD) · Community-dwelling postmenopausal women | 1 g | 2557 days | — |
| Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy 2014 · Active CaD + active hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis | 1 g | 2628 days | — |
| Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy 2014 · Active CaD + placebo hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis | 1 g | 2628 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 1000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 200 mg | 90 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 2000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 200 mg | 90 days | — |
| Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D 2014 · 4000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ | 200 mg | 90 days | — |
| Reducing iron deficiency anemia in Bolivian school children: calcium and iron combined versus iron supplementation alone 2014 · Ca + Fe group · Children aged 6 to 10 years in Bolivia | 700 mg | 90 days | — |
| The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial 2015 · calcium and vitamin D group · Postmenopausal women aged 50–79 years | 1 g | 7 years | — |
| Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials 2017 · Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause | 1 g | — | — |
| Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials 2017 · HT + Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause | 1 g | — | — |
| Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial 2017 · Vitamin D3 plus calcium · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment | 1.2 g | 1376 days | — |
| The influence of genetic susceptibility and calcium plus vitamin D supplementation on fracture risk 2017 · calcium plus vitamin D group · White postmenopausal women | 1 g | 339 weeks | — |
| Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease 2019 · CaD-supplement group · Postmenopausal women in the Women's Health Initiative who entered the calcium and vitamin D trial after one year in a menopausal hormone therapy trial | 1 g | 2264 days | — |
| Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial 2020 · Vitamin D3 plus calcium carbonate · Men and women aged 45–75 recently diagnosed with a colorectal adenoma | 1.2 g | 5 years | — |
| Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial 2023 · Vitamin D3 and calcium · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants | 1.2 g | 5 years | — |
| Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy 2024 · India trial, 1500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation | 1.5 g | — | — |
| Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial 2024 · CaD · Postmenopausal women with no history of breast or colorectal cancer | 1 g | 7 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Sodium fluoride · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 2 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Monofluorophosphate, 200 mg/day · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 2 years | — |
| Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy 1998 · Monofluorophosphate, 150 mg/day · Postmenopausal women with osteoporosis and vertebral fractures | 1 g | 2 years | — |
| Lactose maldigestion is not an impediment to the intake of 1500 mg calcium daily as dairy products 1998 · Conventional dairy products · Women, including 31 with lactose maldigestion and 31 without | 1.3 g | 7 days | 62 |
| Lactose maldigestion is not an impediment to the intake of 1500 mg calcium daily as dairy products 1998 · Lactose-hydrolyzed dairy products · Women, including 31 with lactose maldigestion and 31 without | 1.3 g | 7 days | 62 |
| [Sevelamer vs. Calcium Acetate for Treating Hyperphosphatemia in Maintenance Hemodialysis Patients] 2025 · CA组 (calcium acetate group) · Adults with end-stage renal disease receiving maintenance hemodialysis and hyperphosphatemia; age 52.86 ± 8.45 years, 24 men and 22 women | 2 g | 90 days | 46 |
| Comparison of the effects of calcium carbonate and ossein-hydroxyapatite complex on back and knee pain and quality of life in osteopenic perimenopausal women 2015 · calcium carbonate (CC) · Perimenopausal women with osteopenia; age range and sex beyond women not specified | 1.2 g | 26 weeks | 38 |
| Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial 2017 · calcium carbonate + calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated | 500 mg | 12 weeks | 37 |
| Dairy-rich diets augment fat loss on an energy-restricted diet: a multicenter trial 2009 · calcium-supplemented diet (high calcium) · Overweight and mildly obese adults aged 18–35 years with a low-calcium diet at enrollment; predominantly female | 900 mg | 12 weeks | 36 |
| Comparison of the effects of calcium carbonate and ossein-hydroxyapatite complex on back and knee pain and quality of life in osteopenic perimenopausal women 2015 · ossein-hydroxyapatite complex (OHC) · Perimenopausal women with osteopenia; age range and sex beyond women not specified | 1.66 g | 26 weeks | 36 |
| A randomized controlled trial of high dose vitamin D3 in patients with heart failure 2013 · Placebo group · Adults aged 50 years or older with heart failure (NYHA class II–IV) and serum 25OHD ≤37.5 ng/ml | 800 mg | 26 weeks | 32 |
| [Comparison of the therapeutic effect on skeletal fluorosis and impact on urine fluoride value among fire needle therapy, electroacupuncture and calcium carbonate D3] 2014 · calcium carbonate D3 group · Patients with skeletal fluorosis; age and sex not specified | 1.2 g | 60 days | 31 |
| Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial 2014 · Ca group · Children older than 1 year with active calcium-deficiency rickets | 1.88 g | 24 weeks | 28 |
| Changes in body composition following a dietary and lifestyle intervention trial: the postmenopausal health study 2009 · calcium supplemented group (CaG) · Healthy postmenopausal women | 1.2 g | 1 year | 26 |
| Optimal Dose of Calcium for Treatment of Nutritional Rickets: A Randomized Controlled Trial 2016 · 1000 mg group · Nigerian children with radiographically confirmed nutritional rickets; age and sex not stated | 1 g | 24 weeks | 23 |
| Optimal Dose of Calcium for Treatment of Nutritional Rickets: A Randomized Controlled Trial 2016 · 2000 mg group · Nigerian children with radiographically confirmed nutritional rickets; age and sex not stated | 2 g | 24 weeks | 21 |
| Calcium ingestion suppresses appetite and produces acute overcompensation of energy intake independent of protein in healthy adults 2015 · CAL · Healthy adults; 13 men and 7 women; no stated condition | 1.17 g | 1 day | 20 |
| Calcium ingestion suppresses appetite and produces acute overcompensation of energy intake independent of protein in healthy adults 2015 · PROCAL · Healthy adults; 13 men and 7 women; no stated condition | 1.17 g | 1 day | 20 |
| Dairy augmentation of total and central fat loss in obese subjects 2005 · yogurt · Obese subjects | 1.1 g | 12 weeks | 18 |
| Chronic lactate supplementation does not improve blood buffering capacity and repeated high-intensity exercise 2017 · calcium lactate (CL) · Athletes; age and sex not reported | 500 mg/kg | 5 days | 18 |
| Influence of dietary calcium supplements on ileoanal pouch function and cytokinetics 1992 · calcium · Patients after panproctocolectomy and ileoanal pouch reconstruction | 1.5 g | 60 days | 16 |
| Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study 2012 · Group C (calcium; PTH 5–10) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH 5–10 | 3 g | 22 days | 15 |
| Examination of Amorphous Calcium Carbonate on the Inflammatory and Muscle Damage Response in Experienced Resistance Trained Individuals 2022 · ACC group · Resistance-trained men aged 25.5 ± 4.4 years on average, with at least 1 year of resistance-training experience | 2 g | 3 weeks | 15 |
| Effect of increased calcium consumption from fat-free milk in an energy-restricted diet on the metabolic syndrome and cardiometabolic outcomes in adults with type 2 diabetes mellitus: a randomised cross-over clinical trial 2018 · high-Ca fat-free milk phase (MD) · Adults with type 2 diabetes mellitus and low habitual calcium consumption (<600 mg/day); mean age 49.5 years | 1.5 g | 12 weeks | 14 |
| Effect of increased calcium consumption from fat-free milk in an energy-restricted diet on the metabolic syndrome and cardiometabolic outcomes in adults with type 2 diabetes mellitus: a randomised cross-over clinical trial 2018 · low-Ca phase (CD) · Adults with type 2 diabetes mellitus and low habitual calcium consumption (<600 mg/day); mean age 49.5 years | 800 mg | 12 weeks | 14 |
| High calcium intake from fat-free milk, body composition and glycaemic control in adults with type 2 diabetes: a randomised crossover clinical trial 2019 · high-Ca fat-free milk (HC) · Adults aged 49.5 years on average with type 2 diabetes and low habitual calcium consumption | 700 mg | 12 weeks | 14 |
| High calcium intake from fat-free milk, body composition and glycaemic control in adults with type 2 diabetes: a randomised crossover clinical trial 2019 · low-Ca control (LC) · Adults aged 49.5 years on average with type 2 diabetes and low habitual calcium consumption | 6.4 mg | 12 weeks | 14 |
| Increased consumption of calcium from fat-free milk, energy-restricted diet and educational activities improves metabolic control in overweight type 2 diabetic patients 2020 · DAIR · Overweight adults with type 2 diabetes and low habitual calcium consumption | 700 mg | 90 days | 14 |
| The Effects of Amorphous Calcium Carbonate (ACC) Supplementation on Resistance Exercise Performance in Women 2023 · ACC group · Healthy women aged 18–45 with regular menstrual cycles, not using prescription medication or calcium/hormonal supplements | 1 g | 9 weeks | 14 |
| Milk supplementation facilitates appetite control in obese women during weight loss: a randomised, single-blind, placebo-controlled trial 2011 · milk supplementation · Low-calcium-consumer obese women participating in an energy-restricted weight-loss programme | 1 g | 26 weeks | 13 |
| Effects of 3 diets with various calcium contents on 24-h energy expenditure, fat oxidation, and adipose tissue message RNA expression of lipid metabolism-related proteins 2005 · high calcium, high dairy (high/high) · Healthy, nonobese men; age 28 ± 2 years | 1.26 g | 7 days | 12 |
| Effects of 3 diets with various calcium contents on 24-h energy expenditure, fat oxidation, and adipose tissue message RNA expression of lipid metabolism-related proteins 2005 · high calcium, low dairy (high/low) · Healthy, nonobese men; age 28 ± 2 years | 1.26 g | 7 days | 12 |
| A Multi-Mineral Intervention to Modulate Colonic Mucosal Protein Profile: Results from a 90-Day Trial in Human Subjects 2021 · calcium carbonate · Men and non-pregnant/non-lactating women aged 18–80 years in general good health but at increased risk for colorectal cancer | 800 mg | 90 days | 10 |
| Appetite sensations and substrate metabolism at rest, during exercise, and recovery: impact of a high-calcium meal 2013 · control trial · Active males; age and health condition not reported | 3 mg/kg | 1 day | 9 |
| Appetite sensations and substrate metabolism at rest, during exercise, and recovery: impact of a high-calcium meal 2013 · high milk-calcium (CAL) trial · Active males; age and health condition not reported | 9 mg/kg | 1 day | 9 |
| Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study 2012 · Group A (calcium; PTH <5) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH <5 | 3 g | 22 days | 5 |
| Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control 2002 · Chewable antacid tablets · Subjects experiencing heartburn after a standardized provocative meal; age and sex not reported | 1 g | 1 day | — |
| Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control 2002 · Higher dose gum · Subjects experiencing heartburn after a standardized provocative meal; age and sex not reported | 900 mg | 1 day | — |
| Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? 2002 · group B · Patients who underwent total thyroidectomy | 3 g | 26 weeks | — |
| Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults 2004 · high-calcium diet · Obese adults on a calorie-deficit diet | 800 mg | 24 weeks | — |
| Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche 2005 · Ca-suppl. · Prepubertal girls aged 7.9–8.9 years | 850 mg | 1 year | — |
| Effect of short-term high dietary calcium intake on 24-h energy expenditure, fat oxidation, and fecal fat excretion 2005 · HC/NP · Adults; sex and age not stated; no condition stated | 1.8 g | 7 days | — |
| Effect of short-term high dietary calcium intake on 24-h energy expenditure, fat oxidation, and fecal fat excretion 2005 · HC/HP · Adults; sex and age not stated; no condition stated | 1.8 g | 7 days | — |
| Effects of calcium and dairy on body composition and weight loss in African-American adults 2005 · High-dairy diet, weight-maintenance trial · Obese African-American adults | 1.2 g | 24 weeks | — |
| Effects of calcium and dairy on body composition and weight loss in African-American adults 2005 · High-dairy diet, weight-loss trial · Obese African-American adults assigned to caloric restriction | 1.2 g | 24 weeks | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · resistance training plus calcium alone · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 800 mg | 270 days | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · control (no resistance training) plus calcium alone · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 800 mg | 270 days | — |
| Effects of dietary calcium intervention on adolescent mothers and newborns: A randomized controlled trial 2006 · orange juice fortified with calcium · pregnant adolescent mothers | 1.2 g | — | — |
| Effects of dietary calcium intervention on adolescent mothers and newborns: A randomized controlled trial 2006 · dairy · pregnant adolescent mothers | 1.2 g | — | — |
| Fat mass gain is lower in calcium-supplemented than in unsupplemented preschool children with low dietary calcium intakes 2006 · calcium group · Children aged 3–5 years, without a disorder known to influence bone metabolism | 1 g | 50 weeks | — |
| Analgesic and chondroprotective effects of risedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine 2008 · Group RC · Patients with osteoarthritis of the knee | 900 mg | — | — |
| Analgesic and chondroprotective effects of risedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine 2008 · Group C · Patients with osteoarthritis of the knee | 900 mg | — | — |
| Effects of calcium supplement therapy in women with premenstrual syndrome 2009 · calcium treatment group · Young female college students with premenstrual syndrome; mean age 21.4 ± 3.6 years | 1 g | 90 days | — |
| Comparison of the effects of cows' milk, fortified soy milk, and calcium supplement on weight and fat loss in premenopausal overweight and obese women 2011 · calcium-supplemented diet · Healthy premenopausal overweight or obese women | 800 mg | 8 weeks | — |
| Calcium supplementation for 2 years improves bone mineral accretion and lean body mass in Chinese adolescents 2010 · 660 mg/d group · Healthy Chinese adolescents aged 12–15 years, male and female | 660 mg | 2 years | — |
| Calcium supplementation for 2 years improves bone mineral accretion and lean body mass in Chinese adolescents 2010 · 966 mg/d group · Healthy Chinese adolescents aged 12–15 years, male and female | 966 mg | 2 years | — |
| A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency 2010 · Placebo group (calcium citrate) · Women aged 70 to 90 with vitamin D insufficiency, living in the community | 1 g | 1 year | — |
| Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial 2011 · Calcium group · Adults at high risk of type 2 diabetes; mean age 57 years | 800 mg | 16 weeks | — |
| Skeletal muscle strength in young Asian Indian females after vitamin D and calcium supplementation: a double-blind randomized controlled clinical trial 2012 · calcium/placebo · young adult Asian Indian females with vitamin D deficiency; mean age 21.7 years | 1 g | 26 weeks | — |
| Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial 2013 · calcium · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL | 1.2 g | — | — |
| Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study 2014 · CVS Antacid Supreme · Adults with GERD symptoms and a history of LA A or B esophagitis and/or abnormal pH monitoring | 400 mg | 1 day | — |
| Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial 2015 · 1000 mg/d calcium plus vitamin D3 placebo · People with type 2 diabetes and vitamin D insufficiency | 1 g | 8 weeks | — |
| Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial 2017 · calcium-alone group · Women students with moderate or severe primary dysmenorrhea | 1 g | — | — |
| Long-term effects of maternal calcium supplementation on childhood growth differ between males and females in a population accustomed to a low calcium intake 2017 · calcium supplement group · Pregnant women in The Gambia receiving supplementation from 20 weeks of pregnancy until term | 1.5 g | — | — |
| Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females 1995 · CC group · Postmenopausal females with manifest osteoporosis | 1.4 g | 608 days | — |
| Effect of promethazine on lumbar vertebral bone mass in postmenopausal women 1993 · calcium · Healthy, ambulatory postmenopausal women with lumbar spine bone mineral content two standard deviations below young normal values; some were taking oral oestrogen | 1 g | 913 days | — |
| Effect of promethazine on lumbar vertebral bone mass in postmenopausal women 1993 · promethazine and calcium · Healthy, ambulatory postmenopausal women with lumbar spine bone mineral content two standard deviations below young normal values; some were taking oral oestrogen | 1 g | 913 days | — |
| Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients 1997 · oral calcium supplementation · Nondiabetic adults with essential hypertension | 1.5 g | 8 weeks | — |
| The effect of calcium supplementation on bone density during lactation and after weaning 1997 · calcium group, lactating women in the study of lactation · Postpartum lactating women enrolled a mean of 16 ± 2 days after delivery | 1 g | 26 weeks | — |
| The effect of calcium supplementation on bone density during lactation and after weaning 1997 · calcium group, nonlactating women in the study of lactation · Postpartum nonlactating women enrolled a mean of 16 ± 2 days after delivery | 1 g | 26 weeks | — |
| The effect of calcium supplementation on bone density during lactation and after weaning 1997 · calcium group, lactating women in the study of weaning · Lactating women who weaned their infants within two months after enrollment, enrolled a mean of 5.6 ± 0.8 months postpartum | 1 g | 26 weeks | — |
| The effect of calcium supplementation on bone density during lactation and after weaning 1997 · calcium group, nonlactating women in the study of weaning · Nonlactating women enrolled a mean of 5.6 ± 0.8 months postpartum | 1 g | 26 weeks | — |
| Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group 1998 · calcium-treated group · Premenopausal women aged 18–45 with moderate-to-severe, cyclically recurring premenstrual symptoms | 1.2 g | — | — |
| The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: A randomized placebo-controlled study 2021 · Calcium group · Non-pregnant women aged 18 or older with previous pre-eclampsia or eclampsia | 500 mg | 12 weeks | 678 |
| Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis 2004 · ibandronate 1 mg group · Postmenopausal women, postmenopausal for at least 1 year, with lumbar spine BMD T-score > -2.5 | 500 mg | 2 years | 166 |
| Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis 2004 · ibandronate 2.5 mg group · Postmenopausal women, postmenopausal for at least 1 year, with lumbar spine BMD T-score > -2.5 | 500 mg | 2 years | 163 |
| Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis 2004 · placebo group · Postmenopausal women, postmenopausal for at least 1 year, with lumbar spine BMD T-score > -2.5 | 500 mg | 2 years | 162 |
| Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis 2004 · ibandronate 0.5 mg group · Postmenopausal women, postmenopausal for at least 1 year, with lumbar spine BMD T-score > -2.5 | 500 mg | 2 years | 162 |
| Physical activity modifies the effect of calcium supplements on bone loss in perimenopausal and postmenopausal women: subgroup analysis of a randomized controlled trial 2019 · 500 mg calcium group · Healthy women aged 50–75 years, perimenopausal or postmenopausal | 500 mg | 2 years | 150 |
| No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year 2010 · PP group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese | 500 mg | 1 year | 142 |
| Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids 2001 · calcium alone · Corticosteroid-treated patients; age and sex not reported | 500 mg | 52 weeks | 114 |
| Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women 2006 · Alendronate plus HRT group · Women aged 47–70 years with postmenopausal osteoporosis | 500 mg | 3 years | 79 |
| Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study 1996 · Salmon calcitonin-treated group · Women aged 50–64 years with osteoporosis | 500 mg | 2 years | 78 |
| [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases] 2008 · Alen + calcium group · Patients with rheumatic diseases, normal bone mineral density, and oral glucocorticoid treatment | 600 mg | 24 weeks | 74 |
| Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women 2006 · HRT-only group · Women aged 47–70 years with postmenopausal osteoporosis | 500 mg | 3 years | 72 |
| [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases] 2008 · Control group · Patients with rheumatic diseases, normal bone mineral density, and oral glucocorticoid treatment | 600 mg | 24 weeks | 66 |
| Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium 2003 · alendronate plus calcium carbonate · Females and males commencing or already taking glucocorticoids | 600 mg | 2 years | 64 |
| Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation 2004 · placebo (PL) · renal transplant recipients; age and sex not specified | 500 mg | 1 year | 41 |
| Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists 1994 · placebo-treated subjects · Premenopausal women treated with gonadotropin hormone-releasing hormone agonists | 500 mg | 26 weeks | 39 |
| Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study 1995 · control group · Previously inactive, untrained premenopausal women aged 28–39 | 500 mg | 548 days | 34 |
| Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study 1996 · Calcium-only group · Women aged 50–64 years with osteoporosis | 500 mg | 2 years | 34 |
| Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study 2013 · Placebo · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding | 500 mg | 26 weeks | 33 |
| Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis 2003 · Alendronate-treated group (also received calcium) · Postmenopausal women with osteoporosis | 500 mg | 1 year | 32 |
| Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? 1996 · Ca alone · Women with active rheumatoid arthritis receiving low-dose glucocorticoid therapy | 500 mg | 1 year | 31 |
| Effects of Bisphosphonate on Osteocyte Proliferation and Bone Formation in Patients with Diabetic Osteoporosis 2022 · Control group · Adults aged 40–50 years, either sex, with type 2 diabetes and osteoporosis | 600 mg | 90 days | 30 |
| Effects of Bisphosphonate on Osteocyte Proliferation and Bone Formation in Patients with Diabetic Osteoporosis 2022 · Bisphosphonate group · Adults aged 40–50 years, either sex, with type 2 diabetes and osteoporosis | 600 mg | 90 days | 30 |
| Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women 2005 · alendronate 70 mg once weekly plus calcium carbonate 500 mg daily · Chinese postmenopausal women with osteoporosis | 500 mg | 1 year | 29 |
| Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women 2005 · calcium carbonate 500 mg daily · Chinese postmenopausal women with osteoporosis | 500 mg | 1 year | 29 |
| Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study 2006 · calcium-supplemented group (CaG) · Postmenopausal women aged 55–65 years | 600 mg | 1 year | 26 |
| Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy 1999 · Nasal salmon calcitonin treatment group · Postmenopausal women with severe, established osteoporosis (T score < -2.5 SD) and more than one vertebral fracture | 500 mg | 1 year | 24 |
| Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty 2003 · Group B · Adults who had undergone cementless total hip arthroplasty | 500 mg | 1 year | 23 |
| Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women 1998 · E group · Postmenopausal women with at least one non-traumatic vertebral fracture or z score < -1.5 | 500 mg | 1 year | 23 |
| Effects of alendronate on osteopenic postmenopausal Chinese women 2000 · Placebo plus calcium supplement · Postmenopausal Chinese women with osteopenia | 500 mg | 1 year | 22 |
| Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake 2005 · WL NL-Ca · Overweight postmenopausal women aged 50–75 undergoing weight loss | 400 mg | 180 days | 22 |
| Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study 1995 · exercise group · Previously inactive, untrained premenopausal women aged 28–39 | 500 mg | 548 days | 22 |
| Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study 1995 · group 1 · Postmenopausal women aged 43–59 with vertebral osteopenia and high bone turnover, 2–5 years after natural menopause | 500 mg | 2 years | 21 |
| Prevention of corticosteroid-induced osteoporosis by alfacalcidol 2000 · Group B (control) · Women aged 32–52 with recently diagnosed systemic lupus erythematodes, multiple sclerosis, rheumatoid arthritis, or asthma bronchiale, receiving glucocorticoid therapy | 500 mg | 3 years | 20 |
| Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake 2005 · WM NL-Ca · Overweight postmenopausal women aged 50–75 assigned to weight maintenance | 400 mg | 180 days | 18 |
| Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism 1994 · perimenopausal oligomenorrhoic women receiving calcium supplementation · Perimenopausal oligomenorrhoic women with initial ovarian failure | 500 mg | 2 years | 16 |
| Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women 1993 · sole calcium supplementation · Women after bilateral ovariectomy | 500 mg | 1 year | 16 |
| Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients 2002 · Calcium-only group · Patients with knee osteoarthrosis undergoing total knee arthroplasty | 500 mg | 1 year | 11 |
| The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women 1993 · group 1 · Healthy early postmenopausal women; mean age 53.9 years | 600 mg | 2 years | 11 |
| Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study 2001 · Alendronate + calcium · Patients undergoing uncemented primary total hip arthroplasty; age and sex not reported | 500 mg | 26 weeks | 8 |
| Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients 2002 · Alendronate and calcium group · Patients with knee osteoarthrosis undergoing total knee arthroplasty | 500 mg | 1 year | 8 |
| Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study 2001 · Calcium only · Patients undergoing uncemented primary total hip arthroplasty; age and sex not reported | 500 mg | 26 weeks | 5 |
| The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate 1999 · intermittent cyclical etidronate and calcium group · Patients commencing low to moderate doses of corticosteroids for the first time | 500 mg | 52 weeks | — |
| The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate 1999 · intermittent cyclical placebo with calcium group · Patients commencing low to moderate doses of corticosteroids for the first time | 500 mg | 52 weeks | — |
| Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group 2000 · alendronate group · hysterectomized postmenopausal women with low bone mass | 500 mg | 2 years | — |
| Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group 2000 · conjugated equine estrogen group · hysterectomized postmenopausal women with low bone mass | 500 mg | 2 years | — |
| Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group 2000 · alendronate plus CEE group · hysterectomized postmenopausal women with low bone mass | 500 mg | 2 years | — |
| Effect of calcitriol on bone loss after cardiac or lung transplantation 2000 · Placebo for 24 months with calcium · Patients undergoing cardiac or single lung transplantation; age and sex not specified | 600 mg | 2 years | — |
| The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study 2000 · Alendronate group · Postmenopausal southern Chinese women with osteoporosis | 500 mg | 1 year | — |
| The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study 2000 · Placebo group · Postmenopausal southern Chinese women with osteoporosis | 500 mg | 1 year | — |
| Resistance training over 2 years increases bone mass in calcium-replete postmenopausal women 2001 · strength (S) group · Postmenopausal women, mean age 60 ± 5 years | 600 mg | 2 years | — |
| Resistance training over 2 years increases bone mass in calcium-replete postmenopausal women 2001 · fitness (F) group · Postmenopausal women, mean age 60 ± 5 years | 600 mg | 2 years | — |
| Resistance training over 2 years increases bone mass in calcium-replete postmenopausal women 2001 · nonexercise control (C) group · Postmenopausal women, mean age 60 ± 5 years | 600 mg | 2 years | — |
| Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study 2001 · Alendronate group · Men with established primary osteoporosis | 500 mg | 2 years | — |
| Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study 2001 · Alfacalcidol group · Men with established primary osteoporosis | 500 mg | 2 years | — |
| [Effects of different levels of calcium intake on bone of pregnant women] 1999 · I group · Healthy pregnant women enrolled at 18 weeks of pregnancy | 550 mg | — | — |
| A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers 2002 · nasal placebo · men aged 27–74 years with idiopathic osteoporosis | 500 mg | 1 year | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.625 mg/d · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.625 mg and MPA, 2.5 mg · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.45 mg · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.45 mg and MPA, 2.5 mg · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.45 mg and MPA, 1.5 mg · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.3 mg · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · CEEs, 0.3 mg and MPA, 1.5 mg · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women 2002 · Placebo · Healthy postmenopausal women aged 40 to 65 years, within 4 years of their last menstrual period | 600 mg | 2 years | — |
| Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study 2004 · Alendronate (ALN) group · Men with established primary osteoporosis | 500 mg | 3 years | — |
| Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study 2004 · Alfacalcidol (AC) group · Men with established primary osteoporosis | 500 mg | 3 years | — |
| Preventing bone loss in renal transplant recipients with vitamin D 2003 · group 2 (control) · adult men who were recent renal transplant recipients | 500 mg | — | — |
| A prospective randomized study for prevention of postrenal transplantation bone loss 2005 · group II · adult male recent renal transplant recipients | 500 mg | 1 year | — |
| A prospective randomized study for prevention of postrenal transplantation bone loss 2005 · group III · adult male recent renal transplant recipients | 500 mg | 1 year | — |
| A prospective randomized study for prevention of postrenal transplantation bone loss 2005 · group IV (control group) · adult male recent renal transplant recipients | 500 mg | 1 year | — |
| Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density 1992 · Group A · Postmenopausal women with osteoporosis | 500 mg | 1 year | — |
| Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density 1992 · Group B · Postmenopausal women with osteoporosis | 500 mg | 1 year | — |
| Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density 1992 · Group C · Postmenopausal women with osteoporosis | 500 mg | 1 year | — |
| A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease 2006 · Risedronate group · Ambulatory patients with Crohn's disease or ulcerative colitis and low bone density; age and sex not specified | 600 mg | 1 year | — |
| A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease 2006 · Placebo group · Ambulatory patients with Crohn's disease or ulcerative colitis and low bone density; age and sex not specified | 600 mg | 1 year | — |
| Calcium supplement ingestion may alter lumbar spine bone mineral density measurement 2006 · Citracal tablet · Subjects; age, sex, and health condition not reported | 315 mg | 1 day | — |
| Calcium supplement ingestion may alter lumbar spine bone mineral density measurement 2006 · OsCal tablet · Subjects; age, sex, and health condition not reported | 500 mg | 1 day | — |
| Calcium supplement ingestion may alter lumbar spine bone mineral density measurement 2006 · People's Choice tablet · Subjects; age, sex, and health condition not reported | 600 mg | 1 day | — |
| Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women 1991 · Placebo group · Healthy, ambulatory postmenopausal women with usual vitamin D intakes of 100 IU/day | 377 mg | 1 year | — |
| Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men 2008 · calcium, 600 mg/d · Healthy men aged at least 40 years (mean age 57), without osteoporosis | 600 mg | 2 years | — |
| Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass 2011 · PLC/ALN group · Postmenopausal women aged 73.6 ± 4.7 years with osteoporosis or osteopenia | 500 mg | 3 years | — |
| Change of BMD after weaning or resumption of menstruation in Chinese women with different FokI VDR-genotypes: a randomized, placebo-controlled, calcium supplementation trial 2011 · calcium group · Chinese women with different FokI VDR genotypes after weaning or resumption of menstruation during lactation | 600 mg | 1 year | — |
| Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis 2012 · Group I (alendronate) · Postmenopausal women with osteoporosis and lumbar spine BMD more than 2.5 SD below the young adult reference range | 500 mg | 270 days | — |
| Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis 2012 · Group II (isosorbide mononitrate) · Postmenopausal women with osteoporosis and lumbar spine BMD more than 2.5 SD below the young adult reference range | 500 mg | 270 days | — |
| A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women 1990 · calcium carbonate · Healthy postmenopausal women with dietary calcium intake below 400 mg/day or 400–650 mg/day; menopausal duration varied | 500 mg | 2 years | — |
| A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women 1990 · calcium citrate malate · Healthy postmenopausal women with dietary calcium intake below 400 mg/day or 400–650 mg/day; menopausal duration varied | 500 mg | 2 years | — |
| Effect of low-dose calcium supplements on bone loss in perimenopausal and postmenopausal Asian women: a randomized controlled trial 2012 · 500 mg calcium group · Japanese women aged 50–75 years who were perimenopausal or postmenopausal | 500 mg | 2 years | — |
| The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial 2013 · calcium-supplemented group · Postmenopausal women aged 60 years or older without osteoporosis and with low dietary calcium intake | 500 mg | 2 years | — |
| The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study 2015 · calcium supplementation group · Non-pregnant women with a history of pre-eclampsia | 500 mg | 24 weeks | — |
| No difference in acute effects of supplemental v. dietary calcium on blood pressure and microvascular function in obese women challenged with a high-fat meal: a cross-over randomised study 2016 · high SC (HSCM) · Obese women aged 20–50 years | 500 mg | 1 day | — |
| Effect of soluble corn fibre and calcium supplementation on bone mineral content and bone mineral density in preadolescent Malaysian children-a double-blind randomised controlled trial (PREBONE-Kids Study) 2023 · 600-mg calcium lactate gluconate (Ca) · Healthy Malaysian children aged 9–11 years | 600 mg | 1 year | — |
| Effect of calcium supplementation on blood pressure in children 1995 · calcium intervention group · Fifth-grade children, mean age 11.0 years, with no stated health condition | 600 mg | 12 weeks | — |
| Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids 1994 · calcium supplementation · Postmenopausal women aged 45–65 years with rheumatoid arthritis | 400 mg | 2 years | — |
| Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study 1994 · 100 IU intranasal sCT group · healthy women within 6 months to 3 years after natural menopause | 500 mg | 2 years | — |
| Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study 1994 · 200 IU intranasal sCT group · healthy women within 6 months to 3 years after natural menopause | 500 mg | 2 years | — |
| Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study 1994 · 400 IU intranasal sCT group · healthy women within 6 months to 3 years after natural menopause | 500 mg | 2 years | — |
| A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium 1994 · calcium alone · Healthy postmenopausal women | 500 mg | 2 years | — |
| A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium 1994 · calcium plus nasal salmon calcitonin · Healthy postmenopausal women | 500 mg | 2 years | — |
| Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin 1994 · Calcium alone · Healthy women with 6–36 months of natural menopause | 500 mg | 3 years | — |
| Calcium supplementation and bone mineral density in adolescent girls 1993 · Calcium supplementation group · Adolescent white girls, mean age 11.9 years | 500 mg | 548 days | — |
| Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation 1993 · control population assigned to calcium intake · Healthy postmenopausal women | 500 mg | 2 years | — |
| Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis 1996 · salmon calcitonin group · Postmenopausal women, mean age 65, with osteoporosis who had experienced a Colles' fracture | 500 mg | 2 years | — |
| Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis 1996 · nasal placebo group · Postmenopausal women, mean age 65, with osteoporosis who had experienced a Colles' fracture | 500 mg | 2 years | — |
| The effect of calcium supplementation and Tanner stage on bone density, content and area in teenage women 1996 · calcium-supplemented group · Caucasian girls aged 11.9 ± 0.5 years at entry | 500 mg | 2 years | — |
| Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis 1996 · alendronate 5 mg/day · postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis 1996 · alendronate 10 mg/day · postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis 1996 · alendronate 20 mg/day for 2 years followed by 5 mg/day for 1 year (20/5 mg) · postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers 1997 · placebo · Women aged 60–85 with osteoporosis | 500 mg | 2 years | — |
| Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers 1997 · 1.0 mg alendronate · Women aged 60–85 with osteoporosis | 500 mg | 2 years | — |
| Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers 1997 · 2.5 mg alendronate · Women aged 60–85 with osteoporosis | 500 mg | 2 years | — |
| Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers 1997 · 5.0 mg alendronate · Women aged 60–85 with osteoporosis | 500 mg | 2 years | — |
| Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study 1997 · Cyclical etidronate plus calcium · Adults with Child-Pugh Class A primary biliary cirrhosis receiving corticosteroid treatment | 500 mg | 1 year | — |
| Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study 1997 · Calcium alone · Adults with Child-Pugh Class A primary biliary cirrhosis receiving corticosteroid treatment | 500 mg | 1 year | — |
| The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation 1997 · calcium supplementation (CS) · Early postmenopausal women; mean age 51 years | 500 mg | 1 year | — |
| Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy 1997 · Etidronate group followed by calcium supplementation · Caucasian women aged 45–60 years in early postmenopause who were not undergoing hormone replacement therapy | 500 mg | 2 years | — |
| Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy 1997 · Placebo group followed by calcium supplementation · Caucasian women aged 45–60 years in early postmenopause who were not undergoing hormone replacement therapy | 500 mg | 2 years | — |
| Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) 1997 · Etidronate followed by calcium · Women in the early postmenopausal period; mean age 53 ± 2.8 years and 2.3 ± 1.3 years post menopause | 500 mg | 2 years | — |
| Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) 1997 · Placebo followed by calcium · Women in the early postmenopausal period; mean age 53 ± 2.8 years and 2.3 ± 1.3 years post menopause | 500 mg | 2 years | — |
| Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis 1998 · Coconut oil placebo group · Women with senile osteoporosis, mean age 79.5, with a background diet low in calcium | 600 mg | 548 days | — |
| Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status 2006 · supplementation group · Pregnant women screened positive for low antioxidant status at 8 to 12 weeks of gestation | 800 mg | — | 29 |
| Apparent efficacy of food-based calcium supplementation in preventing rickets in Bangladesh 2008 · 500 mg Ca plus multivitamins, iron, and zinc · Children aged 1–5 years without rickets and in the upper decile of plasma alkaline phosphatase activity in a rickets-endemic area of Bangladesh | 500 mg | 390 days | — |
| Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants 1998 · active medication · Adults with colorectal polyps; age range and sex not stated | 1.6 g | 3 years | — |
| Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative 2011 · CaD group · Postmenopausal women aged 50–79 years | 1 g | 5 years | 1,179 |
| Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women 2017 · group C · Postmenopausal women at high risk of osteoporosis | 600 mg | 2 years | 139 |
| Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women 2017 · group D · Postmenopausal women at high risk of osteoporosis | 600 mg | 2 years | 131 |
| Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children 2012 · RC with Lactobacillus reuteri DSM17938 (reuteri) · Healthy children aged 1 to 6 years in low-socioeconomic communities of Jakarta, Indonesia | 440 mg | 26 weeks | 124 |
| Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years 2013 · reuteri · Healthy Indonesian children aged 1–6 years in low-socioeconomic urban communities of Jakarta | 440 mg | 26 weeks | 124 |
| Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children 2012 · RC with Lactobacillus casei CRL431 (casei) · Healthy children aged 1 to 6 years in low-socioeconomic communities of Jakarta, Indonesia | 440 mg | 26 weeks | 120 |
| Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years 2013 · casei · Healthy Indonesian children aged 1–6 years in low-socioeconomic urban communities of Jakarta | 440 mg | 26 weeks | 120 |
| An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial 2016 · Active · Adults aged 65 years or older who had undergone hip fracture surgery; men and women with a recent surgically repaired hip fracture | 500 mg | 26 weeks | 111 |
| Nutritional supplementation of elderly hip fracture patients. A randomized, double-blind, placebo-controlled trial 2000 · intervention group · Patients aged 70 and older hospitalized for hip fracture | 800 mg | 60 days | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q6M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 1 year | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q2M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 1 year | 85 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · denosumab 60 mg Q3M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 1 year | 82 |
| Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial 2017 · Placebo arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61 | 1.2 g | 24 weeks | 80 |
| Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial 2017 · Vitamin D3 arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61 | 1.2 g | 24 weeks | 80 |
| High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women 2013 · aquatic exercise group (AEG) · Postmenopausal women, mean age 58.8 years | 500 mg | 24 weeks | 64 |
| Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial 2024 · vitamin D + calcium group · Chinese individuals with prediabetes; age and sex not specified | 500 mg | 24 weeks | 53 |
| Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial 2018 · Alfacalcidol group · Indonesian older women with handgrip strength ≤22 kg | 500 mg | 90 days | 47 |
| High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women 2013 · control group (CG) · Postmenopausal women, mean age 58.8 years | 500 mg | 24 weeks | 44 |
| Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial 2014 · Ca+D group · Children older than 1 year with active calcium-deficiency rickets | 1.88 g | 24 weeks | 44 |
| A Nutritionally Complete Oral Nutritional Supplement Powder Improved Nutritional Outcomes in Free-Living Adults at Risk of Malnutrition: A Randomized Controlled Trial 2022 · nutrition supplement (intervention group) · Chinese men and women aged 18 years or older, all classified as at risk of malnutrition; mean age 66.5 years, range 41–89 | 400 mg | 12 weeks | 44 |
| Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV 2020 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy | 1 g | 1 year | 41 |
| Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV 2020 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy | 1 g | 1 year | 41 |
| Changes in body composition following a dietary and lifestyle intervention trial: the postmenopausal health study 2009 · dietary intervention group (DG) · Healthy postmenopausal women | 1.2 g | 1 year | 39 |
| Effect of micronutrient supplementation on the growth of preschool children in China 2002 · +ZnCa · Growth-retarded preschool children | 250 mg | 1 year | 37 |
| Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial 2014 · combined calcium and vitamin D treatment · Multi-ethnic men and women aged 18 years or older, vitamin D-deficient and at risk of type 2 diabetes; BMI 25–40 kg/m² | 1.2 g | 26 weeks | 35 |
| A randomized controlled trial of high dose vitamin D3 in patients with heart failure 2013 · Vitamin D3 group · Adults aged 50 years or older with heart failure (NYHA class II–IV) and serum 25OHD ≤37.5 ng/ml | 800 mg | 26 weeks | 32 |
| Calcium Plus Vitamin D Supplementation During the Third Trimester of Pregnancy in Adolescents Accustomed to Low Calcium Diets Does Not Affect Infant Bone Mass at Early Lactation in a Randomized Controlled Trial 2015 · calcium plus vitamin D supplementation · Brazilian adolescent mothers consuming low-calcium diets, from 26 weeks of gestation until parturition | 600 mg | — | 30 |
| Calcium plus vitamin D supplementation during pregnancy reduces postpartum fat mass in adolescents: A randomized trial 2023 · calcium plus vitamin D supplement · Brazilian pregnant adolescents aged 14–19 years with habitually low calcium intake | 600 mg | — | 30 |
| Effect of micronutrient supplementation on the growth of preschool children in China 2002 · +CaVA · Growth-retarded preschool children | 250 mg | 1 year | 29 |
| The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study 2021 · control group · Postmenopausal women aged 55–75 with osteoporosis and osteoarthritis undergoing total knee arthroplasty | 300 mg | 90 days | 29 |
| Effect of micronutrient supplementation on the growth of preschool children in China 2002 · +ZnCaVA · Growth-retarded preschool children | 250 mg | 1 year | 28 |
| The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study 2021 · monitoring group · Postmenopausal women aged 55–75 with osteoporosis and osteoarthritis undergoing total knee arthroplasty | 300 mg | 214 days | 28 |
| The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial 2022 · Vitamin D3 + calcium carbonate · Women with postpartum depression and a PPD score >12 | 500 mg | 8 weeks | 27 |
| Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial 2013 · calcium+D group · Generally healthy overweight or obese college students aged 18–25 years with daily calcium intake below 600 mg; predominantly female | 600 mg | 12 weeks | 26 |
| The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study 2009 · Group 1 · Infertile women with polycystic ovary syndrome (PCOS); age not stated | 1 g | 90 days | 20 |
| The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study 2009 · Group 2 · Infertile women with polycystic ovary syndrome (PCOS); age not stated | 1 g | 90 days | 20 |
| Effect of cholecalciferol and calcium supplementation on muscle strength and energy metabolism in vitamin D-deficient Asian Indians: a randomized, controlled trial 2010 · Cholecalciferol and calcium supplementation · Healthy adults with hypovitaminosis D; mean age 31.5 years; 24 men and 16 women across both groups | 1 g | 26 weeks | 20 |
| Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial 2019 · intervention group (fortified yogurt) · Females aged 65 years or older with hypovitaminosis D (serum 25OHD <75 nmol/L), living independently at home or in an autonomous residence | 800 mg | 90 days | 20 |
| The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women 2022 · 500 ml semi-skimmed milk with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening | 619 mg | 1 day | 20 |
| [Effects of auricular plaster therapy on quality of life in uremia patients after parathyroidectomy plus autograft] 2017 · Control group · Uremia patients with secondary hyperparathyroidism after parathyroidectomy plus autograft; age and sex not reported | 4.5 g | 8 weeks | 17 |
| [Effects of auricular plaster therapy on quality of life in uremia patients after parathyroidectomy plus autograft] 2017 · Observation group · Uremia patients with secondary hyperparathyroidism after parathyroidectomy plus autograft; age and sex not reported | 4.5 g | 8 weeks | 17 |
| Integrating Calcium Into Antenatal Iron-Folic Acid Supplementation in Ethiopia: Women's Experiences, Perceptions of Acceptability, and Strategies to Support Calcium Supplement Adherence 2020 · 3-event regimen · Healthy pregnant women aged 16 years or older, 12–28 weeks’ gestation, in rural Ethiopia | 1.5 g | 6 weeks | 17 |
| Integrating Calcium Into Antenatal Iron-Folic Acid Supplementation in Ethiopia: Women's Experiences, Perceptions of Acceptability, and Strategies to Support Calcium Supplement Adherence 2020 · 2-event regimen · Healthy pregnant women aged 16 years or older, 12–28 weeks’ gestation, in rural Ethiopia | 1 g | 6 weeks | 16 |
| Integrating Calcium Into Antenatal Iron-Folic Acid Supplementation in Ethiopia: Women's Experiences, Perceptions of Acceptability, and Strategies to Support Calcium Supplement Adherence 2020 · 4-event regimen · Healthy pregnant women aged 16 years or older, 12–28 weeks’ gestation, in rural Ethiopia | 1.5 g | 6 weeks | 15 |
| A Multi-Mineral Intervention to Modulate Colonic Mucosal Protein Profile: Results from a 90-Day Trial in Human Subjects 2021 · Aquamin® · Men and non-pregnant/non-lactating women aged 18–80 years in general good health but at increased risk for colorectal cancer | 800 mg | 90 days | 10 |
| Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study 2012 · Group B (calcium and calcitriol; PTH <5) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH <5 | 3 g | 15 days | 7 |
| Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? 2002 · group C · Patients who underwent total thyroidectomy | 3 g | 26 weeks | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · resistance training plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 800 mg | 270 days | — |
| Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects 2006 · control (no resistance training) plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects | 800 mg | 270 days | — |
| Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis 2007 · RE+ (reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture | 500 mg | 1 year | — |
| Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis 2007 · RE− (no reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture | 500 mg | 1 year | — |
| Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain 2007 · calcium plus cholecalciferol · Postmenopausal women aged 50 to 79 years | 1 g | 7 years | — |
| Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial 2009 · active treatment · Postmenopausal women aged 50–79 years | 1 g | — | — |
| Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control 2009 · calcium+D supplementation · Overweight or obese women, mean age 43 years, with daily calcium intake below 800 mg | 1.2 g | 15 weeks | — |
| Combination of alfacalcidol with calcium can improve quadriceps muscle strength in elderly ambulatory Thai women who have hypovitaminosis D: a randomized controlled trial 2009 · calcium combined with alfacalcidol · Postmenopausal ambulatory Thai women aged 65 years or more with hypovitaminosis D | 1,500 g | 12 weeks | — |
| A comparison between the efficacy of dydrogesterone and calcium plus vitamin D in improving women's general health 2010 · calcium plus vitamin D · Young women who were students at Shiraz University | 1 g | — | — |
| A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency 2010 · Vitamin D group · Women aged 70 to 90 with vitamin D insufficiency, living in the community | 1 g | 1 year | — |
| A pilot randomized controlled trial of oral calcium and vitamin D supplementation using fortified laddoos in underprivileged Indian toddlers 2011 · study group · Underprivileged toddlers, mean age 2.7 years; most were hypocalcaemic and vitamin D deficient | 405 mg | 1 year | — |
| Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial 2011 · Vitamin D and calcium group · Adults at high risk of type 2 diabetes; mean age 57 years | 800 mg | 16 weeks | — |
| Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults 2012 · Calcium and vitamin D-fortified regular orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated | 1.05 g | 16 weeks | — |
| Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults 2012 · Calcium and vitamin D-fortified lite orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated | 1.05 g | 16 weeks | — |
| School-based calcium-vitamin D with micronutrient supplementation enhances bone mass in underprivileged Indian premenarchal girls 2012 · Ca-group · Premenarchal girls aged 8–12 years from low-income groups in Pune, India | 500 mg | 1 year | — |
| Skeletal muscle strength in young Asian Indian females after vitamin D and calcium supplementation: a double-blind randomized controlled clinical trial 2012 · cholecalciferol/calcium · young adult Asian Indian females with vitamin D deficiency; mean age 21.7 years | 1 g | 26 weeks | — |
| Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial 2013 · vitamin D(3) plus calcium · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL | 1.2 g | — | — |
| Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls 2014 · Ca+D group (C2) · Underprivileged premenarchal girls aged 8–12 years | 500 mg | 1 year | — |
| Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial 2014 · control group · Pregnant women at 24–26 weeks of gestation with vitamin D deficiency or insufficiency | 200 mg | 8 weeks | — |
| Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study 2014 · Gaviscon Double Action Liquid · Adults with GERD symptoms and a history of LA A or B esophagitis and/or abnormal pH monitoring | 650 mg | 1 day | — |
| Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial 2015 · 50,000 IU/wk vitamin D3 plus 1000 mg/d calcium · People with type 2 diabetes and vitamin D insufficiency | 1 g | 8 weeks | — |
| A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods 2015 · VDCa group · Adult male and female volunteers aged 50 years or older | 1 g | 26 weeks | — |
| Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial 2017 · calcium-vitamin D group · Women students with moderate or severe primary dysmenorrhea | 1 g | — | — |
| Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial 2016 · CaD group · Postmenopausal women aged 50–79, generally healthy | 1 g | 8 years | — |
| High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women 2017 · high dose group · Postmenopausal women with low bone mineral density | 1 g | 1 year | — |
| High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women 2017 · standard dose group · Postmenopausal women with low bone mineral density | 1 g | 1 year | — |
| Maternal and Infant Lipid-Based Nutritional Supplementation Increases Height of Ghanaian Children at 4-6 Years Only if the Mother Was Not Overweight Before Conception 2019 · IFA group · Women aged 18 years or older enrolled at up to 20 weeks of pregnancy; their children received no supplement | 200 mg | — | — |
| Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial 2020 · Group 1—fortified milk and early therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis | 1 g | — | — |
| Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial 2020 · Group 3—fortified milk and late therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis | 1 g | — | — |
| Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients 2021 · calcium carbonate group · Alcohol-dependent patients undergoing inpatient alcohol-withdrawal treatment; age and sex not specified | 800 mg | 2 weeks | — |
| Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile 2021 · Fortified sachet and powdered milk plus periodontal treatment during pregnancy (early PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation | 1 g | — | — |
| Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile 2021 · Fortified sachet and powdered milk plus periodontal treatment after delivery (late PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation | 1 g | — | — |
| Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial 2021 · Ca-D-fortified yogurt drink (CDY) · Adults with type 2 diabetes | 500 mg | 12 weeks | — |
| Effects of vitamin D on sex steroids, luteinizing hormone, and testosterone to luteinizing hormone ratio in 307 infertile men 2024 · active group · infertile men | 500 mg | 150 days | — |
| Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial 2024 · Calcium supplement (group B) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes | 500 mg | 1 year | — |
| Alcohol use disorder and muscle weakness: Original study of the effect of vitamin D supplementation in ambulatory participants with alcohol use disorder 2024 · CAU (care as usual) · Community-dwelling adults with alcohol use disorder; ages and sex by arm not reported. The reported outcome subgroup had vitamin D concentrations below 50 nmol/L. | 500 mg | 1 year | — |
| Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial 2024 · cholecalciferol group · pre-frail older adults | 500 mg | 12 weeks | — |
| Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial 2025 · D12 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL | 400 mg | 12 weeks | — |
| Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial 2025 · D24 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL | 400 mg | 24 weeks | — |
| Phosphate concentration is exceptionally high in seminal fluid and is linked with semen quality but not influenced by vitamin D and calcium supplementation 2025 · vitamin D and calcium supplementation · infertile men; age range and sex beyond male not specified | 500 mg | 150 days | — |
| Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females 1995 · OHC group · Postmenopausal females with manifest osteoporosis | 1.4 g | 608 days | — |
| Long-term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial 1997 · Calcium group · Mothers assigned during pregnancy; age and pregnancy condition not specified | 2 g | — | 298 |
| Exercise frequency and calcium intake predict 4-year bone changes in postmenopausal women 2005 · Calcium-supplemented women · Postmenopausal women, mean age 56.1 years, sedentary at study entry | 800 mg | 4 years | 167 |
| Maternal calcium supplementation and fetal bone mineralization 1999 · 2 g/day of elemental calcium · Healthy pregnant women with singleton pregnancies | 2 g | — | 128 |
| Skeletal site selectivity in the effects of calcium supplementation on areal bone mineral density gain: a randomized, double-blind, placebo-controlled trial in prepubertal boys 2005 · calcium supplement group · Healthy prepubertal boys, mean age 7.4 ± 0.4 years | 850 mg | 1 year | 116 |
| Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial 2024 · acupuncture group · Patients with osteoporosis; age and sex not reported | 600 mg | 26 weeks | 116 |
| Dietary calcium, calcium supplementation, and blood pressure in African American adolescents 1998 · calcium · African American adolescent girls and boys; mean age 15.8 years | 1.5 g | 8 weeks | 116 |
| Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field 2025 · Group A (PEMF and rhPTH) · Postmenopausal women with osteoporosis; mean age 65.21 years | 600 mg | 548 days | 115 |
| Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field 2025 · Group B (rhPTH) · Postmenopausal women with osteoporosis; mean age 65.23 years | 600 mg | 548 days | 113 |
| [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial] 2004 · Group 2: calcium carbonate · Postmenopausal women with osteopenia; age range not reported | 1.5 g | 1 year | 111 |
| Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial 2024 · control group · Patients with osteoporosis; age and sex not reported | 600 mg | 26 weeks | 110 |
| Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial 2015 · calcium 1,200 mg/day · healthy older men | 1.2 g | 2 years | 108 |
| Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field 2025 · Group C (PEMF) · Postmenopausal women with osteoporosis; mean age 65.37 years | 600 mg | 548 days | 108 |
| Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women 2001 · calcium group · Elderly women with 25-hydroxycholecalciferol below 50 nmol/L; mean age 74 years | 1.2 g | 8 weeks | 74 |
| [Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients] 2006 · Group A (alendronate group) · Postmenopausal women aged 55–60 years with osteoporosis | 1 g | 48 weeks | 69 |
| [Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients] 2006 · Group B (tibolone group) · Postmenopausal women aged 55–60 years with osteoporosis | 1 g | 48 weeks | 66 |
| Effect of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake 2010 · calcium group · Pregnant women in rural Gambia with low calcium intake; mean age 27.4 years; from 20 weeks of pregnancy to delivery | 1.5 g | 136 days | 61 |
| Calcium supplementation in patients with essential hypertension: assessment by office, home and ambulatory blood pressure 1998 · calcium supplementation period · Adults with untreated or treated essential hypertension, mean age 58 years; 35 men and 25 women | 25 mmol | 8 weeks | 60 |
| Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia 1992 · calcium carbonate · Patients with mild to moderate hypercholesterolemia | 1.2 g | 6 weeks | 56 |
| Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis 1999 · alendronate plus calcium · postmenopausal women with osteoporosis | 1 g | 2 years | 50 |
| Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis 1999 · calcium alone · postmenopausal women with osteoporosis | 1 g | 2 years | 50 |
| [Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients] 2006 · Group C (calcium preparation only) · Postmenopausal women aged 55–60 years with osteoporosis | 1 g | 48 weeks | 50 |
| A co-twin study of the effect of calcium supplementation on bone density during adolescence 1997 · calcium group · Females aged 10–17 years, mean age 14 years, participating in twin pairs; no condition reported | 1 g | 548 days | 42 |
| Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial 2002 · strontium ranelate 125 mg/day · Early postmenopausal non-osteoporotic women | 500 mg | 2 years | 40 |
| Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial 2002 · strontium ranelate 500 mg/day · Early postmenopausal non-osteoporotic women | 500 mg | 2 years | 40 |
| Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial 2002 · strontium ranelate 1 g/day · Early postmenopausal non-osteoporotic women | 500 mg | 2 years | 40 |
| Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women 2017 · calcium · Healthy postmenopausal women, mean age 71 years | 1 g | 1 day | 40 |
| Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists 1994 · ipriflavone-treated group · Premenopausal women treated with gonadotropin hormone-releasing hormone agonists | 500 mg | 26 weeks | 39 |
| [Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis] 2019 · experimental group · Adults with primary osteoporosis; mean age 63.97 years; 14 men and 22 women | 600 mg | 1 year | 36 |
| [Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis] 2019 · control group · Adults with primary osteoporosis; mean age 63.36 years; 16 men and 20 women | 600 mg | 1 year | 36 |
| Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? 1996 · sCT and Ca · Women with active rheumatoid arthritis receiving low-dose glucocorticoid therapy | 500 mg | 1 year | 32 |
| Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study 1990 · calcitonin group · Adults with steroid-dependent asthma and steroid-induced osteopenia | 1 g | 1 year | 31 |
| Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women 2001 · Control group (calcium alone) · Postmenopausal women aged 45 to 56 years | 1 g | 2 years | 30 |
| The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis 2004 · Calcium alone group · Post-menopausal women with osteoporosis | 1 g | 26 weeks | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Control group · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 2.25 g | 1 year | 29 |
| Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation 2003 · group B · Girls with central precocious puberty; age at diagnosis 7.19 ± 0.96 years | 1 g | 2 years | 27 |
| Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy 1999 · group E-OHC · recent surgically postmenopausal women | 3.32 g | 1 year | 26 |
| Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study 2007 · calcium-supplemented group · postmenopausal women | 1.2 g | 1 year | 26 |
| [Relationship between estrogen receptor gene Px haplotype and the effect of calcium and soy isoflavone supplementation on bone mineral density of Chinese postmenopausal women] 2008 · Ca group · Chinese postmenopausal women aged 45–65 with baseline BMD T score < -1.5 | 440 mg | 1 year | 26 |
| The effect of calcium citrate on bone density in the early and mid-postmenopausal period: a randomized placebo-controlled study 1999 · calcium citrate group · Postmenopausal women, mostly early postmenopausal and a small number mid-postmenopausal | 800 mg | 2 years | 25 |
| Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate 2001 · C group (control) · Postmenopausal women aged 53–78 with osteoporosis, more than 5 years after menopause | 2 g | 2 years | 24 |
| Decrease in Facial Bone Density with Aging and Maintenance Effect of Calcium Maltobionate Ingestion in Japanese Adult Women: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial 2025 · test food group · Healthy Japanese women aged 30–69 years, including pre- and post-menopausal women | 1.1 g | 24 weeks | 24 |
| Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy 1999 · group OHC · recent surgically postmenopausal women | 3.32 g | 1 year | 23 |
| Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial 2013 · calcium · Adults aged 30–75 with at least one pathology-confirmed adenomatous colorectal polyp in the previous 36 months | 2 g | 26 weeks | 23 |
| A double blind study of intranasal calcitonin for established postmenopausal osteoporosis 1997 · nasal calcitonin group · Postmenopausal women aged 55–75 with established osteoporosis and at least one vertebral fracture | 1 g | 1 year | 23 |
| A double blind study of intranasal calcitonin for established postmenopausal osteoporosis 1997 · placebo group · Postmenopausal women aged 55–75 with established osteoporosis and at least one vertebral fracture | 1 g | 1 year | 23 |
| Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial 1999 · Calcium carbonate group · Postmenopausal women who refused hormone replacement therapy | 2.5 g | 2 years | 21 |
| Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study 1995 · group 2 · Postmenopausal women aged 43–59 with vertebral osteopenia and high bone turnover, 2–5 years after natural menopause | 600 mg | 2 years | 21 |
| Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis 2000 · C group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause | 2 g | 2 years | 20 |
| Dietary modification with dairy products for preventing vertebral bone loss in premenopausal women: a three-year prospective study 1990 · dairy-product group · Premenopausal women aged 30–42 years | 610 mg | 3 years | 20 |
| Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass 1994 · Placebo plus calcium · Postmenopausal women with low bone mass | 1 g | 1 year | 20 |
| Calcium supplementation, bone mineral density and bone mineral content. Predictors of bone mass changes in adolescent mothers during the 6-month postpartum period 2012 · dairy products group · Adolescent mothers aged 19 years or younger, 15 days postpartum | 932 mg | 26 weeks | 19 |
| A 1-y walking program and increased dietary calcium in postmenopausal women: effects on bone 1991 · High dietary calcium (milk supplement) · Postmenopausal women; mean age 60.2 years | 831 mg | 1 year | 18 |
| Calcium supplementation, bone mineral density and bone mineral content. Predictors of bone mass changes in adolescent mothers during the 6-month postpartum period 2012 · calcium citrate tablets group · Adolescent mothers aged 19 years or younger, 15 days postpartum | 1 g | 26 weeks | 18 |
| Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic Patients 2015 · Control group · Adults with osteoporosis; ages 67.94 ± 8.37 years on average; men and women | 1.5 g | 26 weeks | 16 |
| Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women 1993 · ipriflavone plus calcium · Women after bilateral ovariectomy | 500 mg | 1 year | 16 |
| Effect of dairy calcium from cheese and milk on fecal fat excretion, blood lipids, and appetite in young men 2014 · milk diet · healthy young men | 1.7 g | 2 weeks | 15 |
| Effect of dairy calcium from cheese and milk on fecal fat excretion, blood lipids, and appetite in young men 2014 · cheese diet · healthy young men | 1.7 g | 2 weeks | 15 |
| Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study 1995 · group 1 (HRT) · Early postmenopausal women attending metabolic bone disease outpatient clinics | 1 g | 4 years | 15 |
| Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study 1995 · group 3 (HRT and ICE) · Early postmenopausal women attending metabolic bone disease outpatient clinics | 1 g | 4 years | 15 |
| Prevention of post-oophorectomy bone loss with Tibolone 1995 · Tibolone-treated group · Women who had hysterectomy and bilateral oophorectomy | 1 g | 1 year | 15 |
| Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study 1999 · B: calcium · Elite middle- and long-distance runners aged 18–35 with menstrual irregularity due to athletic activity | 1 g | 1 year | 14 |
| Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study 1995 · group 2 (ICE) · Early postmenopausal women attending metabolic bone disease outpatient clinics | 1 g | 4 years | 14 |
| Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study 1995 · group 4 (calcium alone) · Early postmenopausal women attending metabolic bone disease outpatient clinics | 1 g | 4 years | 14 |
| One year of oral calcium supplementation maintains cortical bone density in young adult female distance runners 2004 · supplemental calcium · young adult female distance runners, mean age 23.7 years | 1 g | 1 year | 13 |
| Cumulative effects of calcium supplementation and physical activity on bone accretion in premenarchal children: a double-blind randomised placebo-controlled trial 2005 · exercise/calcium · Healthy premenarchal girls who exercised; age not specified | 800 mg | 1 year | 12 |
| Increase of bone mineral density by calcium supplement with oyster shell electrolysate 1990 · OSE group · Elderly females with osteoporosis | 900 mg | 2 years | 12 |
| Long-term oral calcium supplementation reduces diastolic blood pressure in end stage renal disease. A randomized, double-blind, placebo controlled study 1994 · calcium group · Patients undergoing haemodialysis with end-stage renal disease | 2 g | 26 weeks | 11 |
| A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin 1999 · calcium alone · Adults aged 26–68 years undergoing cardiac transplantation | 2 g | 1 year | 10 |
| Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study 1999 · A: HRT and calcium · Elite middle- and long-distance runners aged 18–35 with menstrual irregularity due to athletic activity | 1 g | 1 year | 10 |
| Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism 2003 · CT group · Patients with primary hyperparathyroidism after successful parathyroidectomy | 1 g | 1 year | 10 |
| Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism 2003 · No-treatment group · Patients with primary hyperparathyroidism after successful parathyroidectomy | 1 g | 1 year | 10 |
| Cumulative effects of calcium supplementation and physical activity on bone accretion in premenarchal children: a double-blind randomised placebo-controlled trial 2005 · sedentary/calcium · Healthy premenarchal girls who were sedentary; age not specified | 800 mg | 1 year | 10 |
| Prevention of post-oophorectomy bone loss with Tibolone 1995 · Calcium-only group · Women who had hysterectomy and bilateral oophorectomy | 1 g | 1 year | 10 |
| Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months 1998 · asthmatic subjects receiving calcium and etidronate therapy · Asthmatic patients receiving long-term high-dose inhaled steroids; adults, sex not specified by arm | 1 g | 548 days | 10 |
| Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months 1998 · asthmatic subjects receiving calcium supplement · Asthmatic patients receiving long-term high-dose inhaled steroids; adults, sex not specified by arm | 1 g | 548 days | 8 |
| Changes in bone mineral density and markers of bone remodeling during lactation and postweaning in women consuming high amounts of calcium 1995 · calcium · Women during lactation; age and health condition not reported | 1 g | 90 days | 7 |
| Effect of dietary calcium on renal prostaglandins 1991 · Calcium loading group · Normotensive women, mean age 21.2 years | 3 g | 7 days | 6 |
| Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report 1996 · Group 3 · Postmenopausal women with primary hyperparathyroidism and osteoporosis who underwent parathyroidectomy | 1 g | 1 year | 5 |
| Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment 1999 · group B · girls with true central precocious puberty treated with triptorelin; age range not reported | 1 g | 1 year | — |
| Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment 1999 · group C · girls with true central precocious puberty treated with triptorelin; age range not reported | 1 g | 2 years | — |
| Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass 1999 · calcium lactate-treated (CL) group · Postmenopausal women with osteopenia or osteoporosis and low bone mass | 800 mg | 1 year | — |
| Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol 1999 · placebo group · Adults after cardiac transplantation; mean age 51 years, 111 male and 21 female across the study; sex-specific arm ages not reported | 1 g | 3 years | — |
| Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study 1999 · HRT · Postmenopausal women aged 60–70 years | 1 g | 96 weeks | — |
| Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study 1999 · Placebo · Postmenopausal women aged 60–70 years | 1 g | 96 weeks | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium alone · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 2 years | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and conjugated equine estrogen (CEE) at 0.3 mg · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 2 years | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and conjugated equine estrogen (CEE) at 0.625 mg · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 2 years | — |
| Peripheral computed tomography (pQCT) detected short-term effect of AAACa (heated oyster shell with heated algal ingredient HAI): a double-blind comparison with CaCO3 and placebo 2000 · Group A (AAACa) · Women; age range and health condition not reported | 900 mg | 120 days | — |
| Peripheral computed tomography (pQCT) detected short-term effect of AAACa (heated oyster shell with heated algal ingredient HAI): a double-blind comparison with CaCO3 and placebo 2000 · Group B (AACa) · Women; age range and health condition not reported | 900 mg | 120 days | — |
| Peripheral computed tomography (pQCT) detected short-term effect of AAACa (heated oyster shell with heated algal ingredient HAI): a double-blind comparison with CaCO3 and placebo 2000 · Group C (CaCO3) · Women; age range and health condition not reported | 900 mg | 120 days | — |
| Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study 2000 · Group 2 · Premenopausal women aged 31.1 ± 6 years with systemic lupus erythematosus taking chronic steroid therapy | 1.2 g | 2 years | — |
| Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60 2000 · calcium · Men and women over age 60; elderly volunteers | 750 mg | 4 years | — |
| Effects of diary food supplements on bone mineral density in teenage girls 2000 · high calcium group · Healthy teenage girls aged 15–18 years | 1.16 g | 2 years | — |
| Milk supplementation of the diet of postmenopausal Chinese women on a low calcium intake retards bone loss 2001 · milk supplementation group · Postmenopausal Chinese women aged 55–59 years on a low-calcium diet | 800 mg | 2 years | — |
| Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study 2001 · calcium group · men with primary osteoporosis and at least one baseline fragility fracture | 1 g | 2 years | — |
| [Effects of oral calcium supplementation on blood pressure in population] 2000 · trial group · Adults aged 30 to 64 years selected through hypertension screening in a rural population with higher average blood pressure; 39 males and 59 females completed the study | 800 mg | 5 weeks | — |
| [Effects of different levels of calcium intake on bone of pregnant women] 1999 · II group · Healthy pregnant women enrolled at 18 weeks of pregnancy | 900 mg | — | — |
| [Effects of different levels of calcium intake on bone of pregnant women] 1999 · III group · Healthy pregnant women enrolled at 18 weeks of pregnancy | 1.5 g | — | — |
| A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers 2002 · nasal SCT · men aged 27–74 years with idiopathic osteoporosis | 500 mg | 1 year | — |
| Bisphosphonates in the treatment of thalassemia-induced osteoporosis 2002 · Placebo · Young patients with beta-thalassemia major and osteoporosis; mean age 26.6 ± 7.1 years; sex not reported | 500 mg | 2 years | — |
| Bisphosphonates in the treatment of thalassemia-induced osteoporosis 2002 · Clodronate · Young patients with beta-thalassemia major and osteoporosis; mean age 26.6 ± 7.1 years; sex not reported | 500 mg | 2 years | — |
| Bisphosphonates in the treatment of thalassemia-induced osteoporosis 2002 · Alendronate · Young patients with beta-thalassemia major and osteoporosis; mean age 26.6 ± 7.1 years; sex not reported | 500 mg | 2 years | — |
| Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure 2002 · high-dose regimen · Men with preterminal chronic renal failure and mean creatinine clearance of approximately 30 ml/min | 1.52 g | 24 weeks | — |
| Effect of calcium supplementation on blood pressure in patients with secondary hyperparathyroidism 2003 · Calcium supplementation, intervention study · Adults with secondary hyperparathyroidism and control subjects; ages and sex not stated | 954 mg | 6 weeks | — |
| Vitamin D supplementation and bone mineral density in early postmenopausal women 2003 · 1000 mg Ca/d · Postmenopausal women at least 1 year after menopause; mean age 56 years | 1 g | 2 years | — |
| Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy 2003 · Exercise group · Healthy postmenopausal women, with and without hormone replacement therapy (HRT) | 800 mg | 1 year | — |
| Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy 2003 · No exercise group · Healthy postmenopausal women, with and without hormone replacement therapy (HRT) | 800 mg | 1 year | — |
| The effect of milk supplementation on bone mineral density in postmenopausal Chinese women in Malaysia 2003 · milk group · Chinese postmenopausal women aged 55–65 years, more than 5 years postmenopausal | 1.2 g | 2 years | — |
| Does baseline serum total calcium level influence the blood pressure response to calcium supplementation? A double-blind study 1992 · calcium treatment group · Adults with high-normal or mildly elevated blood pressure; age and sex not specified | 1.5 g | 8 weeks | — |
| Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis 1992 · placebo group · Postmenopausal patients with established osteoporosis | 1 g | 2 years | — |
| Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium 1992 · Placebo · Postmenopausal women | 1 g | 1 year | — |
| Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium 1992 · 0.15 mg/day conjugated estrogens · Postmenopausal women | 1 g | 1 year | — |
| Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium 1992 · 0.30 mg/day conjugated estrogens · Postmenopausal women | 1 g | 1 year | — |
| Effect of ipriflavone on bone mass in elderly osteoporotic women 1992 · placebo group · Women aged over 65 with osteoporosis and at least one vertebral fracture | 1 g | 1 year | — |
| Calcium supplementation provides an extended window of opportunity for bone mass accretion after menarche 2003 · treatment group · Postmenarcheal adolescent girls, mean age 14 ± 0.5 years, with habitual calcium intakes below 800 mg/day | 1 g | 1 year | — |
| Benefits of milk powder supplementation on bone accretion in Chinese children 2004 · Milk powder equivalent to 1300 mg calcium · Chinese children aged 9–10 years | 1.3 g | 548 days | — |
| Benefits of milk powder supplementation on bone accretion in Chinese children 2004 · Milk powder equivalent to 650 mg calcium · Chinese children aged 9–10 years | 650 mg | 548 days | — |
| Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women 1992 · All subjects (calcium supplementation) · Postmenopausal women; age range and condition details beyond postmenopausal status not reported | 1.5 g | 548 days | — |
| Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial 2005 · calcium-supplemented group · Females recruited at pubertal stage 2, followed from childhood into young adulthood | 670 mg | 7 years | — |
| Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study 2005 · Control group · Adults with chronic spinal cord injury | 1 g | 26 weeks | — |
| Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study 2005 · Experimental group · Adults with chronic spinal cord injury | 1 g | 26 weeks | — |
| The effects of calcium supplementation and exercise on bone density in elderly Chinese women 1992 · calcium supplementation · Chinese women aged 62–92 years living in a hostel for the elderly | 800 mg | 304 days | — |
| The effects of calcium supplementation and exercise on bone density in elderly Chinese women 1992 · calcium supplementation plus load-bearing exercise · Chinese women aged 62–92 years living in a hostel for the elderly | 800 mg | 304 days | — |
| Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial 2005 · calcium (1000 mg) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day | 1 g | 2 years | — |
| Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial 2005 · cheese (1000 mg calcium) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day | 1 g | 2 years | — |
| Randomized controlled trial of calcium in healthy older women 2006 · calcium group · Healthy postmenopausal women aged 74±4 years | 1 g | 5 years | — |
| Skeletal benefits from calcium supplementation are limited in children with calcium intakes near 800 mg daily 2006 · milk minerals (MM) · Boys and girls aged 5–11 years; healthy and pre-pubertal at enrolment | 800 mg | 304 days | — |
| Skeletal benefits from calcium supplementation are limited in children with calcium intakes near 800 mg daily 2006 · calcium carbonate (CC) · Boys and girls aged 5–11 years; healthy and pre-pubertal at enrolment | 800 mg | 304 days | — |
| Premenopausal overweight women do not lose bone during moderate weight loss with adequate or higher calcium intake 2007 · WL HiCa group · Overweight, healthy premenopausal women aged 24–49 undergoing weight loss | 1 g | 26 weeks | — |
| Calcium treatment of essential hypertension in elderly patients evaluated by 24 H monitoring 1991 · calcium supplementation · elderly hospitalized patients with mild to moderate essential hypertension | 1 g | — | — |
| Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients 2007 · risedronate · Patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis; ages and sex not reported | 800 mg | 48 weeks | — |
| Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients 2007 · alfacalcidol · Patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis; ages and sex not reported | 800 mg | 48 weeks | — |
| Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial 2008 · Ca group · Community-dwelling women aged 70–80 years | 1.2 g | 5 years | — |
| Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency 2008 · Calcium plus placebo (control) · Elderly women, mean age 77.2 years, with vitamin D insufficiency (serum 25(OH)D <60 nM) | 1 g | 1 year | — |
| Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen 1991 · Provera 20 mg group · Postmenopausal women, mean age 51.7 years; age range and other conditions not specified | 1 g | — | — |
| Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen 1991 · Premarin 0.6 mg group · Postmenopausal women, mean age 51.7 years; age range and other conditions not specified | 1 g | — | — |
| Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen 1991 · Premarin 0.3 mg plus Provera 10 mg group · Postmenopausal women, mean age 51.7 years; age range and other conditions not specified | 1 g | — | — |
| Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen 1991 · Placebo group · Postmenopausal women, mean age 51.7 years; age range and other conditions not specified | 1 g | — | — |
| Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age 1991 · 1000 mg elemental calcium/day group · Perimenopausal women aged 46–55 | 1 g | 2 years | — |
| Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age 1991 · 2000 mg elemental calcium/day group · Perimenopausal women aged 46–55 | 2 g | 2 years | — |
| Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men 2008 · calcium, 1200 mg/d · Healthy men aged at least 40 years (mean age 57), without osteoporosis | 1.2 g | 2 years | — |
| Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study 2014 · D- · Adults with primary hyperparathyroidism after successful parathyroidectomy; median age 60 years, range 30–80; 79% women | 1 g | 1 year | — |
| Supplementation with calcium and short-chain fructo-oligosaccharides affects markers of bone turnover but not bone mineral density in postmenopausal women 2014 · Ca group · Non-osteoporotic postmenopausal women | 800 mg | 2 years | — |
| Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease 2015 · calcium carbonate · Adults with type 2 diabetes mellitus and stage 2–4 diabetic kidney disease | 3.6 g | — | — |
| Effects of supplementation with a calcium-rich marine-derived multi-mineral supplement and short-chain fructo-oligosaccharides on serum lipids in postmenopausal women 2016 · Ca · Postmenopausal women | 800 mg | 2 years | — |
| The effect of dairy intake on bone mass and body composition in early pubertal girls and boys: a randomized controlled trial 2017 · Dairy intervention · Healthy boys and girls aged 8–15.9 years who consumed low amounts of dairy; included participants who were overweight and healthy-weight | 1.5 g | — | — |
| Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy 2017 · Calcium carbonate alone · Adults with primary hyperparathyroidism undergoing parathyroidectomy; median age 60 years, 119 women | 1 g | 1 year | — |
| Effect of prenatal calcium supplementation on bone during pregnancy and 1 y postpartum 2019 · 1000 mg Ca/d group · Pregnant women enrolled at 16 weeks of gestation | 1 g | — | — |
| Effects of maternal calcium supplementation on offspring blood pressure and growth in childhood and adolescence in a population with a low-calcium intake: follow-up study of a randomized controlled trial 2024 · calcium group · Pregnant women in rural Gambia with low customary calcium intake; offspring were followed from childhood into young adulthood | 1.5 g | — | — |
| The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women 1995 · Milk powder containing calcium · Women more than 10 years postmenopausal | 1 g | 2 years | — |
| The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women 1995 · Calcium tablets · Women more than 10 years postmenopausal | 1 g | 2 years | — |
| The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women 1995 · Calcium tablets and exercise · Women more than 10 years postmenopausal | 1 g | 2 years | — |
| Effect of calcium supplementation on bone density and parathyroid function in elderly subjects 1995 · Group A · Hospitalized women, mean age 82 years | 900 mg | 548 days | — |
| Effect of calcium supplementation on bone density and parathyroid function in elderly subjects 1995 · Group B · Hospitalized women, mean age 82 years | 900 mg | 548 days | — |
| Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study 1995 · C (calcium) · Patients aged 50–70 years with severe osteopenia and no previous vertebral fracture | 1 g | 2 years | — |
| Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin 1993 · Double placebo · Patients starting long-term corticosteroid therapy | 1 g | 1 year | — |
| Effects of dairy products on bone and body composition in pubertal girls 1995 · Dairy group · White pubertal girls, mean age 11 years, Tanner stage 2 | 1.2 g | 1 year | — |
| Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients 1994 · Calcium form 1, non-fractured subjects · Healthy vitamin-D-replete elderly subjects; the abstract does not specify the arm’s age range or sex beyond reporting results for non-fractured women | 800 mg | 548 days | — |
| Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients 1994 · Calcium form 2, non-fractured subjects · Healthy vitamin-D-replete elderly subjects; the abstract does not specify the arm’s age range or sex beyond reporting results for non-fractured women | 800 mg | 548 days | — |
| Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients 1994 · Calcium form 1, patients with a recent hip fracture · Elderly patients with a recent hip fracture; age range and sex are not specified | 800 mg | 548 days | — |
| Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients 1994 · Calcium form 2, patients with a recent hip fracture · Elderly patients with a recent hip fracture; age range and sex are not specified | 800 mg | 548 days | — |
| Long-term effect of calcium supplementation on bone loss in perimenopausal women 1994 · 1000 mg calcium group · Perimenopausal women | 1 g | 3 years | — |
| Long-term effect of calcium supplementation on bone loss in perimenopausal women 1994 · 2000 mg calcium group · Perimenopausal women | 2 g | 3 years | — |
| Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals 1994 · calcium only · Healthy postmenopausal women, mean age 66 years | 1 g | 2 years | — |
| Clinical observation of treatment of hypertension with calcium 1994 · calcium-treated group · Borderline and mild-to-moderate hypertensive patients; age and sex not reported | 1 g | 14 weeks | — |
| Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin 1994 · Calcium plus nasal salmon calcitonin · Healthy women with 6–36 months of natural menopause | 500 mg | 3 years | — |
| Effect of calcium supplementation on bone loss in postmenopausal women 1993 · calcium · Normal postmenopausal women at least three years after menopause; mean dietary calcium intake 750 mg/day | 1 g | 2 years | — |
| Dietary calcium, blood pressure and cell membrane cation transport systems in males 1995 · calcium group · adult men described as normal subjects | 2 g | 16 weeks | — |
| Heated oyster shell-seaweed calcium (AAA Ca) on osteoporosis 1996 · Group A · Elderly hospitalized women, mean age 80, with osteoporosis | 900 mg | 913 days | — |
| In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study 1996 · Calcium group · Adults aged 21–65 with asthma or other respiratory diseases who had received long-term corticosteroid treatment | 1 g | 2 years | — |
| Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin 1996 · Intranasal calcitonin plus calcium · Postmenopausal women with thyroid carcinoma receiving suppressive L-T4 therapy | 1 g | 2 years | — |
| Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin 1996 · Calcium alone · Postmenopausal women with thyroid carcinoma receiving suppressive L-T4 therapy | 1 g | 2 years | — |
| Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and serum levels of calcitrophic hormones 1996 · calcium augmentation group · postmenopausal women, the vast majority less than 2 years postmenopause | 1.7 g | 1059 days | — |
| Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and serum levels of calcitrophic hormones 1996 · HRT and dietary calcium augmentation group · postmenopausal women, the vast majority less than 2 years postmenopause | 1.7 g | 1059 days | — |
| Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial 1997 · Ca-suppl. · Healthy prepubertal girls aged about 7.9 years | 850 mg | 1 year | — |
| Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years 1997 · Matched placebo group (background calcium) · Postmenopausal women with distal forearm BMD 1 SD below the mean for normal age-matched postmenopausal subjects | 1 g | 2 years | — |
| A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss 1997 · placebo group · Postmenopausal women aged 50–65 years with vertebral bone density 1 SD below the age-matched postmenopausal mean | 1 g | 2 years | — |
| Efficacy of ipriflavone in established osteoporosis and long-term safety 1997 · placebo plus calcium · Women aged 65–79 with established osteoporosis and prevalent vertebral fractures | 1 g | 2 years | — |
| Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial 1997 · pamidronate group · In- or outpatients requiring first-time long-term corticosteroid therapy at at least 10 mg prednisolone daily | 800 mg | 1 year | — |
| Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial 1997 · calcium group · In- or outpatients requiring first-time long-term corticosteroid therapy at at least 10 mg prednisolone daily | 800 mg | 1 year | — |
| Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake 1998 · calcium · Normotensive women, mean age 39, with low habitual intake of potassium, calcium, and magnesium | 30 mmol | 16 weeks | — |
| Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women 1998 · calcium group · Normal postmenopausal women; mean age 66.3 years | 1.6 g | 4 years | — |
| Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate 1998 · Group B · Men with idiopathic osteoporosis, mean age 53 years, with no previous vertebral fractures | 1 g | 3 years | — |
| Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial 1998 · Calcium carbonate · Older postmenopausal women without osteoporosis | 1 g | 2 years | — |
| Acute effect of poly-gamma-glutamic acid on calcium absorption in post-menopausal women 2007 · Without-PGA condition · Healthy, non-smoking postmenopausal women; mean age 56.4 years | 200 mg | 1 day | 24 |
| Effects of double-blind controlled calcium supplementation on calcium absorption in Chinese children measured with stable isotopes (42Ca and 44Ca) 1995 · study group · 7-year-old Chinese children from Hong Kong and Jiangmen, China | 300 mg | 26 weeks | 17 |
| Which therapy to prevent post-thyroidectomy hypocalcemia? 2005 · group A · Patients undergoing total thyroidectomy for benign thyroid disease or malignancy; age and sex not specified | 300 mg | — | — |
| Calcium absorption from fortified ice cream formulations compared with calcium absorption from milk 2009 · 3% butterfat ice cream · Healthy adults aged 25–45 years, without a medical history of disease known to influence calcium absorption or metabolism | 220 mg | 1 day | — |
| Calcium absorption from fortified ice cream formulations compared with calcium absorption from milk 2009 · 9% coconut oil ice cream · Healthy adults aged 25–45 years, without a medical history of disease known to influence calcium absorption or metabolism | 220 mg | 1 day | — |
| Calcium absorption from fortified ice cream formulations compared with calcium absorption from milk 2009 · Reduced-fat milk · Healthy adults aged 25–45 years, without a medical history of disease known to influence calcium absorption or metabolism | 220 mg | 1 day | — |
| Effect of vitamin D supplementation in the institutionalized elderly 2009 · group (A) · Institutionalized elderly with low baseline vitamin D status | 200 mg | 30 days | — |
| Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3) 2009 · Ca group · Institutionalized elderly; age and sex not specified; baseline serum 25-hydroxyvitamin D was in the hypovitaminosis D range | 200 mg | 30 days | — |
| Prenatal and postnatal lipid-based nutrient supplementation and cognitive, social-emotional, and motor function in preschool-aged children in Ghana: a follow-up of a randomized controlled trial 2019 · LNS group · Pregnant women aged 18 years or older and their children, from pregnancy through the child's age of 18 months | 560 mg | — | 440 |
| A smartphone application to improve adherence to vitamin and mineral supplementation after bariatric surgery 2022 · Intervention group · Adults aged over 18 to 60 years undergoing gastric bypass or sleeve gastrectomy | 1 g | 1 year | 71 |
| A smartphone application to improve adherence to vitamin and mineral supplementation after bariatric surgery 2022 · Control group · Adults aged over 18 to 60 years undergoing gastric bypass or sleeve gastrectomy | 1 g | 1 year | 69 |
| Leucine-Enriched Protein Supplementation Increases Lean Body Mass in Healthy Korean Adults Aged 50 Years and Older: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · protein mixture powder (intervention group) · Healthy Korean adults aged 50–80 years, men and women, without sarcopenia | 600 mg | 12 weeks | 54 |
| The effect of 12-weeks Nutritional supplementation on Nutritional Intake and Status among Indonesian Older Outpatients with Malnutrition Risk, the Prolansia study: a randomized controlled trial 2025 · intervention group (standard care plus NDD) · Men and women aged 60 years and older with malnutrition or at risk of malnutrition, attending outpatient clinics in Indonesia | 500 mg | 12 weeks | 54 |
| Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause 2006 · ES (Estromineral serena) · Symptomatic menopausal women with sleep or mood alterations | 141 mg | 24 weeks | 44 |
| Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial 2024 · combo group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment | 800 mg | 16 weeks | 36 |
| Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial 2024 · training group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment | 800 mg | 16 weeks | 36 |
| Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial 2018 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS); age not reported | 800 mg | 12 weeks | 30 |
| A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial 2017 · SUPP (multi-ingredient nutritional supplement) · Healthy men aged 60 years or older | 800 mg | 20 weeks | 25 |
| A prospective randomized comparative trial evaluating postoperative nutritional intervention in patients with oral cancer 2022 · Intervention group · Adults with oral cancer after surgery; ages 18 and older, both sexes | 1 g | 26 weeks | 22 |
| Analysis of the Efficacy of Two Treatment Protocols for Patients with Symptomatic Oral Lichen Planus: A Randomized Clinical Trial 2020 · anti-inflammatory group · Adults aged 27–80 with symptomatic oral lichen planus | 60 mL | 90 days | 20 |
| Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management 2024 · Muscle 5 (M5) · Men aged 66–91 years; older, sedentary or low-active participants, with the subgroup analysis including overweight or obese men with at least one additional metabolic-syndrome risk factor | 416 mg | 12 weeks | 16 |
| The Effect of a Multi-ingredient Supplement on Resistance Training-induced Adaptations 2021 · SUPP group · Healthy young adults, male and female, mean age 22 ± 2 years, undertaking resistance exercise training | 600 mg | 10 weeks | 13 |
| School-based calcium-vitamin D with micronutrient supplementation enhances bone mass in underprivileged Indian premenarchal girls 2012 · Ca+MZ-group · Premenarchal girls aged 8–12 years from low-income groups in Pune, India | 500 mg | 1 year | — |
| Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls 2014 · Ca+MZn+D group (C1) · Underprivileged premenarchal girls aged 8–12 years | 500 mg | 1 year | — |
| Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial 2014 · intervention group · Pregnant women at 24–26 weeks of gestation with vitamin D deficiency or insufficiency | 200 mg | 8 weeks | — |
| Three-month B vitamin supplementation in pre-school children affects folate status and homocysteine, but not cognitive performance 2014 · B vitamin supplementation group · Healthy preschool children selected for low urinary folate-status ranking | 130 mg | 90 days | — |
| Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study 2009 · control group · Postmenopausal patients with osteoporosis | 134 mg | 26 weeks | 53 |
| Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study 2015 · CFB-1 (group A) · Men and women aged 40–60 years, clinically healthy, with elevated cardiovascular risk markers | 112 mg | 30 days | 26 |
| Effects of Eggshell Calcium Supplementation on Bone Mass in Postmenopausal Vietnamese Women 2017 · eggshell calcium group · postmenopausal Vietnamese women | 300 mg | 1 year | 18 |
| Effects of Eggshell Calcium Supplementation on Bone Mass in Postmenopausal Vietnamese Women 2017 · calcium carbonate group · postmenopausal Vietnamese women | 300 mg | 1 year | 18 |
| Increased calcium absorption from synthetic stable amorphous calcium carbonate: double-blind randomized crossover clinical trial in postmenopausal women 2014 · synthetic stable amorphous calcium carbonate (ACC) · Postmenopausal women aged 54.9 ± 2.8 years, without major medical illness, metabolic bone disorder, excess calcium intake, or vitamin D deficiency | 192 mg | 1 day | 15 |
| Increased calcium absorption from synthetic stable amorphous calcium carbonate: double-blind randomized crossover clinical trial in postmenopausal women 2014 · crystalline calcium carbonate (CCC) · Postmenopausal women aged 54.9 ± 2.8 years, without major medical illness, metabolic bone disorder, excess calcium intake, or vitamin D deficiency | 192 mg | 1 day | 15 |
| Calcium phosphate supplementation increases faecal Lactobacillus spp. in a randomised trial of young adults 2016 · Ca1 (calcium carbonate), Study 1 · Healthy adults; age range and sex not reported | 250 mg | 2 weeks | 15 |
| Calcium phosphate supplementation increases faecal Lactobacillus spp. in a randomised trial of young adults 2016 · Ca2 (calcium phosphate), Study 1 · Healthy adults; age range and sex not reported | 250 mg | 2 weeks | 15 |
| Mineral water as a source of dietary calcium: acute effects on parathyroid function and bone resorption in young men 2000 · High-calcium mineral water · Healthy young men, mean age 21.1 years | 172 mg | 1 day | 12 |
| [Effects of calcium supplementation on bone mineral accretion in adolescents] 2002 · experimental group · healthy adolescents aged 9 to 20 years | 300 mg | — | — |
| The hypoglycemic effects of soy isoflavones on postmenopausal women 2004 · estrogen active control group · Postmenopausal Taiwanese women | 300 mg | 26 weeks | — |
| Effects of multivitamin and mineral supplementation on adiposity, energy expenditure and lipid profiles in obese Chinese women 2010 · Calcium group · Obese Chinese women aged 18–55 years | 162 mg | 26 weeks | — |
| Effects of calcium-fortified ice cream on markers of bone health 2011 · 244 mg calcium group · Premenopausal women aged 20–39 years with calcium intake below 750 mg/day | 244 mg | 4 weeks | — |
| A randomized double-blind controlled calcium supplementation trial, and bone and height acquisition in children 1995 · Calcium supplementation group · 7-year-old Hong Kong Chinese children | 300 mg | 548 days | — |
| Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet 1994 · study group · 7-year-old Chinese children, boys and girls, with habitually low calcium intake | 300 mg | 548 days | — |
| Vitamin D insufficiency does not affect bone mineral density response to raloxifene 2005 · All participants: daily calcium and cholecalciferol supplementation · Postmenopausal women participating in the Multiple Outcomes of Raloxifene Evaluation trial | 500 mg | 213 days | 7,522 |
| Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective 2006 · placebo group with daily supplements · Postmenopausal women aged 42–86 with osteoporosis; age-subgroup analysis included women younger than 75 and women 75 and older | 1 g | 578 days | 544 |
| Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective 2006 · teriparatide group with daily supplements · Postmenopausal women aged 42–86 with osteoporosis; age-subgroup analysis included women younger than 75 and women 75 and older | 1 g | 578 days | 541 |
| Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 · placebo-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated | 600 mg | 2 years | 481 |
| Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 · denosumab-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated | 600 mg | 2 years | 475 |
| Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial 2014 · CaD · Postmenopausal women aged 50–79 years from the general community | 1 g | — | 291 |
| Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS) 2010 · supplementation group · Ambulatory postmenopausal women aged 66 to 71 years | 1 g | 3 years | 287 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate 10 mg/elemental calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 1 g | 2 years | 280 |
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis 2012 · 1 mg daily minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis | 610 mg | 1 year | 234 |
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis 2012 · 30 mg monthly minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis | 610 mg | 1 year | 229 |
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis 2012 · 50 mg monthly minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis | 610 mg | 1 year | 229 |
| Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study 2012 · open-label extension · Men with osteoporosis; age range not reported | 1 g | 2 years | 218 |
| The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease 2012 · calcium-vitamin D3 fixed combination group (Ca-D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency | 1.2 g | 2 years | 206 |
| The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease 2012 · separate calcium and vitamin D3 supplements group (Ca + D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency | 1.2 g | 2 years | 189 |
| Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide 2016 · TPTD group · Postmenopausal women and men with osteoporosis; age range not stated | 610 mg | 72 weeks | 153 |
| No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year 2010 · DD group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese | 500 mg | 1 year | 147 |
| Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density 2007 · alendronate-placebo/calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day | 1 g | 2 years | 140 |
| Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide 2016 · Placebo group · Postmenopausal women and men with osteoporosis; age range not stated | 610 mg | 72 weeks | 137 |
| No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year 2010 · DP group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese | 500 mg | 1 year | 132 |
| Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy 2006 · Placebo subcutaneous plus HRT · Postmenopausal women with low bone mass or osteoporosis | 1 g | 60 weeks | 125 |
| Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy 2006 · Teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT) · Postmenopausal women with low bone mass or osteoporosis | 1 g | 60 weeks | 122 |
| Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 2006 · letrozole · Postmenopausal women with primary breast cancer who completed at least 5 years of adjuvant tamoxifen and had baseline BMD T score of at least 2.0 in either the hip or L2–4 spine | 500 mg | 2 years | 122 |
| Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial 2014 · Group M (menatetrenone) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis | 500 mg | 1 year | 118 |
| Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial 2014 · Group A (alfacalcidol) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis | 500 mg | 1 year | 118 |
| [Long term observation in effects of potassium and calcium supplementation on arterial blood pressure and sodium metabolism in adolescents with higher blood pressure] 2003 · supplementary group · Adolescents aged 18–22 with higher blood pressure | 10 mmol | 2 years | 110 |
| Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis 2015 · ALN + VitD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture | 610 mg | 48 weeks | 109 |
| Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial 2018 · Placebo group · Youth aged 16–24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy for at least 180 days | 162 mg | 48 weeks | 105 |
| Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 2006 · placebo · Postmenopausal women with primary breast cancer who completed at least 5 years of adjuvant tamoxifen and had baseline BMD T score of at least 2.0 in either the hip or L2–4 spine | 500 mg | 2 years | 104 |
| Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis 2004 · group A · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica | 500 mg | 3 years | 103 |
| A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis 2006 · Calcium group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months | 1 g | 2 years | 103 |
| [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis] 2004 · RLX group · Chinese postmenopausal women with osteoporosis | 500 mg | 1 year | 102 |
| [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis] 2004 · placebo group · Chinese postmenopausal women with osteoporosis | 500 mg | 1 year | 102 |
| Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis 2004 · group B · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica | 500 mg | 3 years | 101 |
| Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis 1994 · NaF group · Postmenopausal women with osteoporosis | 1.5 g | 6 years | 101 |
| Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study 2025 · All patients · Patients aged 18–60 years with early active rheumatoid arthritis and no earlier use of disease-modifying anti-rheumatic drugs | 1 g | — | 99 |
| Formula Milk Supplementation and Bone Acquisition in 4-6 Years Chinese Children: A 12-Month Cluster-Randomized Controlled Trial 2023 · formula milk group · Healthy Chinese children aged 4–6 years in rural Northwest China who were willing to drink milk but consumed little for economic reasons | 720 mg | 1 year | 96 |
| Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation 2003 · supplementation · Ambulatory elderly women, mean age 75 years, with vitamin D insufficiency | 1 g | 1 year | 95 |
| Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial 2015 · VitD/Cal group · HIV-infected adults initiating their first ART regimen with EFV/FTC/TDF | 1 g | 48 weeks | 81 |
| Efficacy of strontium ranelate on bone mineral density in men with osteoporosis 2010 · Strontium ranelate group · Men with primary osteoporosis | 1.2 g | 1 year | 76 |
| Efficacy of strontium ranelate on bone mineral density in men with osteoporosis 2010 · Alendronate group · Men with primary osteoporosis | 1.2 g | 1 year | 76 |
| Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women 2001 · vitamin D(3) and calcium group · Elderly women with 25-hydroxycholecalciferol below 50 nmol/L; mean age 74 years | 1.2 g | 8 weeks | 74 |
| Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis 2006 · vitamin D plus calcium group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels | 1 g | 547 days | 72 |
| Estimating the causal effect of milk powder supplementation on bone mineral density: a randomized controlled trial with both non-compliance and loss to follow-up 2015 · milk powder supplementation group · Healthy postmenopausal women | 900 mg | 2 years | 69 |
| The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women 2014 · Aquatic Exercise Group (AEG) · Postmenopausal women, mean age 58.8 ± 6.4 years | 500 mg | 24 weeks | 64 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group B · Patients with Crohn's disease and reduced BMD (T-score < -1) | 800 mg | 1278 days | 62 |
| Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium 2003 · simple vitamin D (ergocalciferol) plus calcium carbonate · Females and males commencing or already taking glucocorticoids | 600 mg | 2 years | 61 |
| Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study 2012 · 500 mg calcium with 400 international unis (iu) vitamin D daily · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0) | 500 mg | 1 year | 59 |
| Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study 2012 · 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0) | 500 mg | 1 year | 59 |
| A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study 2006 · calcitonin group · Postmenopausal Asian women with osteoporosis | 500 mg | 26 weeks | 57 |
| Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients 2021 · bazedoxifene group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids | 1.2 g | 56 weeks | 57 |
| Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients 2021 · control group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids | 1.2 g | 56 weeks | 57 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca6D group · Healthy Chinese adolescents aged 11.9–15.2 years | 600 mg | 548 days | 56 |
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation 2006 · Control group · Patients with orthotopic liver transplantation | 1 g | 2 years | 54 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group C · Patients with Crohn's disease and reduced BMD (T-score < -1) | 800 mg | 1278 days | 54 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca9D group · Healthy Chinese adolescents aged 11.9–15.2 years | 900 mg | 548 days | 54 |
| Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients 2008 · experiment I group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified | 4.5 g | 1 year | 50 |
| Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients 2008 · experiment II group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified | 4.5 g | 1 year | 50 |
| The Effect of the Modified Eighth Section of Eight-Section Brocade on Osteoporosis in Postmenopausal Women: A Prospective Randomized Trial 2015 · Ca alone · Postmenopausal women aged 50–75 with inadequate bone mass or osteoporosis | 1.5 g | 1 year | 50 |
| The Effect of the Modified Eighth Section of Eight-Section Brocade on Osteoporosis in Postmenopausal Women: A Prospective Randomized Trial 2015 · MESE + Ca · Postmenopausal women aged 50–75 with inadequate bone mass or osteoporosis | 1.5 g | 1 year | 50 |
| Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis 2020 · Arm A (TDF/FTC + Oskept) · Young men who have sex with men and young transgender women aged 15–24 years initiating PrEP | 1.2 g | 26 weeks | 50 |
| Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride 2002 · calcium-vitamin D-placebo group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D | 1 g | 1 year | 49 |
| Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents 2019 · Ca3D group · Healthy Chinese adolescents aged 11.9–15.2 years | 300 mg | 548 days | 49 |
| A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study 2006 · teriparatide group · Postmenopausal Asian women with osteoporosis | 500 mg | 26 weeks | 47 |
| Effect of pamidronate on bone loss after kidney transplantation: a randomized trial 2009 · control group · Kidney transplant recipients with parathyroid hormone level at least 150 pg/mL | 500 mg | 2 years | 47 |
| Effect of pamidronate on bone loss after kidney transplantation: a randomized trial 2009 · treatment group · Kidney transplant recipients with parathyroid hormone level at least 150 pg/mL | 500 mg | 2 years | 46 |
| Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids 2009 · Group B · Patients with rheumatic diseases, osteopenia or osteoporosis, and gastric or esophageal conditions contraindicating oral bisphosphonates; receiving chronic low-dose glucocorticoids | 1 g | 1 year | 46 |
| Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride 2002 · calcium-vitamin D-fluoride group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D | 1 g | 1 year | 45 |
| Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation 2004 · calcitriol therapy (CT) · renal transplant recipients; age and sex not specified | 500 mg | 90 days | 45 |
| Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study 2011 · Risedronate plus calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation | 1 g | 1 year | 45 |
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation 2006 · ALN 70 mg weekly · Patients with orthotopic liver transplantation | 1 g | 2 years | 44 |
| Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study 2011 · Calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation | 1 g | 1 year | 44 |
| The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women 2014 · Control Group (CG) · Postmenopausal women, mean age 58.8 ± 6.4 years | 500 mg | 24 weeks | 44 |
| Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis 2018 · PTH group · Postmenopausal women aged 45–80 with osteoporosis | 1.25 g | 48 weeks | 43 |
| A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV 2019 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy | 1 g | 1 year | 43 |
| Dairy matrix effects: response to consumption of dairy fat differs when eaten within the cheese matrix-a randomized controlled trial 2018 · Group C (BCC) · Overweight adults aged 50 years or older; sex distribution not stated | 500 mg | 6 weeks | 42 |
| A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV 2019 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy | 1 g | 1 year | 42 |
| Effect of two forms of alendronate administration upon bone mass after two years of treatment 2002 · Group I · Women with postmenopausal osteoporosis | 1.2 g | 2 years | 40 |
| Effect of two forms of alendronate administration upon bone mass after two years of treatment 2002 · Group II · Women with postmenopausal osteoporosis | 1.2 g | 2 years | 40 |
| The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis 2004 · Calcitriol and calcium group · Post-menopausal women with osteoporosis | 1 g | 26 weeks | 40 |
| The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study 2005 · Treatment group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures | 1 g | 548 days | 40 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old | 630 mg | 26 weeks | 40 |
| Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis 1994 · 1 alpha(OH)D3 treatment · Postmenopausal Japanese women with osteoporosis; mean age 71.9 years | 300 mg | 1 year | 40 |
| Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis 2003 · Neridronate group · Postmenopausal women with spine bone mineral density at least 2.5 SD below peak | 500 mg | 3 years | 39 |
| Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis 2003 · Control group · Postmenopausal women with spine bone mineral density at least 2.5 SD below peak | 500 mg | 3 years | 39 |
| Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study 2006 · dairy group (DG) · Postmenopausal women aged 55–65 years | 1.2 g | 1 year | 39 |
| Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study 2007 · dairy intervention group · postmenopausal women | 1.2 g | 1 year | 39 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · control group · Postmenopausal Korean women over 60 years old | 630 mg | 26 weeks | 38 |
| Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women 2022 · Supplement group (S) · Overweight/obese, generally healthy postmenopausal women with dietary calcium intake of 800 mg/day or less | 315 mg | 26 weeks | 37 |
| Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial 2003 · Group 2 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis | 1 g | 1 year | 36 |
| Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial 2003 · Group 1 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis | 1 g | 1 year | 35 |
| The effects of a 30-month dietary intervention on bone mineral density: the Postmenopausal Health Study 2010 · dietary group (DG) · Postmenopausal women aged 55–65 years | 1.2 g | 913 days | 35 |
| Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial 2011 · Vitamin D3 · Adults aged 18–50 with clinically definite multiple sclerosis, fully ambulatory (EDSS ≤4.5) | 500 mg | 96 weeks | 35 |
| Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women 2002 · placebo · Postmenopausal African-American women aged 45–88 with osteoporosis | 500 mg | 2 years | 33 |
| Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake 2005 · WL Hi-Ca · Overweight postmenopausal women aged 50–75 undergoing weight loss | 1.2 g | 180 days | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · raloxifene group · Postmenopausal women with diagnosed osteoporosis | 500 mg | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · placebo group · Postmenopausal women with diagnosed osteoporosis | 500 mg | 2 years | 33 |
| The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis 2006 · continuation of open-label alendronate group · Postmenopausal women with diagnosed osteoporosis | 500 mg | 2 years | 33 |
| Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia 2006 · vitamin K2 group · Postmenopausal women with osteoporosis | 1.5 g | 48 weeks | 33 |
| Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women 2002 · alendronate group · Postmenopausal African-American women aged 45–88 with osteoporosis | 500 mg | 2 years | 32 |
| Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D 2011 · group A · Patients with Crohn's disease and reduced BMD (T-score < -1) | 800 mg | 1278 days | 32 |
| The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study 2005 · Control group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures | 1 g | 548 days | 31 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH250 · Adults aged 52–84 years with osteoporosis | 300 mg | 90 days | 31 |
| Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial 2004 · treatment group · Healthy adults; age and sex not specified | 500 mg | 213 days | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Group A · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 2.25 g | 1 year | 30 |
| [Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis] 2005 · Group B · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment | 2.25 g | 1 year | 30 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH500 · Adults aged 52–84 years with osteoporosis | 300 mg | 90 days | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group A · Adults with established postmenopausal or male osteoporosis | 500 mg | 2 years | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group B · Adults with established postmenopausal or male osteoporosis | 1 g | 2 years | 30 |
| Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) 2007 · group C · Adults with established postmenopausal or male osteoporosis | 500 mg | 2 years | 30 |
| Clodronic acid in the treatment of postmenopausal osteoporosis 2007 · clodronic acid group · Postmenopausal women aged 48–73 years with osteoporosis | 500 mg | 3 years | 30 |
| Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial 2013 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low-calcium diets | 600 mg | — | 30 |
| Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: A randomized controlled trial 2016 · calcium plus cholecalciferol · Pregnant adolescents aged 14–19 years | 600 mg | — | 30 |
| Reduction in Bone Loss from 5 to 20 Weeks Postpartum in Adolescents Supplemented with Calcium Plus Vitamin D during Pregnancy Is Not Sustained at 1 Year Postpartum: Follow-up Study of a Randomized Controlled Trial 2021 · supplemented group · Pregnant adolescents aged 14–19 years with habitually low calcium intake | 600 mg | — | 30 |
| Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation 1997 · treatment group · Patients with hemiplegia after stroke; mean duration of illness 4.8 years; age and sex not reported | 300 mg | 26 weeks | 30 |
| Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study 2006 · PTH1000 · Adults aged 52–84 years with osteoporosis | 300 mg | 90 days | 29 |
| Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial) 2008 · Control group · Adults aged 18 years or older with cystic fibrosis and low bone mass | 500 mg | 1 year | 29 |
| Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial 2015 · Resistance training (RT) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active | 1 g | 1 year | 29 |
| Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial 2015 · Jump training (JUMP) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active | 1 g | 1 year | 29 |
| [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis] 2002 · alendronate group · Postmenopausal women with osteopenia or osteoporosis | 600 mg | 26 weeks | 28 |
| [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis] 2002 · placebo group · Postmenopausal women with osteopenia or osteoporosis | 600 mg | 26 weeks | 28 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · B · Adults aged 61–96 years with a recent hip fracture | 1 g | 1 year | 28 |
| Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial) 2008 · Alendronate group · Adults aged 18 years or older with cystic fibrosis and low bone mass | 500 mg | 1 year | 27 |
| [Relationship between estrogen receptor gene Px haplotype and the effect of calcium and soy isoflavone supplementation on bone mineral density of Chinese postmenopausal women] 2008 · Ca + soy isoflavone group · Chinese postmenopausal women aged 45–65 with baseline BMD T score < -1.5 | 440 mg | 1 year | 26 |
| Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? 2009 · Group A · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion | 100 mg | 1 year | 26 |
| Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss? 2009 · Group B · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion | 2.1 g | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaD group · Postmenopausal women | 800 mg | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK1 group · Postmenopausal women | 800 mg | 1 year | 26 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · BN · Adults aged 61–96 years with a recent hip fracture | 1 g | 26 weeks | 26 |
| Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids 2001 · Alendronate+calcium group · 25 female patients with rheumatoid arthritis | 1 g | 26 weeks | 25 |
| Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids 2001 · Calcium-only group · 25 female patients with rheumatoid arthritis | 1 g | 26 weeks | 25 |
| Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study 2014 · C · Adults aged 61–96 years with a recent hip fracture | 1 g | 1 year | 25 |
| Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial 2017 · multispecies probiotic supplement (GeriLact) · Postmenopausal women aged 50–72 years with osteopenia | 500 mg | 26 weeks | 25 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK2 group · Postmenopausal women | 800 mg | 1 year | 24 |
| Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120) 2012 · placebo group · HIV-1-infected adults with low bone mineral density and no other known risk factors for low BMD; antiretroviral-treated | 500 mg | 96 weeks | 24 |
| Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic Patients 2015 · Treatment group · Adults with osteoporosis; ages 64.08 ± 14.51 years on average; men and women | 1.5 g | 26 weeks | 24 |
| Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women 1998 · E + C group · Postmenopausal women with at least one non-traumatic vertebral fracture or z score < -1.5 | 500 mg | 1 year | 24 |
| Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids 2009 · Group A · Patients with rheumatic diseases, osteopenia or osteoporosis, and gastric or esophageal conditions contraindicating oral bisphosphonates; receiving chronic low-dose glucocorticoids | 1 g | 1 year | 23 |
| Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome 2009 · group 1 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia | 500 mg | 1 year | 23 |
| Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome 2009 · group 2 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia | 500 mg | 1 year | 23 |
| Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis 2018 · Alendronate (ALN) group · Postmenopausal women aged 45–80 with osteoporosis | 1.25 g | 48 weeks | 22 |
| Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids 2001 · Postmenopausal control group · 20 postmenopausal patients with osteoporosis | 1 g | 26 weeks | 20 |
| Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography 2004 · RLX 120 mg/day · Postmenopausal women with osteoporosis | 500 mg | 2 years | 20 |
| Effects of neridronate treatment in elderly women with osteoporosis 2005 · Neridronate plus calcium and vitamin D · Postmenopausal women aged 65–80 with osteoporosis | 500 mg | 1 year | 20 |
| Effects of neridronate treatment in elderly women with osteoporosis 2005 · Calcium plus vitamin D supplements alone · Postmenopausal women aged 65–80 with osteoporosis | 500 mg | 1 year | 20 |
| Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study 2011 · dietary group (DG) · Postmenopausal women aged 55–65 with osteopenia | 1.2 g | 913 days | 20 |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Algal oil containing DHA · Individuals with osteopenia | 1.2 g | 1 year | 20 |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Placebo group · Individuals with osteopenia | 1.2 g | 1 year | 20 |
| Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120) 2012 · alendronate group · HIV-1-infected adults with low bone mineral density and no other known risk factors for low BMD; antiretroviral-treated | 500 mg | 96 weeks | 20 |
| Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass 1994 · IP 600 mg/day plus calcium · Postmenopausal women with low bone mass | 1 g | 1 year | 20 |
| Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study 1997 · calcium supplementation together with nasal SCT · Women who had undergone bilateral ovariectomy 7 days previously | 1 g | 2 years | 19 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · Combined therapy group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | 4 years | 19 |
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease 2000 · calcium/vitamin D/fluoride group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year | 1 g | 1 year | 18 |
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation 2000 · Control subjects · Patients with cystic fibrosis after lung transplantation | 1 g | 2 years | 18 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · Control group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | 4 years | 18 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · HRT group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | 4 years | 18 |
| Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography 2004 · RLX 60 mg/day · Postmenopausal women with osteoporosis | 500 mg | 2 years | 17 |
| A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis 1998 · Etidronate group · Postmenopausal women with established osteoporosis; mean age 64.9 years | 1 g | 4 years | 17 |
| Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation 2000 · treatment group · Long-term renal transplant recipients with serum creatinine levels less than 2.0 mg/dL | 500 mg | 1 year | 16 |
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation 2000 · Pamidronate treatment group · Patients with cystic fibrosis after lung transplantation | 1 g | 2 years | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · SrRan monotherapy · Postmenopausal women aged 54–73 with osteoporosis | 1 g | 26 weeks | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · SrRan + AD3 · Postmenopausal women aged 54–73 with osteoporosis | 1 g | 26 weeks | 16 |
| Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis 2014 · Control · Postmenopausal women aged 54–73 with osteoporosis | 1 g | 26 weeks | 16 |
| Increase of bone mineral density with sodium fluoride in patients with Crohn's disease 2000 · calcium/vitamin D only group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year | 1 g | 1 year | 15 |
| Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis 2004 · calcium and vitamin D treatment group · Adults with cystic fibrosis and a BMD Z score of -1 or less in the lumbar spine, proximal femur or distal forearm | 1 g | 1 year | 15 |
| Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study 2013 · Group B (drug arm) · Adults aged 18 years or older with newly diagnosed celiac disease and low bone mineral density | 1 g | 1 year | 15 |
| Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate 1994 · treated group · Adults with asthma undergoing long-term systemic corticosteroid treatment | 1 g | 26 weeks | 14 |
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers 2000 · Vehicle group · Men aged 30–68 with idiopathic osteoporosis | 1.5 g | 548 days | 13 |
| Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study 2013 · Group A (control arm) · Adults aged 18 years or older with newly diagnosed celiac disease and low bone mineral density | 1 g | 1 year | 13 |
| Effect of milk and calcium supplementation on bone density and bone turnover in pregnant Chinese women: a randomized controlled trail 2011 · III: usual diet + milk powder + calcium · Chinese pregnant women aged 24–31 years, with habitual low calcium intake | 600 mg | — | 12 |
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers 2000 · PTH-(1-34) group · Men aged 30–68 with idiopathic osteoporosis | 1.5 g | 548 days | 10 |
| Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial 2020 · study group · Adults aged 18–50 with HIV infection, ART-naïve at enrollment and starting TDF/FTC/EFV; mostly men | 1.25 g | 24 weeks | 9 |
| Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study 1996 · Group 1 · Adults with renal grafts or skin, bronchopulmonary, or Crohn's disease, chronically treated with glucocorticosteroids | 1 g | 1 year | 8 |
| Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients 1997 · diet plus calcium and vitamin D · Adults with newly diagnosed, untreated celiac disease; 11 of the 14 patients had osteopenia at diagnosis | 1 g | 1 year | 7 |
| Prevention of bone loss after withdrawal of tamoxifen 2008 · alendronate group · Postmenopausal women with a history of breast cancer who had stopped tamoxifen; mean age 58 years | 1.2 g | 1 year | 6 |
| Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women 1990 · Ergocalciferol-treated group · Women over 60 years of age with osteopenia | 1 g | 1 year | 6 |
| Prevention of bone loss after withdrawal of tamoxifen 2008 · placebo group · Postmenopausal women with a history of breast cancer who had stopped tamoxifen; mean age 58 years | 1.2 g | 1 year | 5 |
| Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women 1990 · Calcitriol-treated group · Women over 60 years of age with osteopenia | 1 g | 1 year | 4 |
| Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol 1999 · calcitriol group · Adults after cardiac transplantation; mean age 51 years, 111 male and 21 female across the study; sex-specific arm ages not reported | 1 g | 3 years | — |
| Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study 1999 · MFP · Postmenopausal women aged 60–70 years | 1 g | 96 weeks | — |
| Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study 1999 · HRT+MFP · Postmenopausal women aged 60–70 years | 1 g | 96 weeks | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and calcitriol at 0.25 microg daily · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 2 years | — |
| Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen 2000 · calcium and calcitriol at 0.5 microg daily · Thai postmenopausal women no more than 6 years postmenopausal | 750 mg | 2 years | — |
| Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study 2000 · Group 1 · Premenopausal women aged 31.1 ± 6 years with systemic lupus erythematosus taking chronic steroid therapy | 1.2 g | 2 years | — |
| Effect of calcitriol on bone loss after cardiac or lung transplantation 2000 · Calcitriol for 12 months followed by calcium for 12 months · Patients undergoing cardiac or single lung transplantation; age and sex not specified | 600 mg | 2 years | — |
| Effect of calcitriol on bone loss after cardiac or lung transplantation 2000 · Calcitriol for 24 months · Patients undergoing cardiac or single lung transplantation; age and sex not specified | 600 mg | 2 years | — |
| Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis 2001 · HEBP group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain | 2 g | 2 years | — |
| Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis 2001 · Ca. D group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain | 2 g | 2 years | — |
| Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study 2002 · CaD group · Adult renal transplant recipients; 65 men and 46 women, mean age 47 years | 1 g | 26 weeks | — |
| Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate 2003 · group A · Patients with Crohn's disease and pathological bone mineral density findings | 800 mg | 821 days | — |
| Vitamin D supplementation and bone mineral density in early postmenopausal women 2003 · 1000 mg Ca/d plus 10 000 U vitamin D(2)/wk · Postmenopausal women at least 1 year after menopause; mean age 56 years | 1 g | 2 years | — |
| Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis 1992 · ipriflavone group · Postmenopausal patients with established osteoporosis | 1 g | 2 years | — |
| Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium 1992 · 0.15 mg/day conjugated estrogens plus ipriflavone · Postmenopausal women | 1 g | 1 year | — |
| Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium 1992 · 0.30 mg/day conjugated estrogens plus ipriflavone · Postmenopausal women | 1 g | 1 year | — |
| Effect of ipriflavone on bone mass in elderly osteoporotic women 1992 · ipriflavone group · Women aged over 65 with osteoporosis and at least one vertebral fracture | 1 g | 1 year | — |
| A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density 2003 · HRT/D group · Postmenopausal women aged 53–79 years with osteoporosis, at least one minimal-trauma vertebral fracture, and low lumbar bone mineral density | 600 mg | 2 years | — |
| Preventing bone loss in renal transplant recipients with vitamin D 2003 · group 1 · adult men who were recent renal transplant recipients | 500 mg | — | — |
| A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease 2003 · calcium and vitamin D alone · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip | 500 mg | 1 year | — |
| A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease 2003 · calcium and vitamin D with intravenous pamidronate · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip | 500 mg | 1 year | — |
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis 2004 · Transdermal HRT group · Postmenopausal women with primary biliary cirrhosis | 1 g | 2 years | — |
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis 2004 · Control group · Postmenopausal women with primary biliary cirrhosis | 1 g | 2 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · alendronate 10 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 500 mg | 3 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · alendronate 5 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 500 mg | 3 years | — |
| Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension 2004 · placebo group · Women aged 60–86 years with low BMD who had received alendronate in FIT | 500 mg | 3 years | — |
| The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study 2004 · vitamin D3 plus calcium · Women aged 58–88 with a proximal humerus fracture and osteoporosis or osteopenia | 1 g | 12 weeks | — |
| Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease 2005 · Etidronate group · Patients with Crohn's disease and decreased bone mineral density | 500 mg | 2 years | — |
| Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease 2005 · Non-etidronate group · Patients with Crohn's disease and decreased bone mineral density | 500 mg | 2 years | — |
| Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate 2005 · Calcium, vitamin D, and sex hormone replacement group · Adults who received an allogeneic stem cell transplant | 1 g | 1 year | — |
| Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate 2005 · Calcium, vitamin D, sex hormone replacement, and pamidronate group · Adults who received an allogeneic stem cell transplant | 1 g | 1 year | — |
| A prospective randomized study for prevention of postrenal transplantation bone loss 2005 · group I · adult male recent renal transplant recipients | 500 mg | 1 year | — |
| Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial 2005 · calcium (1000 mg) + vitamin D3 (200 IU) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day | 1 g | 2 years | — |
| Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome 2006 · treatment group · Children with nephrotic syndrome receiving prednisolone; mean age 4.6 years, 27 boys and 13 girls across the study | 1 g | 60 days | — |
| Calcium plus vitamin D supplementation and the risk of fractures 2006 · calcium plus vitamin D group · Healthy postmenopausal women aged 50 to 79 years | 1 g | 7 years | — |
| Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial 2006 · calcium- and vitamin D3-fortified milk group · Men older than 50 years living in the community; mean age 61.9 years | 1 g | 2 years | — |
| Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men 2006 · milk supplementation group · men aged over 50 years; older subgroup analyses included men over 62 years | 1 g | 2 years | — |
| Pamidronate reduces bone loss after allogeneic stem cell transplantation 2006 · pamidronate · Patients undergoing allogeneic stem cell transplantation | 1 g | 1 year | — |
| Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations 2007 · calcium + vitamin D supplement group · Healthy overweight or obese women with daily calcium intake below 800 mg | 1.2 g | 15 weeks | — |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · vitamin D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 1 g | 2 years | — |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 1 g | 2 years | — |
| Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and vitamin D 2007 · calcium and vitamin D intervention group · Patients with a recent low-energy fracture of the hip, forearm, shoulder, or spine; mean age 70 ± 11 years, 84% women | 3 g | 1 year | — |
| Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis 2007 · Raloxifene group · Postmenopausal women with osteoporosis | 600 mg | 1 year | — |
| Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis 2007 · Low-dose HRT group · Postmenopausal women with osteoporosis | 600 mg | 1 year | — |
| Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup 2008 · E · Japanese patients with connective tissue disease and corticosteroid-induced osteoporosis who had received more than 7.5 mg/day prednisolone for at least 90 days | 3 g | 2557 days | — |
| Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup 2008 · C · Japanese patients with connective tissue disease and corticosteroid-induced osteoporosis who had received more than 7.5 mg/day prednisolone for at least 90 days | 3 g | 2557 days | — |
| Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial 2008 · CaD group · Community-dwelling women aged 70–80 years | 1.2 g | 5 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 2 mg IV ibandronate every 2 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 500 mg | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 3 mg IV ibandronate every 3 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 500 mg | 2 years | — |
| Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study 2008 · 2.5 mg daily oral ibandronate · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis | 500 mg | 2 years | — |
| Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency 2008 · Calcium plus vitamin D · Elderly women, mean age 77.2 years, with vitamin D insufficiency (serum 25(OH)D <60 nM) | 1 g | 1 year | — |
| Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women 1991 · Vitamin D group · Healthy, ambulatory postmenopausal women with usual vitamin D intakes of 100 IU/day | 377 mg | 1 year | — |
| Effect of alendronate in elderly patients after low trauma hip fracture repair 2009 · Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women | 500 mg | 1 year | — |
| Effect of alendronate in elderly patients after low trauma hip fracture repair 2009 · ALN + Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women | 500 mg | 1 year | — |
| Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial 2009 · exercise + fortified milk · Men aged 50–79 years; older, well-nourished men | 1 g | 1 year | — |
| Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial 2009 · fortified milk · Men aged 50–79 years; older, well-nourished men | 1 g | 1 year | — |
| Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial 2008 · calcium supplementation group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment | 1 g | 2 years | — |
| Vitamin D insufficiency does not affect response of bone mineral density to alendronate 2009 · Calcium and cholecalciferol recipients · Postmenopausal women with low bone mineral density | 500 mg | — | — |
| Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC 2009 · upfront zoledronic acid arm · Postmenopausal women with stage I–IIIa hormone receptor-positive breast cancer who had completed up to 6 years of tamoxifen and were starting letrozole | 1 g | 5 years | — |
| Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC 2009 · delayed zoledronic acid arm · Postmenopausal women with stage I–IIIa hormone receptor-positive breast cancer who had completed up to 6 years of tamoxifen and were starting letrozole | 1 g | 5 years | — |
| Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone 2009 · DHEA group · Men and women aged 65–75 years | 700 mg | 2 years | — |
| Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone 2009 · Placebo group, then open-label DHEA in year 2 · Men and women aged 65–75 years | 700 mg | 1 year | — |
| Phosphate and carbonate salts of calcium support robust bone building in osteoporosis 2010 · Tricalcium phosphate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day | 1.8 g | 1 year | — |
| Phosphate and carbonate salts of calcium support robust bone building in osteoporosis 2010 · Calcium carbonate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day | 1.8 g | 1 year | — |
| Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass 2011 · Alfa/ALN group · Postmenopausal women aged 73.6 ± 4.7 years with osteoporosis or osteopenia | 500 mg | 3 years | — |
| The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial 2012 · high-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip) | 1 g | 1 year | — |
| The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial 2012 · standard-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip) | 1 g | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Placebo group · Japanese postmenopausal women with osteoporosis | 600 mg | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 14 mg group · Japanese postmenopausal women with osteoporosis | 600 mg | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 60 mg group · Japanese postmenopausal women with osteoporosis | 600 mg | 1 year | — |
| Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis 2012 · Denosumab 100 mg group · Japanese postmenopausal women with osteoporosis | 600 mg | 1 year | — |
| Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study 1990 · calcitriol · Postmenopausal women with vertebral fractures; age range not reported | 600 mg | 2 years | — |
| Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer 2012 · denosumab group · Men aged 70 years or older, or younger men with osteoporotic fracture history or low BMD, with nonmetastatic prostate cancer receiving androgen-deprivation therapy | 1 g | 3 years | — |
| Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer 2012 · placebo group · Men aged 70 years or older, or younger men with osteoporotic fracture history or low BMD, with nonmetastatic prostate cancer receiving androgen-deprivation therapy | 1 g | 3 years | — |
| A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation 2012 · Ibandronate group · Renal transplant recipients with early stable renal function | 1 g | 1 year | — |
| A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation 2012 · Placebo group · Renal transplant recipients with early stable renal function | 1 g | 1 year | — |
| Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis 2013 · low-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis | 600 mg | 1 year | — |
| Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis 2013 · standard-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis | 600 mg | 1 year | — |
| Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial 2013 · Control group · Adults aged 18 years or older with newly diagnosed lymphoma, without osteoporosis; vitamin D- or testosterone-deficient patients were eligible if receiving appropriate therapy | 1.2 g | 1 year | — |
| Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial 2013 · Zoledronic acid group · Adults aged 18 years or older with newly diagnosed lymphoma, without osteoporosis; vitamin D- or testosterone-deficient patients were eligible if receiving appropriate therapy | 1.2 g | 1 year | — |
| Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study 2014 · D+ · Adults with primary hyperparathyroidism after successful parathyroidectomy; median age 60 years, range 30–80; 79% women | 1 g | 1 year | — |
| Supplementation with calcium and short-chain fructo-oligosaccharides affects markers of bone turnover but not bone mineral density in postmenopausal women 2014 · CaFOS group · Non-osteoporotic postmenopausal women | 800 mg | 2 years | — |
| Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial 2014 · Exemestane group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0 | 1 g | 2 years | — |
| Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial 2014 · Anastrozole group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0 | 1 g | 2 years | — |
| The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial 2014 · 100 g dried plum/d group · Osteopenic postmenopausal women | 500 mg | 1 year | — |
| The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial 2014 · 75 g dried apple/d comparative control group · Osteopenic postmenopausal women | 500 mg | 1 year | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · Low-Ca group · Girls and boys aged 12–14 years | 300 mg | 2 years | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · Mid-Ca group · Girls and boys aged 12–14 years | 600 mg | 2 years | — |
| Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial 2014 · High-Ca group · Girls and boys aged 12–14 years | 600 mg | 2 years | — |
| A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial 2015 · CC group · Postmenopausal women with osteopenia | 500 mg | 1 year | — |
| A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial 2015 · Control group · Postmenopausal women with osteopenia | 500 mg | 1 year | — |
| Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis 2016 · SrR group · Women with thalassemia major-related osteoporosis | 1 g | 2 years | — |
| Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study 2015 · GH 1.0 U group · Women aged 50–70 with postmenopausal osteoporosis receiving estrogen hormone replacement | 750 mg | 3 years | — |
| Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study 2015 · GH 2.5 U group · Women aged 50–70 with postmenopausal osteoporosis receiving estrogen hormone replacement | 750 mg | 3 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group A · Postmenopausal women aged 50–65 years | 300 mg | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group B · Postmenopausal women aged 50–65 years | 600 mg | 2 years | — |
| Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial 2016 · Group C · Postmenopausal women aged 50–65 years | 900 mg | 2 years | — |
| Effects of supplementation with a calcium-rich marine-derived multi-mineral supplement and short-chain fructo-oligosaccharides on serum lipids in postmenopausal women 2016 · CaFOS · Postmenopausal women | 800 mg | 2 years | — |
| Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy 2017 · Cholecalciferol and calcium carbonate · Adults with primary hyperparathyroidism undergoing parathyroidectomy; median age 60 years, 119 women | 1 g | 1 year | — |
| Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial 2017 · Control · Postmenopausal women with osteopenia; age range not stated | 1.2 g | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · PATCH · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside hormone treatment | 1.2 g | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · PILL · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside combined oral contraceptive treatment | 1.2 g | 1 year | — |
| Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial 2019 · NONE · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation and no oestrogen or progesterone | 1.2 g | 1 year | — |
| Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women 2019 · Supplement group (S) · Overweight or obese Caucasian women 2–10 years postmenopausal, generally healthy, with dietary calcium intake of 800 mg/day or less | 630 mg | 26 weeks | — |
| Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study 2020 · Co-supplementation group · Community-dwelling men and postmenopausal women aged 50–75 years | 500 mg | 1 year | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia | 800 mg | 1096 days | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · Placebo group · Postmenopausal women with osteopenia | 800 mg | 1096 days | — |
| Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial 2021 · standard-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART | 1.2 g | 48 weeks | — |
| Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial 2021 · high-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART | 1.2 g | 48 weeks | — |
| Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia 2022 · Group A · Postmenopausal women with osteopenia | 500 mg | 1 year | — |
| Effect of soluble corn fibre and calcium supplementation on bone mineral content and bone mineral density in preadolescent Malaysian children-a double-blind randomised controlled trial (PREBONE-Kids Study) 2023 · 12-g SCF + 600-mg calcium lactate gluconate (SCF + Ca) · Healthy Malaysian children aged 9–11 years | 600 mg | 1 year | — |
| High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 · Arm 2 (placebo arm; daily supplements) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL | 1.01 g | 24 weeks | — |
| Impact of high-dose vitamin D and calcium carbonate supplementation on bone density in adolescents living with HIV: a randomised, placebo-controlled trial 2026 · intervention · Adolescents aged 11–19 years with perinatally acquired HIV, taking antiretroviral therapy | 500 mg | 48 weeks | — |
| Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study 1995 · FC (sodium monofluorophosphate and calcium) · Patients aged 50–70 years with severe osteopenia and no previous vertebral fracture | 1 g | 2 years | — |
| Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin 1993 · Calcitriol plus salmon calcitonin · Patients starting long-term corticosteroid therapy | 1 g | 1 year | — |
| Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin 1993 · Calcitriol plus placebo nasal spray · Patients starting long-term corticosteroid therapy | 1 g | 1 year | — |
| Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D 1995 · 2.5 micrograms (100 IU) vitamin D/d group · Healthy ambulatory postmenopausal women | 500 mg | 2 years | — |
| Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D 1995 · 17.5 micrograms (700 IU) vitamin D/d group · Healthy ambulatory postmenopausal women | 500 mg | 2 years | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · calcium augmentation · Healthy white women 3 to 6 years after spontaneous menopause | 1.7 g | 1059 days | — |
| Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss 1994 · estrogen-progesterone-calcium · Healthy white women 3 to 6 years after spontaneous menopause | 1.7 g | 1059 days | — |
| Heated oyster shell-seaweed calcium (AAA Ca) on osteoporosis 1996 · Group B · Elderly hospitalized women, mean age 80, with osteoporosis | 900 mg | 913 days | — |
| In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study 1996 · MFP-Ca group · Adults aged 21–65 with asthma or other respiratory diseases who had received long-term corticosteroid treatment | 1 g | 2 years | — |
| Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial 1996 · Calcium carbonate and vitamin D3 · Patients with rheumatoid arthritis; some were receiving corticosteroids and some were not | 1 g | 2 years | — |
| Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years 1997 · Oral ipriflavone · Postmenopausal women with distal forearm BMD 1 SD below the mean for normal age-matched postmenopausal subjects | 1 g | 2 years | — |
| A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss 1997 · ipriflavone group · Postmenopausal women aged 50–65 years with vertebral bone density 1 SD below the age-matched postmenopausal mean | 1 g | 2 years | — |
| Efficacy of ipriflavone in established osteoporosis and long-term safety 1997 · ipriflavone plus calcium · Women aged 65–79 with established osteoporosis and prevalent vertebral fractures | 1 g | 2 years | — |
| Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older 1997 · calcium and vitamin D group · Men and women 65 years of age or older living at home | 500 mg | 3 years | — |
| Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake 1998 · all three minerals together · Normotensive women, mean age 39, with low habitual intake of potassium, calcium, and magnesium | 30 mmol | 16 weeks | — |
| Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women 1998 · Calcium and vitamin D supplement group · Healthy postmenopausal women aged 58–67 | 1 g | 2 years | — |
| Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis 1998 · GLA + EPA treatment group · Women with senile osteoporosis, mean age 79.5, with a background diet low in calcium | 600 mg | 548 days | — |
| Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal 2018 · Calcitriol · Postmenopausal women in China aged over 55 with postmenopausal osteoporosis | 500 mg | 1 year | 108 |
| A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects 2022 · Calcium · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates | 600 mg | 26 weeks | 75 |
| Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women 2000 · calcium citrate · postmenopausal women | 500 mg | 1 day | 25 |
| Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women 2000 · calcium carbonate · postmenopausal women | 500 mg | 1 day | 25 |
| Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men 2007 · low-dose lactulose (2 g) · 24 healthy adult men | 300 mg | 1 day | 24 |
| Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men 2007 · high-dose lactulose (4 g) · 24 healthy adult men | 300 mg | 1 day | 24 |
| Acute effect of poly-gamma-glutamic acid on calcium absorption in post-menopausal women 2007 · PGA condition · Healthy, non-smoking postmenopausal women; mean age 56.4 years | 200 mg | 1 day | 24 |
| Partial resistance of low density lipoprotein to oxidation in vivo after increased intake of berries 2000 · control group · Healthy 60-year-old men | 500 mg | 8 weeks | 20 |
| Effect of calcium carbonate particle size on calcium absorption and retention in adolescent girls 2011 · large-particle CaCO3 · Adolescent girls aged 11 to 14 years; n=19 | 600 mg | 3 weeks | 19 |
| Effect of calcium carbonate particle size on calcium absorption and retention in adolescent girls 2011 · small-particle CaCO3 in large-versus-small comparison · Adolescent girls aged 11 to 14 years; n=19 | 600 mg | 3 weeks | 19 |
| High bioavailability of calcium in fortified Horlicks 2001 · Calcium carbonate-fortified Horlicks · Pre-menopausal women aged 23–40 years, habituated to a high-calcium diet | 500 mg | 1 day | 16 |
| Effect of calcium carbonate particle size on calcium absorption and retention in adolescent girls 2011 · small-particle CaCO3 in small-particle-versus-placebo comparison · Adolescent girls aged 11 to 14 years; n=12 | 600 mg | 3 weeks | 12 |
| Comparison of calcium retention measured using a radionuclide method after administration of 1000 mg elemental calcium in two different galenic forms, in one or two doses 1996 · treatment A2 (two Orocal 500 mg tablets in a single dose) · adult volunteers; no condition stated | 500 mg | 1 day | 8 |
| Calcium fortification of breakfast cereal enhances calcium absorption in children without affecting iron absorption 2001 · Fortified-calcium cereal group · Children aged 6–9 years | 312 mg | 2 weeks | — |
| Calcium fortification of breakfast cereal enhances calcium absorption in children without affecting iron absorption 2001 · Low-calcium cereal group · Children aged 6–9 years | 78 mg | 2 weeks | — |
| Calcium fortification systems differ in bioavailability 2005 · calcium citrate malate · Healthy premenopausal women | 500 mg | 1 day | — |
| Calcium fortification systems differ in bioavailability 2005 · tricalcium phosphate/calcium lactate · Healthy premenopausal women | 500 mg | 1 day | — |
| Treatment of vitamin D deficiency in Chinese inflammatory bowel disease patients: A prospective, randomized, open-label, pilot study 2018 · arm B · Chinese adults with ulcerative colitis or Crohn's disease and vitamin D insufficiency or deficiency | 600 mg | 1 year | — |
| Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D 1998 · Placebo group · Postmenopausal women | 500 mg | 1 year | — |
| [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial] 2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported | 1.2 g | 1 year | 125 |
| Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial 2018 · VITD3 group · Youth aged 16–24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy for at least 180 days | 162 mg | 48 weeks | 109 |
| Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year 2018 · intervention · Chinese postmenopausal women in Malaysia; mean age 59 years | 1.2 g | 1 year | 61 |
| Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study 2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding | 500 mg | 26 weeks | 31 |
| The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study 2016 · intervention group · Women and similarly aged men with BMI >38 kg/m² after Roux-en-Y gastric bypass or sleeve gastrectomy; median age 40.7 years | 1 g | 2 years | — |
| Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial 2017 · RCE · Postmenopausal women with osteopenia; age range not stated | 1.2 g | 1 year | — |
| High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 · Arm 1 (high-dose vitamin D) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL | 1.01 g | 24 weeks | — |
| Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals 1994 · calcium plus trace minerals · Healthy postmenopausal women, mean age 66 years | 1 g | 2 years | — |
| Discrepant influence of vitamin D status on parathyroid hormone and bone mass after two years of calcium supplementation 2010 · elemental calcium group · Healthy postmenopausal women aged 60–97 years without osteoporosis | 500 mg | 2 years | 175 |
| Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate 2001 · alendronate group · Postmenopausal women with osteoporosis | 500 mg | 3 years | 134 |
| The effects of Acanthopanax senticosus extract on bone turnover and bone mineral density in Korean postmenopausal women 2009 · control group · Postmenopausal women younger than 65 years with osteopenia or osteoporosis | 500 mg | 26 weeks | 40 |
| Consumption of calcium-fortified cereal bars to improve dietary calcium intake of healthy women: randomized controlled feasibility study 2015 · Cereal-bar intervention (received by Group I and Group II during their respective intervention periods) · Healthy women aged 21–58 years; eligible participants were women aged 18 years and older. | 400 mg | 3 weeks | 35 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · low VitD control group · Postmenopausal women with osteoporosis and serum 25(OH)D <10 ng/mL | 600 mg | 26 weeks | 35 |
| Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study 2015 · CFB-2 (group C) · Men and women aged 40–60 years, clinically healthy, with elevated cardiovascular risk markers | 56 mg | 30 days | 26 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · high VitD control group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥10 ng/mL | 600 mg | 26 weeks | 26 |
| No influence of supplemental dietary calcium intake on the bioavailability of spinach carotenoids in humans 2017 · 500 mg calcium meal · Healthy, non-obese men aged 20–46 years | 500 mg | 1 day | 25 |
| Calcium supplementation during lactation blunts erythrocyte lead levels and delta-aminolevulinic acid dehydratase zinc-reactivation in women non-exposed to lead and with marginal calcium intakes 2002 · calcium-supplemented group · Women with habitually low calcium intake and low lead exposure, receiving supplementation during lactation after pregnancy | 500 mg | 6 weeks | 22 |
| Calcium absorption in postmenopausal Chinese women: a randomized crossover intervention study 2007 · 500 mg Ca/d · Healthy postmenopausal Chinese women aged 49–64 years | 500 mg | 5 weeks | 21 |
| [Effect of hormone replacement therapy on hemorheology in postmenopausal women] 2001 · Group A · Healthy postmenopausal women | 600 mg | 26 weeks | 20 |
| [Effect of hormone replacement therapy on hemorheology in postmenopausal women] 2001 · Group B · Healthy postmenopausal women | 600 mg | 26 weeks | 20 |
| Effect of low- and high-calcium dairy-based diets on macronutrient oxidation in humans 2005 · low-dairy (LD) diet · 19 adult men and women; no specific condition stated | 500 mg | 7 days | 19 |
| Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared 1997 · calcium carbonate · postmenopausal women with a lumbar spine T score of at least -1 | 500 mg | 12 weeks | 18 |
| The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake 2002 · calcium supplementation group · Patients with asymptomatic primary hyperparathyroidism and daily calcium intake below 450 mg; age and sex not specified | 500 mg | 1 year | 17 |
| Short-term changes in calcium but not protein intake alter the rate of bone resorption in healthy subjects as assessed by urinary pyridinium cross-link excretion 1995 · low nitrogen and low calcium diet · 15 young healthy adults, 7 males and 8 females | 429 mg | 5 days | 15 |
| Effects of high compared with low calcium intake on calcium absorption and incorporation of iron by red blood cells in small children 1999 · low-calcium diet · Preschool children aged 3–5 years | 502 mg | 5 weeks | 11 |
| Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial 2015 · calcium citrate fasting · Women, mean age 69 years; no specific condition reported | 500 mg | 1 day | 10 |
| Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial 2015 · calcium citrate with a meal · Women, mean age 69 years; no specific condition reported | 500 mg | 1 day | 10 |
| Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial 2015 · calcium-fortified juice · Women, mean age 69 years; no specific condition reported | 500 mg | 1 day | 10 |
| Efficacy of two calcium phosphate pastes on the remineralization of artificial caries: a randomized controlled double-blind in situ study 2013 · Tooth Mousse Plus (CPP–ACPF) · Healthy adults, 19 ± 7 years; eight females and one male, without clinically active caries or other oral pathology | 500 mg | 2 weeks | 9 |
| Efficacy of two calcium phosphate pastes on the remineralization of artificial caries: a randomized controlled double-blind in situ study 2013 · Clinpro Tooth Crème · Healthy adults, 19 ± 7 years; eight females and one male, without clinically active caries or other oral pathology | 500 mg | 2 weeks | 9 |
| Postprandial parathyroid hormone response to four calcium-rich foodstuffs 1997 · Emmental cheese session · Nine female volunteers | 400 mg | 1 day | 9 |
| Postprandial parathyroid hormone response to four calcium-rich foodstuffs 1997 · Milk session · Nine female volunteers | 400 mg | 1 day | 9 |
| Postprandial parathyroid hormone response to four calcium-rich foodstuffs 1997 · Sesame seeds session · Nine female volunteers | 400 mg | 1 day | 9 |
| Postprandial parathyroid hormone response to four calcium-rich foodstuffs 1997 · Spinach session · Nine female volunteers | 400 mg | 1 day | 9 |
| Postprandial parathyroid hormone response to four calcium-rich foodstuffs 1997 · Calcium salt session · Nine female volunteers | 400 mg | 1 day | 9 |
| [Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3] 1995 · placebo group · Postmenopausal women with osteoporosis | 500 mg | 26 weeks | 8 |
| Calcium bioavailability from a fortified cereal-legume snack (laddoo) 2011 · Group A · Children aged 8–12 years with low habitual dietary calcium intake | 500 mg | 1 day | 8 |
| Calcium bioavailability from a fortified cereal-legume snack (laddoo) 2011 · Group C · Children aged 8–12 years with low habitual dietary calcium intake | 500 mg | 1 day | 8 |
| Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study 2001 · calcium supplementation · Five patients with previous renal stone disease (stone formers); age and sex not stated | 500 mg | 10 weeks | 5 |
| Calcium absorption in postmenopausal osteoporosis: benefit of HRT plus calcitriol, but not HRT alone, in both malabsorbers and normal absorbers 2000 · HRT alone · Postmenopausal women with osteoporosis and vertebral compression fractures; age not reported | 600 mg | 243 days | — |
| A five way crossover human volunteer study to compare the pharmacokinetics of paracetamol following oral administration of two commercially available paracetamol tablets and three development tablets containing paracetamol in combination with sodium bicarbonate or calcium carbonate 2000 · Paracetamol 500 mg with calcium carbonate 375 mg · Human volunteers; age, sex and health condition not stated | 375 mg | 1 day | — |
| Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels 2002 · calcium group · postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL | 500 mg | 90 days | — |
| Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial 2003 · moderate-impact exercise with calcium · Girls aged 8.8 ± 0.1 years, pre- and early-pubertal | 434 mg | 258 days | — |
| Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial 2003 · low-impact exercise with calcium · Girls aged 8.8 ± 0.1 years, pre- and early-pubertal | 434 mg | 258 days | — |
| Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women 2004 · Normal calcium, weight-loss group · Overweight postmenopausal women aged 52–75 years assigned to weight loss and normal calcium intake | 400 mg | 6 weeks | — |
| Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women 2004 · Normal calcium, weight-maintenance group · Overweight postmenopausal women aged 52–75 years assigned to weight maintenance and normal calcium intake | 400 mg | 6 weeks | — |
| Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial 2004 · ossein-hydroxyapatite (OHC) · Postmenopausal osteopenic women with low calcium intake | 500 mg | 1 year | — |
| Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial 2004 · tricalcium phosphate (TCP) · Postmenopausal osteopenic women with low calcium intake | 500 mg | 26 weeks | — |
| Effect of habitual dietary calcium intake on calcium supplementation in 12-14-y-old girls 2004 · Subgroup A, calcium supplementation · Girls aged 12–14 years with habitual calcium intake of 1000–1307 mg/day | 500 mg | 1 year | — |
| Effect of habitual dietary calcium intake on calcium supplementation in 12-14-y-old girls 2004 · Subgroup B, calcium supplementation · Girls aged 12–14 years with habitual calcium intake below 713 mg/day | 500 mg | 1 year | — |
| Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake 2005 · High-calcium mineral water · Postmenopausal women with dietary calcium intake below 700 mg/day; mean age 70.1 years | 596 mg | 26 weeks | — |
| Long-term calcium supplementation does not affect the iron status of 12-14-y-old girls 2005 · calcium group · Adolescent girls aged 13.2 ± 0.4 years at enrollment | 500 mg | 1 year | — |
| Comparing the effect of short term post meals and bedtime calcium supplementation on the C-terminal telopeptide crosslinks and PTH levels in postmenopausal osteopenic women 2005 · Bedtime calcium supplementation · Postmenopausal women with osteopenia; mean age 63.9 years | 334 mg | 2 weeks | — |
| Exercise and calcium combined results in a greater osteogenic effect than either factor alone: a blinded randomized placebo-controlled trial in boys 2007 · Ex+Ca · Pre- and early-pubertal boys | 392 mg | 37 weeks | — |
| Exercise and calcium combined results in a greater osteogenic effect than either factor alone: a blinded randomized placebo-controlled trial in boys 2007 · No-Ex+Ca · Pre- and early-pubertal boys | 392 mg | 37 weeks | — |
| Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine 1992 · Group I · Postmenopausal women with osteoporosis and at least one vertebral crush fracture | 500 mg | 3 years | — |
| Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine 1992 · Group III · Postmenopausal women with osteoporosis and at least one vertebral crush fracture | 500 mg | 3 years | — |
| Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure 2008 · Ca group · Ambulatory men with congestive heart failure, low vitamin D status, and insufficient dietary calcium intake | 500 mg | 270 days | — |
| Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women 2008 · calcium citrate · Healthy postmenopausal women | 500 mg | 1 day | — |
| Effects of calcium-fortified ice cream on markers of bone health 2011 · 96 mg calcium group · Premenopausal women aged 20–39 years with calcium intake below 750 mg/day | 96 mg | 4 weeks | — |
| Effects of calcium-fortified ice cream on markers of bone health 2011 · 459 mg calcium group · Premenopausal women aged 20–39 years with calcium intake below 750 mg/day | 459 mg | 4 weeks | — |
| Superior calcium bioavailability of effervescent potassium calcium citrate over tablet formulation of calcium citrate after Roux-en-Y gastric bypass 2013 · Citracal Petite · Patients who had undergone Roux-en-Y gastric bypass; age and sex not reported | 400 mg | 1 day | — |
| [Effect of added dietary calcium on human esophageal precancerous lesion in the high risk area for esophageal cancer--a randomized double blind intervention trial] 1990 · calcium supplementation group · People aged 25–75 with esophageal basal cell hyperplasia or dysplasia in a high-risk area for esophageal cancer | 600 mg | 30 weeks | — |
| Effect of soy isoflavone supplementation on vascular endothelial function and oxidative stress in postmenopausal women: a community randomized controlled trial 2013 · control group · Indonesian postmenopausal women aged 47 to 60 years | 500 mg | 1 year | — |
| Effect of soy isoflavone supplementation on endothelial dysfunction and oxidative stress in equol-producing postmenopausal women 2015 · Control group · Postmenopausal Indonesian women aged 47–60 years, stratified by equol-producer status | 500 mg | 26 weeks | — |
| Effects of Hydration and Calcium Supplementation on Urine Calcium Concentration in Healthy Postmenopausal Women 2015 · calcium supplementation · White postmenopausal women aged 40–70 years in good general health | 500 mg | 1 year | — |
| Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial 2023 · calcium group · Chinese adults with prediabetes | 500 mg | 24 weeks | — |
| Effects of calcium supplementation on changes in the IL2, IL4, IL6, IL10 axes and oxidative stress in pregnant women at risk for pre-eclampsia 2024 · Calcium group 500 mg/day · Pregnant women over 18 years with gestational hypertension, overweight or obesity, low socioeconomic status, low dietary calcium intake, and at least 20 weeks’ gestation | 500 mg | 6 weeks | — |
| Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis 1994 · placebo/placebo · Postmenopausal women with vertebral compression fractures | 500 mg | 104 weeks | — |
| Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis 1994 · placebo/etidronate · Postmenopausal women with vertebral compression fractures | 500 mg | 104 weeks | — |
| Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations 1993 · tablets · Healthy Caucasian men aged 25–38 years | 300 mg | 1 day | — |
| Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations 1993 · powder for oral use · Healthy Caucasian men aged 25–38 years | 300 mg | 1 day | — |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · CaMEWS calcium only group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 1.5 g | 1 year | 155 |
| Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients 2014 · strontium ranelate 2 g daily · Men and postmenopausal women aged 50 years or older with primary osteoporosis and serum 25(OH)D >22.5 nmol/l | 1 g | 26 weeks | 105 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Randomized trial, denosumab group · Infertile men; mean age approximately 34 years | 400 mg | 160 days | 49 |
| Postprandial metabolic responses to milk enriched with milk calcium are different from responses to milk enriched with calcium carbonate 2003 · SMP + milk calcium · Men and women over 55 years of age | 1.2 g | 1 day | 45 |
| Postprandial metabolic responses to milk enriched with milk calcium are different from responses to milk enriched with calcium carbonate 2003 · SMP + CaCO3 · Men and women over 55 years of age | 1.2 g | 1 day | 45 |
| Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving 2009 · Vitamin D- and calcium-fortified bun · Older nursing home residents; sex and age range not reported; vitamin D-deficient | 320 mg | 1 year | 45 |
| Meals and dephytinization affect calcium and zinc absorption in Nigerian children with rickets 2009 · Calcium and ergocalciferol supplementation · Nigerian children aged 2–10 years, including children with rickets and age-matched controls | 600 mg | 7 weeks | 34 |
| Dietary protein and calcium interact to influence calcium retention: a controlled feeding study 2009 · low calcium, low protein · Healthy postmenopausal women | 675 mg | 7 weeks | 27 |
| Dietary protein and calcium interact to influence calcium retention: a controlled feeding study 2009 · low calcium, high protein · Healthy postmenopausal women | 675 mg | 7 weeks | 27 |
| Dietary protein and calcium interact to influence calcium retention: a controlled feeding study 2009 · high calcium, low protein · Healthy postmenopausal women | 1.51 g | 7 weeks | 27 |
| Dietary protein and calcium interact to influence calcium retention: a controlled feeding study 2009 · high calcium, high protein · Healthy postmenopausal women | 1.51 g | 7 weeks | 27 |
| Comparison of calcium retention measured using a radionuclide method after administration of 1000 mg elemental calcium in two different galenic forms, in one or two doses 1996 · treatment A1 (Orocal 500 mg) · adult volunteers; no condition stated | 1 g | 1 day | 22 |
| Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites 2012 · calcium · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months | 2 g | 26 weeks | 21 |
| Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass 2009 · calcium citrate phase · Adults aged 30–61 years who had undergone Roux-en-Y gastric bypass approximately 1 year earlier; 17 women and 1 man | 500 mg | 1 day | 18 |
| Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass 2009 · calcium carbonate phase · Adults aged 30–61 years who had undergone Roux-en-Y gastric bypass approximately 1 year earlier; 17 women and 1 man | 500 mg | 1 day | 18 |
| Absorbability of the calcium in a high-calcium mineral water 1994 · Sangemini water · Healthy women; age range and sex details beyond women are not reported | 2.5 mmol | 1 day | 18 |
| The Impact of Acute Calcium Intake on Bone Turnover Markers during a Training Day in Elite Male Rowers 2023 · CAL (high calcium) · Elite male rowers aged 20.7–32.4 years preparing for potential Olympic representation | 2 g | 1 day | 16 |
| Comparison of calcium retention measured using a radionuclide method after administration of 1000 mg elemental calcium in two different galenic forms, in one or two doses 1996 · treatment B (Cacit 1000) · adult volunteers; no condition stated | 1 g | 1 day | 14 |
| Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women 2006 · 125 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years | 500 mg | 90 days | 13 |
| Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women 2006 · 250 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years | 500 mg | 90 days | 12 |
| Calcium absorption in Australian osteopenic post-menopausal women: an acute comparative study of fortified soymilk to cows' milk 2010 · fortified soymilk · Osteopenic post-menopausal women; mean age 56.7 years | 44 mg | 1 day | 12 |
| Evaluation of an inexpensive calcium absorption index in healthy older men and women 2010 · Placebo group · Healthy men and postmenopausal women aged 50 years or older | 15 mmol | 10 days | 11 |
| Dietary calcium impairs tomato lycopene bioavailability in healthy humans 2016 · Test meal with tomato paste plus calcium carbonate · Healthy adults | 500 mg | 1 day | 10 |
| Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations 1994 · MFP-Ca · Adults aged 35–80 years without gastrointestinal disorders, renal impairment, liver disease, or prior fluoride intake | 26.4 mg | 3 days | 10 |
| Short-term high dietary calcium intake during bedrest has no effect on markers of bone turnover in healthy men 2010 · Study A: 1000 mg/d calcium intake · Healthy men, ages 23.6 ± 3.0 years, undergoing bedrest and ambulatory control conditions | 1 g | 2 weeks | 9 |
| Postprandial effects of calcium phosphate supplementation on plasma concentration-double-blind, placebo-controlled cross-over human study 2013 · CaP supplementation · Men aged 20–35 years in good physical health | 1 g | 3 weeks | 9 |
| Short-term high dietary calcium intake during bedrest has no effect on markers of bone turnover in healthy men 2010 · Study B: 2000 mg/d high calcium intake · Healthy men, ages 25.5 ± 2.9 years, undergoing bedrest and ambulatory control conditions | 2 g | 6 days | 8 |
| Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women 2005 · calcium citrate · postmenopausal women | 800 mg | 2 weeks | — |
| Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults 2006 · control group · Healthy university students aged 18–27 years, male and female | 1.5 g | 8 weeks | — |
| Effects of two marine dietary supplements with high calcium content on calcium metabolism and biochemical marker of bone resorption 2008 · Phoscalim (fishbone powder) · 20 male volunteers; age and health condition not stated | 836 mg | 1 day | — |
| Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States 2009 · 2,000 mg elemental calcium daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months | 2 g | 26 weeks | — |
| Long-term effects of dietary calcium on risk markers for colon cancer in patients with familial polyposis 1990 · group B · Patients with familial polyposis after subtotal colectomy | 1.2 g | 270 days | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · Ca · Children aged approximately 8 years | 700 mg | 12 weeks | — |
| Obstetric and neonatal outcomes of maternal vitamin D supplementation: results of an open-label, randomized controlled trial of antenatal vitamin D supplementation in Pakistani women 2014 · Group A (routine care) · Pregnant women in Karachi, Pakistan; age range and vitamin D status not specified | 600 mg | — | — |
| Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women 2014 · calcium citrate · Postmenopausal women, mean age 71 years | 1 g | 90 days | — |
| Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women 2014 · calcium carbonate · Postmenopausal women, mean age 71 years | 1 g | 90 days | — |
| Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women 2015 · calcium group · post-menopausal women | 1 g | 90 days | — |
| Intestinal calcium absorption of women during lactation and after weaning 1996 · calcium-supplemented group · Postpartum women, including lactating and nonlactating women; ages and health conditions not reported | 1 g | — | — |
| Iron status, menarche, and calcium supplementation in adolescent girls 1998 · calcium treatment · Girls aged about 10.8 years who were premenarcheal at baseline | 1 g | 4 years | — |
| Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure 2002 · low-dose regimen · Men with preterminal chronic renal failure and mean creatinine clearance of approximately 30 ml/min | 507 mg | 24 weeks | — |
| Effect of calcium supplementation on blood lead levels in pregnancy: a randomized placebo-controlled trial 2009 · calcium · Pregnant women recruited from prenatal clinics in Mexico City, with enrollment during the first trimester; low- to moderate-income population. | 1.2 g | 26 weeks | 334 |
| The joint effect of energy reduction with calcium supplementation on the risk factors of type 2 diabetes in the overweight population: a two-year randomized controlled trial 2021 · energy-reduction with calcium supplementation group (ER-CSG) · Overweight adults aged 20–70 with low dietary calcium intake and no major disease; received dietary energy-reduction education as well as supplements | 400 mg | 2 years | 300 |
| The joint effect of energy reduction with calcium supplementation on the risk factors of type 2 diabetes in the overweight population: a two-year randomized controlled trial 2021 · calcium supplementation group (CSG) · Overweight adults aged 20–70 with low dietary calcium intake and no major disease | 400 mg | 2 years | 298 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group C · Patients after total thyroidectomy | 1.5 g | — | 202 |
| Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation 2015 · teriparatide group · Japanese men and postmenopausal women aged 55 years or older with osteoporosis at high risk of fracture | 610 mg | 2 years | 137 |
| Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial 2002 · calcium group · Postmenopausal women, mean age 72 years, not receiving therapy for hyperlipidemia or osteoporosis | 1 g | 1 year | 111 |
| Impact of increasing calcium in the diet on nutrient consumption, plasma lipids, and lipoproteins in humans 1994 · 1000-mg/d calcium supplement · Hypertensive and normotensive participants; age and sex not reported | 1 g | 12 weeks | 109 |
| Effect of calcium supplementation on bone mineral accretion in gambian children accustomed to a low-calcium diet 2000 · calcium supplement · Rural Gambian children aged 8.3–11.9 years, boys and girls, accustomed to a low-calcium diet | 1 g | 1 year | 80 |
| Acute C-Terminal Crosslinking Telopeptide of Type I Collagen (CTX-1) Suppression with Milk Calcium or Calcium Carbonate Is Independent of Visceral Fat in a Randomized Crossover Study in Lean and Overweight Postmenopausal Women 2022 · milk (1000 mg calcium) · Postmenopausal women aged 53–79 years, lean and overweight | 1 g | 1 day | 77 |
| Acute C-Terminal Crosslinking Telopeptide of Type I Collagen (CTX-1) Suppression with Milk Calcium or Calcium Carbonate Is Independent of Visceral Fat in a Randomized Crossover Study in Lean and Overweight Postmenopausal Women 2022 · calcium carbonate tablet (1000 mg calcium) · Postmenopausal women aged 53–79 years, lean and overweight | 1 g | 1 day | 77 |
| Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study 2013 · D− group · Adults with primary hyperparathyroidism after parathyroidectomy | 1 g | 1 year | 75 |
| Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation 2015 · placebo group · Japanese men and postmenopausal women aged 55 years or older with osteoporosis at high risk of fracture | 610 mg | 2 years | 70 |
| Circulating insulin-like growth factor-related biomarkers: Correlates and responses to calcium supplementation in colorectal adenoma patients 2017 · 1.0 g elemental calcium supplementation group · Adults aged 30–74 with a history of a pathology-confirmed colorectal adenomatous polyp within the previous 5 years | 1 g | 26 weeks | 64 |
| Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial 1995 · 1.0 g calcium group · Patients with sporadic adenomas | 1 g | 26 weeks | 64 |
| Circulating insulin-like growth factor-related biomarkers: Correlates and responses to calcium supplementation in colorectal adenoma patients 2017 · 2.0 g elemental calcium supplementation group · Adults aged 30–74 with a history of a pathology-confirmed colorectal adenomatous polyp within the previous 5 years | 2 g | 26 weeks | 63 |
| Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial 1995 · 2.0 g calcium group · Patients with sporadic adenomas | 2 g | 26 weeks | 63 |
| Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake 1998 · calcium carbonate · Postmenopausal women, mean age 64 ± 5 years | 1.2 g | 60 days | 60 |
| Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method 2005 · CaCO(3) · Healthy younger women and older women and men; median ages 30 and 66, respectively | 1.2 g | 4 weeks | 53 |
| Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method 2005 · Milk · Healthy younger women and older women and men; median ages 30 and 66, respectively | 1.2 g | 4 weeks | 53 |
| Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial 2017 · intensive group · Adults receiving maintenance hemodialysis and already receiving calcium carbonate as a phosphate binder | 1.8 g | 26 weeks | 53 |
| Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients 2000 · calcium carbonate · Adults with end-stage renal disease receiving hemodialysis | 6.2 g | 4 weeks | 51 |
| Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial 2017 · liberalized group · Adults receiving maintenance hemodialysis and already receiving calcium carbonate as a phosphate binder | 10.9 mcg | 26 weeks | 51 |
| Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients 2000 · calcium acetate · Adults with end-stage renal disease receiving hemodialysis | 5.6 g | 4 weeks | 50 |
| The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study 2024 · Intervention group · Adults aged 58–71 with type 2 diabetes and osteoporosis | 600 mg | 26 weeks | 50 |
| The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study 2024 · Control group · Adults aged 59–72 with type 2 diabetes and osteoporosis | 600 mg | 26 weeks | 49 |
| The effect of calcium supplementation on bone calcium balance and calcium and bone metabolism during load carriage in women: a randomized controlled crossover trial 2025 · Calcium · Women, average age 29 years; military personnel and civilians | 1 g | 1 day | 48 |
| Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report 2010 · GTP group · Postmenopausal women with osteopenia; at least 2 years after menopause | 500 mg | 24 weeks | 47 |
| Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study 2017 · CC group · Adults aged over 20 and under 65 with diabetic nephropathy, maintenance hemodialysis, and adynamic bone disease | 1.13 g | 1 year | 46 |
| An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate 2002 · calcium carbonate · Adults with end-stage renal disease receiving haemodialysis; 23 women and 22 men in the study sample, average age 52.5 years | 3 g | 4 weeks | 45 |
| Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report 2010 · Placebo + TC group · Postmenopausal women with osteopenia; at least 2 years after menopause | 500 mg | 24 weeks | 42 |
| Alfacalcidol (alpha D3) and calcium in osteoporosis 1994 · control group · Postmenopausal women with osteoporosis; mean age 67 years | 1 g | 3 years | 42 |
| Calcium supplementation lowers serum parathyroid hormone levels in elderly subjects 1990 · calcium supplementation · Healthy elderly volunteers at risk for developing senile osteoporosis | 1 g | 4 weeks | 40 |
| Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report 2010 · GTP + TC group · Postmenopausal women with osteopenia; at least 2 years after menopause | 500 mg | 24 weeks | 38 |
| Calcium supplements interact significantly with long-term diet while suppressing rectal epithelial proliferation of adenoma patients 2001 · calcium supplementation · Adenoma patients without a family history of colorectal neoplasia | 3.75 g | 1 year | 33 |
| The effects of a calcium-rich pre-exercise meal on biomarkers of calcium homeostasis in competitive female cyclists: a randomised crossover trial 2015 · calcium-rich meal (CAL) · Competitive female cyclists aged 17–32 years, without a stated calcium-homeostasis condition; vitamin D deficient participants were excluded. | 1.35 g | 1 day | 32 |
| Calcium supplements and bone resorption in pregnancy: a randomized crossover trial 2003 · calcium supplement · 31 pregnant Mexican women at 25–35 weeks gestation | 1.2 g | 10 days | 31 |
| [Effect of dietary calcium vs calcium citrate on conventional biochemical markers in perimenopausal women] 2005 · third group · Women aged 30 to 35 years; some were osteopenic | 1.1 g | 30 weeks | 31 |
| Faecal steroid excretion in humans is affected by calcium supplementation and shows gender-specific differences 2009 · calcium supplemented bread · healthy adult volunteers; sex not specified | 1 g | 4 weeks | 31 |
| Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation 2001 · calcium-supplemented group · Obese women undergoing a low-calorie diet; age and sex beyond women not specified | 1 g | 90 days | 30 |
| Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen 2002 · Group B · Postmenopausal women more than 10 years postmenopausal with vertebral or femoral osteoporosis; mean age 65.1 years | 1.88 g | 90 days | 30 |
| Hypocalcemia in healthy young girls in Tehran 2006 · Calcium supplementation · Healthy girls aged 11–15 years with low or normal serum calcium and raised alkaline phosphatase | 2 g | 20 days | 29 |
| Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women 2000 · calcium carbonate supplement alone · Thai postmenopausal women with osteoporosis, more than 10 years postmenopausal | 750 mg | 90 days | 28 |
| [Effect of dietary calcium vs calcium citrate on conventional biochemical markers in perimenopausal women] 2005 · second group · Women aged 30 to 35 years; some were osteopenic | 1 g | 30 weeks | 28 |
| Short-term calcium supplementation has no effect on biochemical markers of bone remodeling in early postmenopausal women 2004 · calcium supplementation · early postmenopausal women | 1 g | 6 weeks | 27 |
| Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients 2016 · Calcium carbonate · Adults aged 45 years or older with end-stage renal disease, hyperphosphatemia and receiving maintenance hemodialysis | 1.5 g | 48 weeks | 27 |
| Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen 2002 · Group A · Postmenopausal women more than 10 years postmenopausal with vertebral or femoral osteoporosis; mean age 66.3 years | 1.88 g | 90 days | 26 |
| Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan 2005 · group B · Hemodialysis patients in Japan with hyperphosphatemia | 3 g | 4 weeks | 26 |
| Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products 2009 · calcium-supplemented group (SG) · Post-menopausal women | 1.2 g | 150 days | 26 |
| Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2015 · Group A · Overweight, vitamin D-deficient women aged 18–40 years with PCOS | 1 g | 8 weeks | 26 |
| Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial 2008 · CaCO3 group · Adults with end-stage renal disease on maintenance hemodialysis; age range not specified | 2.84 g | 26 weeks | 25 |
| No influence of supplemental dietary calcium intake on the bioavailability of spinach carotenoids in humans 2017 · 1000 mg calcium meal · Healthy, non-obese men aged 20–46 years | 1 g | 1 day | 25 |
| [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients] 2011 · Group III · Adults aged 29–84 with end-stage renal disease, hyperphosphatemia and decreased serum calcium receiving hemodialysis | 6 g | 12 weeks | 24 |
| Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial 2009 · 2.0 g elemental calcium supplementation · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months | 2 g | 26 weeks | 23 |
| Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial 2009 · calcium supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months | 2 g | 26 weeks | 23 |
| Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients 2010 · 2.0 g elemental calcium supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months | 2 g | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients 2011 · calcium group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months | 2 g | 180 days | 23 |
| Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial 2011 · 2.0 g elemental calcium group · Adults aged 30–75 with a history of sporadic colorectal adenoma | 2 g | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients 2012 · 2.0 g elemental calcium supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months | 2 g | 26 weeks | 23 |
| Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial 2015 · calcium group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes | 2 g | 26 weeks | 23 |
| Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption 2003 · TCP drink · Healthy postmenopausal women | 1.2 g | 1 day | 21 |
| Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study 2003 · CaCO3 alone · Dialysis patients with moderate hyperparathyroidism; age and sex not reported | 4.8 g | 150 days | 21 |
| Calcium absorption in postmenopausal Chinese women: a randomized crossover intervention study 2007 · 1000 mg Ca/d · Healthy postmenopausal Chinese women aged 49–64 years | 1 g | 5 weeks | 21 |
| Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan 2005 · group C · Hemodialysis patients in Japan with hyperphosphatemia | 3 g | 4 weeks | 20 |
| Acute calcium ingestion attenuates exercise-induced disruption of calcium homeostasis 2011 · Calcium before exercise · Healthy adult male road cyclists and triathletes | 1 g | 1 day | 20 |
| Consequences of a high phosphorus intake on mineral metabolism and bone remodeling in dependence of calcium intake in healthy subjects - a randomized placebo-controlled human intervention study 2016 · P1000/Ca500 · Healthy omnivorous adults aged 18–60 years, men and women | 500 mg | 8 weeks | 20 |
| Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial 2021 · calcium carbonate group · Adults older than 18 with pre-dialysis CKD, eGFR below 60 mL/min/1.73 m², and hyperphosphatemia | 1.5 g | 24 weeks | 20 |
| Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D 1996 · three tablets containing 1000 mg CaCO3/d · Healthy women aged 28–59 years | 1 g | 3 days | 20 |
| Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis 1999 · placebo plus calcium · Postmenopausal women aged 50–75 with symptomatic osteoporosis | 800 mg | 2 years | 19 |
| Effect of low- and high-calcium dairy-based diets on macronutrient oxidation in humans 2005 · high-dairy (HD) diet · 19 adult men and women; no specific condition stated | 1.4 g | 7 days | 19 |
| Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women 2006 · low dose · women in natural postmenopause | 1 mg | 26 weeks | 18 |
| Application of Molecular Hydrogen as an Antioxidant in Responses to Ventilatory and Ergogenic Adjustments during Incremental Exercise in Humans 2021 · H2-rich calcium powder (HCP) · Healthy males, mean age 21 years, without cardiac, ventilatory, gas-exchange, or musculoskeletal disorders | 375 mg | 3 days | 18 |
| The effect of short-term calcium supplementation on biochemical markers of bone metabolism in healthy young adults 1998 · Self-selected diet with a 20 mmol/d Ca supplement · Healthy young adults aged 21–26 years | 20 mmol | 2 weeks | 18 |
| [Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis] 1999 · Omeprazole period with ongoing calcium carbonate · Adults with stable chronic hemodialysis and hyperphosphatemia | 9.4 g | 60 days | 16 |
| Schedule of taking calcium supplement and the risk of nephrolithiasis 2004 · Group A · Healthy men, mean age 22.7 years, with normal renal function and no history of renal stones | 3 g | 7 days | 16 |
| Schedule of taking calcium supplement and the risk of nephrolithiasis 2004 · Group B · Healthy men, mean age 22.7 years, with normal renal function and no history of renal stones | 3 g | 7 days | 16 |
| Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin 1990 · Calcium carbonate antacid · 32 subjects; age, sex, and health status not specified | 5 mL | 1 day | 16 |
| Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients 2018 · Calcium (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women | 1.2 g | 1 year | 16 |
| Calcium affects biomarkers of colon carcinogenesis after right hemicolectomy 2002 · calcium period · right hemicolectomy patients; age and sex not reported | 1 g | 60 days | 15 |
| Insulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with Type 2 diabetes 2009 · calcium supplementation group · Patients with Type 2 diabetes and hypertension | 1.5 g | 8 weeks | 15 |
| Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist 2019 · Fasted state with coadministration of calcium carbonate (study 2) · Healthy subjects | 4 g | 1 day | 15 |
| Short-term changes in calcium but not protein intake alter the rate of bone resorption in healthy subjects as assessed by urinary pyridinium cross-link excretion 1995 · low nitrogen and high calcium diet · 15 young healthy adults, 7 males and 8 females | 1.64 g | 5 days | 15 |
| Short-term changes in calcium but not protein intake alter the rate of bone resorption in healthy subjects as assessed by urinary pyridinium cross-link excretion 1995 · high nitrogen and high calcium diet · 15 young healthy adults, 7 males and 8 females | 1.59 g | 5 days | 15 |
| Complementary medical treatment for Colles' fracture: a comparative, randomized, longitudinal study 1997 · SCT+Ca group · Women aged 68.6 ± 5.7 years with Colles' fracture | 1.2 g | 1 year | 15 |
| Calcium supplementation suppresses bone turnover during weight reduction in postmenopausal women 1998 · calcium supplementation · Obese postmenopausal women; mean age 60.9 years | 1 g | 26 weeks | 15 |
| Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis 1999 · hormone analogue plus calcium · Postmenopausal women aged 52–68 with symptomatic osteoporosis | 800 mg | 2 years | 14 |
| [A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis] 2000 · Group 1 · Adults with chronic renal failure awaiting dialysis; mean creatinine clearance 21 ml/min; sex and age range not reported | 2.5 g | — | 14 |
| Calcium from milk or calcium-fortified foods does not inhibit nonheme-iron absorption from a whole diet consumed over a 4-d period 2004 · BD with a glass of milk served at each meal · Women aged 21–34 years | 826 mg | 4 days | 14 |
| Calcium from milk or calcium-fortified foods does not inhibit nonheme-iron absorption from a whole diet consumed over a 4-d period 2004 · BD with calcium lactate · Women aged 21–34 years | 802 mg | 4 days | 14 |
| Calcium from milk or calcium-fortified foods does not inhibit nonheme-iron absorption from a whole diet consumed over a 4-d period 2004 · BD with a milk mineral isolate containing calcium · Women aged 21–34 years | 801 mg | 4 days | 14 |
| Reduction of mucosal crypt cell proliferation in patients with colorectal adenomatous polyps by dietary calcium supplementation 1992 · dietary calcium supplementation · Patients with adenomatous colorectal polyps | 1.25 g | 60 days | 14 |
| High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans 1998 · normal-calcium, oxalate-rich diet · Healthy men aged 23–44 years | 1.21 g | — | 14 |
| High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans 1998 · high-calcium, oxalate-rich diet · Healthy men aged 23–44 years | 3.86 g | — | 14 |
| Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women 2006 · control group · women in natural postmenopause | 1 mg | 26 weeks | 12 |
| Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women 2009 · calcium carbonate · Healthy women aged 22–30 years | 1 g | 1 day | 12 |
| Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women 2009 · calcium citrate · Healthy women aged 22–30 years | 1 g | 1 day | 12 |
| Fermentation of calcium-fortified soya milk does not appear to enhance acute calcium absorption in osteopenic post-menopausal women 2011 · fortified soya milk · 12 osteopenic post-menopausal women; mean age 54.8 years | 44 mg | 1 day | 12 |
| Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets 2012 · 800 mg elemental calcium diet · Adults with late stage 3 or stage 4 chronic kidney disease and adults with normal kidney function; age and sex not specified | 800 mg | 9 days | 12 |
| Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets 2012 · 2000 mg elemental calcium diet · Adults with late stage 3 or stage 4 chronic kidney disease and adults with normal kidney function; age and sex not specified | 2 g | 9 days | 12 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Pilot cohort · Infertile men; mean age 33.4 years | 400 mg | 270 days | 12 |
| Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study 1993 · calcium group · Hemodialysis patients with secondary hyperparathyroidism | 2 g | 26 weeks | 12 |
| Effects of high compared with low calcium intake on calcium absorption and incorporation of iron by red blood cells in small children 1999 · high-calcium diet · Preschool children aged 3–5 years | 1.18 g | 5 weeks | 11 |
| Does it make a difference how and when you take your calcium? The acute effects of calcium on calcium and bone metabolism 2001 · 200 mg calcium load four times daily · Women; age and health condition not stated | 800 mg | 1 day | 10 |
| An intervention study of the effects of calcium intake on faecal fat excretion, energy metabolism and adipose tissue mRNA expression of lipid-metabolism related proteins 2007 · 1200 mg calcium from calcium carbonate (1200S) · Healthy men and women, mean age 28 years, without a stated condition | 1.2 g | 7 days | 10 |
| Effect of calcium pre-rinse and fluoride dentifrice on remineralisation of artificially demineralised enamel and on the composition of the dental biofilm formed in situ 2007 · Calcium rinse before fluoride dentifrice · 10 volunteers wearing appliances with artificially demineralised bovine enamel blocks; age and sex not reported | 30 mL | 2 weeks | 10 |
| Effect of calcium pre-rinse and fluoride dentifrice on remineralisation of artificially demineralised enamel and on the composition of the dental biofilm formed in situ 2007 · Calcium rinse before placebo dentifrice · 10 volunteers wearing appliances with artificially demineralised bovine enamel blocks; age and sex not reported | 30 mL | 2 weeks | 10 |
| Dairy calcium supplementation in overweight or obese persons: its effect on markers of fat metabolism 2008 · Dairy calcium supplementation · Overweight or obese adults who were low calcium consumers | 800 mg | 5 weeks | 10 |
| Influence of calcium acetate or calcium citrate on intestinal aluminum absorption 1990 · Al[OH]3 plus Ca acetate · 10 normal volunteers | 5.32 g | 3 days | 10 |
| Influence of calcium acetate or calcium citrate on intestinal aluminum absorption 1990 · Al[OH]3 plus Ca citr · 10 normal volunteers | 3.8 g | 3 days | 10 |
| A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial 2020 · Calcium · Adults aged 20–66, male or nonpregnant female, in general good health but at increased risk for colon cancer | 800 mg | 90 days | 10 |
| The Postprandial Calcium Absorption of a Milk-Derived Calcium Permeate - The Acute RENEW Double-Blinded Randomized Controlled Cross-Over Study 2023 · Calcium permeate (CP) · Healthy postmenopausal females aged 50–65 years | 800 mg | 1 day | 10 |
| The Postprandial Calcium Absorption of a Milk-Derived Calcium Permeate - The Acute RENEW Double-Blinded Randomized Controlled Cross-Over Study 2023 · Calcium carbonate (CC) · Healthy postmenopausal females aged 50–65 years | 800 mg | 1 day | 10 |
| Calcium supplementation attenuates an enhanced platelet function in salt-loaded mildly hypertensive patients 1995 · calcium-supplemented patients · Patients with mild hypertension receiving a high-salt, low-calcium diet; age and sex not reported | 54 mmol | 7 days | 10 |
| Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study 1994 · calcium group · Patients undergoing hemodialysis | 2 g | 26 weeks | 9 |
| Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin 1994 · oral calcium · Healthy postmenopausal women | 1 g | 1 day | 9 |
| A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis 1993 · Control group: 3.5 mEq/L calcium dialysate without calcitriol · Patients on peritoneal dialysis | 1.1 g | 8 weeks | 9 |
| Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia 1992 · Calcium acetate, first period · Patients on chronic dialysis with predialytic hyperphosphatemia | 620 mg | 10 weeks | 8 |
| Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia 1992 · Calcium carbonate period · Patients on chronic dialysis with predialytic hyperphosphatemia | 1.31 g | 10 weeks | 8 |
| Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia 1992 · Calcium acetate, third period · Patients on chronic dialysis with predialytic hyperphosphatemia | 710 mg | 10 weeks | 8 |
| Effect of Calcium Alginate on the Suppression of Postprandial Elevation of Serum Triglyceride Level in Humans-A Placebo-Controlled, Randomized, Double-Blind, Crossover Study 2025 · calcium alginate (Ca-Alg) intake group · healthy adults; age range and sex not reported | 1.5 g | 1 day | 8 |
| Effect of reduced-calcium and high-calcium cheddar cheese consumption on the excretion of faecal fat: a 2-week cross-over dietary intervention study 2023 · Reduced calcium cheese diet + supplement (RCC + Supp) · Healthy males aged 18–35 years with BMI 18–25 kg/m² | 821 mg | 2 weeks | 7 |
| Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma 1992 · 1500 mg calcium carbonate trial · Six subjects with a current history of sporadic adenoma; age and sex not reported | 1.5 g | 90 days | 6 |
| Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma 1992 · 2000 mg calcium trial · Six subjects with a current history of sporadic adenoma; age and sex not reported | 2 g | 30 days | 6 |
| Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate 2006 · Patients with cystic fibrosis receiving levofloxacin with calcium carbonate · Adults with cystic fibrosis | 1.5 g | 5 days | 5 |
| Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate 2006 · Healthy volunteers receiving levofloxacin with calcium carbonate · Age-, sex-, race-, and serum-creatinine-matched healthy adult volunteers | 1.5 g | 5 days | 5 |
| Magnesium kinetics in adolescent girls determined using stable isotopes: effects of high and low calcium intake 1997 · control (800 mg/day) calcium intake · adolescent girls | 800 mg | 2 weeks | 5 |
| Magnesium kinetics in adolescent girls determined using stable isotopes: effects of high and low calcium intake 1997 · high (1,800 mg/day) calcium intake · adolescent girls | 1.8 g | 2 weeks | 5 |
| Modification of intracellular calcium and plasma renin by dietary calcium in men 1999 · calcium group · Normal male subjects | 2 g | 16 weeks | — |
| Calcium absorption in postmenopausal osteoporosis: benefit of HRT plus calcitriol, but not HRT alone, in both malabsorbers and normal absorbers 2000 · HRT plus calcitriol · Postmenopausal women with osteoporosis and vertebral compression fractures; age not reported | 600 mg | 243 days | — |
| Calcium supplementation of chocolate: effect on cocoa butter digestibility and blood lipids in humans 2001 · Calcium-supplemented chocolate · Men; age and health condition not stated | 900 mg | 2 weeks | — |
| Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis 2001 · R-CP-P · Postmenopausal women with spinal osteoporosis and at least one radiographically confirmed vertebral compression fracture | 1 g | 8 weeks | — |
| Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis 2001 · R-CP-R-CP · Postmenopausal women with spinal osteoporosis and at least one radiographically confirmed vertebral compression fracture | 1 g | 8 weeks | — |
| Bone mineral contents and plasma osteocalcin concentrations of Gambian children 12 and 24 mo after the withdrawal of a calcium supplement 2002 · calcium group · Rural Gambian children aged 8.3–11.9 years, with no condition specified | 714 mg | 1 year | — |
| Comparisons of oral calcium, high dose vitamin D and a combination of these in the treatment of nutritional rickets in children 2002 · Calcium group · Infants aged 6–30 months with nutritional rickets | 3 g | 4 weeks | — |
| Dietary calcium supplements to lower blood lead levels in lactating women: a randomized placebo-controlled trial 2003 · calcium supplement · Lactating women in Mexico City; mean age 24 years | 1.2 g | 26 weeks | — |
| Effect of a calcium and exercise intervention on the bone mineral status of 16-18-y-old adolescent girls 2003 · exercise group · Adolescent girls aged 16–18 years, mean age 17.3 years | 1 g | 472 days | — |
| Effect of a calcium and exercise intervention on the bone mineral status of 16-18-y-old adolescent girls 2003 · nonexercise group · Adolescent girls aged 16–18 years, mean age 17.3 years | 1 g | 472 days | — |
| Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year-old children 2003 · calcium with gross motor activities · Children aged 3–5 years participating in gross motor activities | 1 g | 1 year | — |
| Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year-old children 2003 · calcium with fine motor activities · Children aged 3–5 years participating in fine motor activities | 1 g | 1 year | — |
| The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients 2003 · calcium acetate · hemodialysis patients with hyperphosphatemia | 4.6 g | 1 year | — |
| Stone forming risk of calcium citrate supplementation in healthy postmenopausal women 2004 · calcium citrate · Postmenopausal women without kidney stones | 800 mg | 2 weeks | — |
| Calcium supplementation increases stature and bone mineral mass of 16- to 18-year-old boys 2005 · 1000 mg Ca/d group · boys aged 16–18 years | 1 g | 396 days | — |
| Comparing the effect of short term post meals and bedtime calcium supplementation on the C-terminal telopeptide crosslinks and PTH levels in postmenopausal osteopenic women 2005 · Post-meal calcium supplementation · Postmenopausal women with osteopenia; mean age 63.9 years | 668 mg | 2 weeks | — |
| Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women 2006 · High calcium skim milk without added phylloquinone · Premenopausal women aged 20 to 35 years | 1 g | 16 weeks | — |
| Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure 2008 · CaD group · Ambulatory men with congestive heart failure, low vitamin D status, and insufficient dietary calcium intake | 500 mg | 270 days | — |
| Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up 2008 · calcium supplementation · Girls with low habitual calcium intake (mean age 12 years) | 792 mg | 548 days | — |
| Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function 2008 · CC (calcium carbonate) · Healthy male individuals; age not reported | 2 g | 6 days | — |
| Calcium and dairy product modulation of lipid utilization and energy expenditure 2008 · 900 mg/day calcium supplement · Women aged 18–31 years with overweight | 900 mg | — | — |
| Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women 2008 · calcium carbonate · Healthy postmenopausal women | 1 g | 1 day | — |
| Effect of dairy calcium on fecal fat excretion: a randomized crossover trial 2008 · high-Ca diet · 11 adult subjects; age and sex not stated; no condition stated | 2.3 g | 7 days | — |
| The effect of exercise on water balance in premenopausal physically active women 2008 · 800 mg calcium supplementation and exercise · Physically active premenopausal women, mean age 25 years | 800 mg | 8 days | — |
| Effects of three different calcium preparations on urinary calcium and hydroxyproline excretion in postmenopausal osteoporotic women 1991 · Sandocal · Postmenopausal women with osteoporosis | 1 g | 1 day | — |
| Effects of three different calcium preparations on urinary calcium and hydroxyproline excretion in postmenopausal osteoporotic women 1991 · Calsup · Postmenopausal women with osteoporosis | 1 g | 1 day | — |
| Effects of three different calcium preparations on urinary calcium and hydroxyproline excretion in postmenopausal osteoporotic women 1991 · Caltrate · Postmenopausal women with osteoporosis | 1.2 g | 1 day | — |
| Oral calcium supplementation reverses the biochemical pattern of parathyroid hormone resistance in underprivileged Indian toddlers 2009 · Calcium supplement group · Toddlers aged 2.4 years on average from an urban slum in Pune, India, with low dietary calcium intake and vitamin D replete status | 500 mg | 8 weeks | — |
| The metabolic effects of calcium supplementation in the elderly 1991 · calcium-supplemented group · Healthy, ambulatory men and women with a mean age of 71 | 1.2 g | 26 weeks | — |
| Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial 2010 · calcium supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp | 2 g | 26 weeks | — |
| The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design 2010 · calcium plus placebo · Healthy men and women aged 20–80 years | 1.2 g | 90 days | — |
| Effects of calcium-fortified ice cream on markers of bone health 2011 · 676 mg calcium group · Premenopausal women aged 20–39 years with calcium intake below 750 mg/day | 676 mg | 4 weeks | — |
| Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet 2011 · LC/LF · Adults; sex and health condition not stated | 700 mg | 10 days | — |
| Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet 2011 · HC/LF · Adults; sex and health condition not stated | 2.8 g | 10 days | — |
| Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet 2011 · LC/HF · Adults; sex and health condition not stated | 700 mg | 10 days | — |
| Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet 2011 · HC/HF · Adults; sex and health condition not stated | 2.8 g | 10 days | — |
| [Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes] 2011 · group I · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis | 440 mg | 1 year | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · Placebo · Postmenopausal women with osteopenia | 500 mg | 26 weeks | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · GTP · Postmenopausal women with osteopenia | 500 mg | 26 weeks | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · Placebo + TC · Postmenopausal women with osteopenia | 500 mg | 26 weeks | — |
| Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial 2012 · GTP + TC · Postmenopausal women with osteopenia | 500 mg | 26 weeks | — |
| Management of nutritional rickets in Indian children: a randomized controlled trial 2013 · calcium · Children aged 6 months to 5 years with nutritional rickets | 75 mg/kg | 12 weeks | — |
| [Comparison of the fluoride bioavailability from two oral preparations of monofluorophosphate disodium in combination with various calcium salts] 1990 · first oral preparation · 12 healthy volunteers; age and sex not reported | 500 mg | 1 day | — |
| [Comparison of the fluoride bioavailability from two oral preparations of monofluorophosphate disodium in combination with various calcium salts] 1990 · second oral preparation · 12 healthy volunteers; age and sex not reported | 500 mg | 1 day | — |
| Long-term calcium supplementation may have adverse effects on serum cholesterol and carotid intima-media thickness in postmenopausal women: a double-blind, randomized, placebo-controlled trial 2013 · calcium supplementation, premenopausal women · Premenopausal women aged 30–40 with dyslipidemia | 800 mg | 2 years | — |
| Long-term calcium supplementation may have adverse effects on serum cholesterol and carotid intima-media thickness in postmenopausal women: a double-blind, randomized, placebo-controlled trial 2013 · calcium supplementation, postmenopausal women · Postmenopausal women aged 50–60 with dyslipidemia | 800 mg | 2 years | — |
| Calcium and vitamin d supplementation in postmenopausal women 2013 · calcium plus placebo · healthy postmenopausal white women | 1.2 g | 26 weeks | — |
| The effects of 3 years of calcium supplementation on common carotid artery intimal medial thickness and carotid atherosclerosis in older women: an ancillary study of the CAIFOS randomized controlled trial 2014 · calcium supplementation · Older women; mean age 75.2 ± 2.7 years | 1.2 g | 5 years | — |
| MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial 2015 · CaCO3 alone group · Adults with peritoneal dialysis | 1.8 g | 90 days | — |
| The effect of prepubertal calcium carbonate supplementation on skeletal development in Gambian boys-a 12-year follow-up study 2014 · calcium group · Boys in rural Gambia, initially aged 8.0–11.9 years, with a low-calcium diet | 1 g | 1 year | — |
| Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial 2014 · calcium group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated | 1 g | 8 weeks | — |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · Vitamin D3 plus calcium carbonate · Older German adults, mean age 67 years | 456 mg | 1 year | — |
| Calcium supplementation increases blood creatinine concentration in a randomized controlled trial 2014 · Calcium alone · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male | 1.2 g | 5 years | — |
| Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial 2016 · calcium carbonate group · postmenopausal women | 1 g | 90 days | — |
| Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients 2017 · 1,200 mg/day calcium supplementation · Adults aged 45–75 with a history of colorectal adenomas | 1.2 g | 1 year | — |
| Calcium Supplementation Attenuates Disruptions in Calcium Homeostasis during Exercise 2017 · Ca group · Male competitive road cyclists aged 18–45 years | 1 g | 1 day | — |
| High phosphorus intake and gut-related parameters - results of a randomized placebo-controlled human intervention study 2018 · P1000/Ca500 · Healthy omnivorous men and women aged 18–60 years | 500 mg | 8 weeks | — |
| Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux-en-Y gastric bypass. A double-blinded, randomized trial 2018 · calcium citrate · Patients after Roux-en-Y gastric bypass with elevated PTH, normal plasma calcium and normal 25-hydroxyvitamin D | 1.2 g | 12 weeks | — |
| Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux-en-Y gastric bypass. A double-blinded, randomized trial 2018 · calcium carbonate · Patients after Roux-en-Y gastric bypass with elevated PTH, normal plasma calcium and normal 25-hydroxyvitamin D | 1.2 g | 12 weeks | — |
| Pregnancy supplementation of Gambian mothers with calcium carbonate alters mid-childhood IGF1 in a sex-specific manner 2019 · calcium-supplemented group · Pregnant rural Gambian women; offspring outcomes were assessed in their children at mean age 7.5 years | 1.5 g | — | — |
| Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial 2019 · calcium group · People with sporadic colorectal adenomas; age and sex not specified | 1.2 g | 1 year | — |
| Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients 2019 · calcium supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms | 1.2 g | 1 year | — |
| Effects of calcium supplementation on circulating osteocalcin and glycated haemoglobin in older women 2019 · calcium supplementation · Older community-dwelling women; mean age 75.2 years | 1.2 g | 1 year | — |
| Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial 2021 · calcium group · Adults aged 45–75 with a histologically verified colorectal adenoma | 1.2 g | 1 year | — |
| Urate-lowering effect of calcium supplementation: Analyses of a randomized controlled trial 2022 · CIT (high-calcium breakfast from calcium citrate) · Adult women aged 18–42 years with low calcium consumption (<800 mg/day) | 770 mg | 45 days | — |
| Urate-lowering effect of calcium supplementation: Analyses of a randomized controlled trial 2022 · SM (high-calcium breakfast from skim milk) · Adult women aged 18–42 years with low calcium consumption (<800 mg/day) | 770 mg | 45 days | — |
| Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial 2022 · CC group · Japanese hemodialysis patients with hyperphosphatemia and at least one risk factor for vascular calcification | 3 g | 2 years | — |
| Effects of calcium supplementation on changes in the IL2, IL4, IL6, IL10 axes and oxidative stress in pregnant women at risk for pre-eclampsia 2024 · Calcium group 1,500 mg/day · Pregnant women over 18 years with gestational hypertension, overweight or obesity, low socioeconomic status, low dietary calcium intake, and at least 20 weeks’ gestation | 1.5 g | 6 weeks | — |
| Increased calcium intake from skimmed milk in energy-restricted diets reduces glycation markers in adults with type 2 diabetes and overweight: A secondary analysis of a randomized clinical trial 2024 · high calcium · Adults with type 2 diabetes, overweight, and habitual calcium intake below 600 mg/day | 700 mg | 12 weeks | — |
| Calcium plus vitamin D supplementation during pregnancy has no impact on postpartum transient longitudinal changes in hip geometry in adolescent mothers: a secondary analysis of a randomised controlled trial 2024 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low daily calcium intake (approximately 600 mg/day); lactating postpartum adolescents were assessed | 600 mg | — | — |
| Effect of oral calcium supplementation on intracellular calcium and plasma renin in men 1995 · calcium group · normal adult men | 2 g | 16 weeks | — |
| Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients 1994 · calcium acetate (CaAC) · Chronic hemodialysis patients; age and sex not specified | 4.1 g | 12 weeks | — |
| Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients 1994 · calcium carbonate (CaCO3) · Chronic hemodialysis patients; age and sex not specified | 4.01 g | 12 weeks | — |
| The effect of calcium supplementation on the circadian rhythm of bone resorption 1994 · 0800 h calcium supplementation · Premenopausal women; ages not reported; no condition stated | 1 g | 2 weeks | — |
| The effect of calcium supplementation on the circadian rhythm of bone resorption 1994 · 2300 h calcium supplementation · Premenopausal women; ages not reported; no condition stated | 1 g | 2 weeks | — |
| 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients 1993 · Calcium carbonate control group · Adults with predialytic chronic kidney disease and elevated serum parathyroid hormone; mean age 56 years | 3 g | 26 weeks | — |
| Oral calcium inhibits rectal epithelial proliferation in familial adenomatous polyposis 1993 · calcium treatment · Patients with familial adenomatous polyposis who had undergone previous abdominal colectomy and ileorectal anastomosis | 1.5 g | 26 weeks | — |
| Calcium supplementation modifies the relative amounts of bile acids in bile and affects key aspects of human colon physiology 1996 · 2000 mg calcium group · Individuals with a history of resected colon adenocarcinoma, currently free of cancer | 2 g | 16 weeks | — |
| Calcium supplementation modifies the relative amounts of bile acids in bile and affects key aspects of human colon physiology 1996 · 3000 mg calcium group · Individuals with a history of resected colon adenocarcinoma, currently free of cancer | 3 g | 16 weeks | — |
| Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial 1996 · calcium carbonate antacid tablets · Healthy adults aged 25 to 62 years with normal gastric acid secretion rates; men and women | 1 g | 1 day | — |
| Magnesium balance in adolescent females consuming a low- or high-calcium diet 1996 · High-calcium group · Adolescent girls, mean age 11.3 years, without a stated medical condition | 1 g | 2 weeks | — |
| Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study 1996 · CaCO3 alone in the usual dose · Chronic hemodialysis patients | 2.9 g | — | — |
| Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods: a randomized controlled trial 1998 · higher-calcium diet · Adults with a history of polypectomy for colonic adenomatous polyps | 1.2 g | 1 year | — |
| A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients 1999 · RenaGel with calcium · Hemodialysis patients with ESRD-related hyperphosphatemia | 900 mg | 12 weeks | — |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · D&Cancer Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 1.5 g | 1 year | 915 |
| Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients 2014 · strontium ranelate 2 g/vitamin D₃ 1000 IU daily · Men and postmenopausal women aged 50 years or older with primary osteoporosis and serum 25(OH)D >22.5 nmol/l | 1 g | 26 weeks | 413 |
| Does Vitamin D3 Supplementation Improve Depression Scores among Rural Adolescents? A Randomized Controlled Trial 2024 · calcium intervention arm · Rural adolescent boys and girls aged 14–19 years with any form of depression | 500 mg | 9 weeks | 216 |
| SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial 2017 · CaMEWS Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health | 1.5 g | 1 year | 203 |
| Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study 2002 · calcium-vitamin D3 fixed combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population | 1.2 g | 2 years | 199 |
| Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study 2002 · calcium plus vitamin D3 separate combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population | 1.2 g | 2 years | 190 |
| Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation 2011 · active treatment arm · Healthy men and women aged 65 and older | 500 mg | 2 years | 152 |
| Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults 2008 · calcium-vitamin D supplementation treatment group · Men and women aged 65 years or older; healthy and ambulatory | 500 mg | 3 years | 132 |
| Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study 2021 · Group A (2000 IU) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 50 years; treated in orthopaedic, obstetrics and gynaecology clinics | 600 mg | 90 days | 121 |
| Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal 2018 · ALN/D5600 · Postmenopausal women in China aged over 55 with postmenopausal osteoporosis | 500 mg | 1 year | 111 |
| Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly 2021 · Low dose (600 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL | 1 g | 1 year | 111 |
| Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly 2021 · High dose (3750 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL | 1 g | 1 year | 110 |
| Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study 2021 · Group B (125 IU/kg/m²) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 52 years; treated in orthopaedic, obstetrics and gynaecology clinics | 600 mg | 90 days | 109 |
| Response of serum 25(OH)D to Vitamin D and calcium supplementation in school-children from a semi-rural setting in India 2018 · Daily vitamin D and calcium supplementation · Schoolchildren aged 6–12 years, boys and girls, from a semi-rural setting in India; baseline vitamin D status varied | 500 mg | 26 weeks | 106 |
| Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Bone Turnover in Older Women 2014 · n-3 LCPUFA group · Postmenopausal women, mean age 75±7 years | 315 mg | 26 weeks | 85 |
| Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0-16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks 2018 · depot therapy · Refugee children aged 5.5 months to 16 years with serum 25(OH)D below 78 nmol/L | 200 mg | 40 weeks | 84 |
| Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0-16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks 2018 · daily therapy · Refugee children aged 5.5 months to 16 years with serum 25(OH)D below 78 nmol/L | 200 mg | 40 weeks | 73 |
| A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects 2022 · Vitamin D3 + Calcium · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates | 600 mg | 26 weeks | 68 |
| Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial 2014 · 400 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months | 200 mg | 26 weeks | 67 |
| A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation 2005 · treatment arm · Adults aged 44–80 with previously resected colonic adenomatous polyps or intramucosal carcinoma | 1.5 g | 4 weeks | 50 |
| Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial 2011 · vitamin D3-fortified doogh (FYD) · Adults aged 29–67 years with type 2 diabetes; 57 women and 43 men overall | 340 mg | 12 weeks | 50 |
| Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes 2012 · vitamin D3-fortified doogh (FD) · People with type 2 diabetes | 340 mg | 12 weeks | 50 |
| Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial 2023 · Daily (D) group · Infants with symptomatic vitamin D deficiency | 50 mg/kg | 90 days | 46 |
| Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents 1995 · G1 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure | 1 g | 26 weeks | 46 |
| Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents 1995 · G2 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure | 1 g | 26 weeks | 45 |
| Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial 2023 · Bolus (B) group · Infants with symptomatic vitamin D deficiency | 50 mg/kg | 90 days | 44 |
| Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial 2024 · group daily (D) · Children aged 1–10 years with symptomatic vitamin D deficiency | 500 mg | 12 weeks | 40 |
| Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial 2024 · group bolus (B) · Children aged 1–10 years with symptomatic vitamin D deficiency | 500 mg | 12 weeks | 40 |
| Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial 2021 · vitamin D3 monthly group (VDM) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle | 400 mg | 14 weeks | 37 |
| Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial 2009 · group 1 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass | 1.5 g | 1 year | 30 |
| Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial 2009 · group 2 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass | 1.5 g | 1 year | 30 |
| Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial 2021 · vitamin D3 daily group (VDD) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle | 400 mg | 14 weeks | 30 |
| Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents 2009 · VD+ · HIV-infected children and adolescents aged 6–16 years | 1 g | 1 year | 29 |
| Fortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling Home 2015 · Fortified Yogurt (FY) · Women aged 61–90 with serum 25OHD ≤20 ng/mL, living in community sheltered accommodation | 520 mg | 12 weeks | 28 |
| Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome 2015 · 1000 mg calcium/d + 50,000 IU/wk vitamin D · Overweight and obese vitamin D deficient women diagnosed with PCOS | 1 g | 8 weeks | 26 |
| Effect of phosphate binders on supplemental iron absorption in healthy subjects 2002 · iron with calcium carbonate · healthy subjects; age and sex not stated | 3 g | 1 day | 23 |
| Effect of phosphate binders on supplemental iron absorption in healthy subjects 2002 · iron with calcium acetate · healthy subjects; age and sex not stated | 2.67 g | 1 day | 23 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight loss and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss | 1.2 g | 6 weeks | 22 |
| Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites 2012 · calcium plus vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months | 2 g | 26 weeks | 21 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight maintenance and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance | 1.2 g | 6 weeks | 21 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight maintenance and vitamin D3-supplementation (WM-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance | 1.2 g | 6 weeks | 20 |
| Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation 2013 · Vitamin D3 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency | 675 mg | 90 days | 20 |
| Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial 2013 · weight loss and vitamin D3-supplementation (WL-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss | 1.2 g | 6 weeks | 19 |
| Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation 2013 · Vitamin D2 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency | 500 mg | 90 days | 19 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 1 g | 6 weeks | 17 |
| Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D₃ per day: a randomized clinical trial 2012 · oral vitamin D(3) and calcium group · Participants with vitamin D deficiency (25(OH)D(3) ≤ 25 nmol L(-1)); age and sex not reported | 1 g | 6 weeks | 16 |
| Effect of Lactobacillus sporogenes on oral isoflavones bioavailability: single dose pharmacokinetic study in menopausal women 2011 · E (Estromineral test formulation) · Menopausal women, mean age 54.3 years, receiving antibiotic therapy | 141 mg | 1 day | 12 |
| Bioavailability of fluoride in postmenopausal women: comparative study between sodium fluoride and disodium monofluorophosphate-calcium carbonate 1992 · disodium monofluorophosphate-calcium carbonate (MFP-Ca) · Postmenopausal women aged 48–77 years without bone disease | 1.25 g | 1 day | 10 |
| Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study 2010 · Silicon-rich Water (SW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA | 1.2 g | 14 weeks | 10 |
| Calcium and vitamin D intakes in children: a randomized controlled trial 2013 · Group 1 (dietary counseling plus Ca and Vitamin D supplementation) · Children aged 9.7–11.4 years with dietary calcium and vitamin D intake below 70% of the recommended intake | 400 mg | 120 days | 10 |
| The Temporal Change in Ionised Calcium, Parathyroid Hormone and Bone Metabolism Following Ingestion of a Plant-Sourced Marine Mineral + Protein Isolate in Healthy Young Adults 2024 · supplement (SUPP) · Healthy adults aged 18–35 years; men and women | 800 mg | 1 day | 10 |
| Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study 2010 · Purified Water (PW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA | 1.2 g | 14 weeks | 9 |
| Negative balance of calcium and magnesium under relatively low sodium intake in humans 2003 · Relatively low sodium intake with adequate calcium and magnesium intake · Six female students; ages and health status not reported | 800 mg | 10 days | 6 |
| Small bowel absorption of magnesium and calcium sulphate from a natural mineral water in subjects with ileostomy 2006 · High-mineral-content natural mineral water · Six subjects with ileostomy | 6.9 mmol | 2 days | 6 |
| A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study 2004 · injected vitamin D(2) plus oral calcium · elderly women recruited after surgery for hip fracture | 1 g | 1 year | — |
| A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study 2004 · oral vitamin D(3) plus calcium · elderly women recruited after surgery for hip fracture | 1 g | 1 year | — |
| Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3 2005 · Calcium group · Healthy older men and women | 1 g | 90 days | — |
| Which therapy to prevent post-thyroidectomy hypocalcemia? 2005 · group B · Patients undergoing total thyroidectomy for benign thyroid disease or malignancy; age and sex not specified | 1.5 g | — | — |
| Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults 2006 · vitamin D group · Healthy university students aged 18–27 years, male and female | 1.5 g | 8 weeks | — |
| Effects of two marine dietary supplements with high calcium content on calcium metabolism and biochemical marker of bone resorption 2008 · Glycollagene (ray cartilage hydrolysate) · 20 male volunteers; age and health condition not stated | 836 mg | 1 day | — |
| Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients 2008 · Group II (400 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent | 500 mg | 26 weeks | — |
| Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients 2008 · Group III (1200 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent | 500 mg | 26 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D2 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 50 mg/kg | 6 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D2 weekly · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 50 mg/kg | 6 weeks | — |
| Treatment of hypovitaminosis D in infants and toddlers 2008 · Vitamin D3 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported | 50 mg/kg | 6 weeks | — |
| The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit 2008 · group 1 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit | 1.25 g | 39 weeks | — |
| The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit 2008 · group 2 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit | 1.25 g | 39 weeks | — |
| Effect of vitamin D supplementation in the institutionalized elderly 2009 · group (B) · Institutionalized elderly with low baseline vitamin D status | 200 mg | 30 days | — |
| The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function 2010 · D group · Women aged 69.3–78.8 years | 1 g | 1 year | — |
| The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function 2010 · 4 M group · Women aged 69.3–78.8 years | 1 g | 1 year | — |
| Is a lower dose of vitamin D supplementation enough to increase 25(OH)D status in a sunny country? 2010 · supplement group · Postmenopausal women with osteoporosis, mean age 62 ± 8 years | 1.2 g | 90 days | — |
| Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3) 2009 · Ca+VD group · Institutionalized elderly; age and sex not specified; baseline serum 25-hydroxyvitamin D was in the hypovitaminosis D range | 200 mg | 30 days | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · VD and Ca (VD-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 600 mg | 1 year | — |
| Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention 2010 · Multiple micronutrient and Ca (MMN-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D | 600 mg | 1 year | — |
| Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States 2009 · 2,000 mg calcium plus 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months | 2 g | 26 weeks | — |
| Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting 2010 · high-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L | 500 mg | 10 days | — |
| Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting 2010 · continuous low-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L | 500 mg | 90 days | — |
| Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomised controlled trial 2012 · vitamin D(3) plus calcium group · Community-dwelling adults aged 55–84 years | 1 g | 1 year | — |
| Changes in vitamin D metabolites during teriparatide treatment 2012 · teriparatide group · postmenopausal women and men with osteoporosis | 1 g | 1 year | — |
| Changes in vitamin D metabolites during teriparatide treatment 2012 · placebo group · postmenopausal women and men with osteoporosis | 1 g | 1 year | — |
| The necessity and safety of calcium and vitamin D in the elderly 1990 · Treatment group, independently living elderly women · Independently living elderly women | 1.56 g | 11 weeks | — |
| The necessity and safety of calcium and vitamin D in the elderly 1990 · Treatment group, institutionalized elderly women · Institutionalized elderly women | 1.56 g | 11 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaD · Children aged approximately 8 years | 700 mg | 12 weeks | — |
| Calcium-vitamin D-fortified milk is as effective on circulating bone biomarkers as fortified juice and supplement but has less acceptance: a randomised controlled school-based trial 2014 · supplement · Children aged 9–12 years, both sexes, in Tehran | 500 mg | 12 weeks | — |
| How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women 2016 · 100 000 IU vitamin D3 group (group 1D) · Women aged about 75 years receiving intermittent vitamin D therapy | 1 g | 1 year | — |
| How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women 2016 · 200 000 IU vitamin D3 group (2D) · Women aged about 75 years receiving intermittent vitamin D therapy | 1 g | 1 year | — |
| Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training 2017 · calcium and vitamin D · Young adults undergoing Army or Air Force initial military training | 2 g | 9 weeks | — |
| A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia 2017 · Initial daily Vitamin D3 + calcium citrate formulation · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency | 1 g | — | — |
| A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia 2017 · DOT Vitamin D3 intervention · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency | 800 mg | 204 days | — |
| Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation 2017 · VitD/Ca arm · HIV-infected, ART-naive participants with 25-(OH)D ≥10 and <75 ng/mL, CrCl ≥60 mL/min, and serum calcium <10.5 mg/dL; age and sex not specified | 1 g | 48 weeks | — |
| Treatment of vitamin D deficiency in Chinese inflammatory bowel disease patients: A prospective, randomized, open-label, pilot study 2018 · arm A · Chinese adults with ulcerative colitis or Crohn's disease and vitamin D insufficiency or deficiency | 600 mg | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D3 2,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D3 3,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D2 50,000 IU weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 1 year | — |
| A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS 2019 · D2 50,000 IU twice weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL | 500 mg | 1 year | — |
| Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults 2019 · Vitamin D3 group · Adults aged 60–80 with low serum 25(OH)D, clinically relevant depressive symptoms, and at least one functional limitation | 500 mg | 26 weeks | — |
| Calcium and vitamin D supplementation and bone health in Marine recruits: Effect of season 2019 · Ca + D fortified snack bars · Male and female Marine recruits, mean age 18.9 years, undergoing 12 weeks of initial military training | 2 g | 12 weeks | — |
| Vitamin D-A Risk Factor for Bone Fractures in Children: A Population-Based Prospective Case-Control Randomized Cross-Sectional Study 2023 · study group · Children aged 2–17 years with fractures; supplementation was given when serum 25-OH-vitamin D was below 30 ng/mL. | 600 mg | 26 weeks | — |
| High-dose cholecalciferol supplementation to obese infertile men is sufficient to reach adequate vitamin D status 2024 · active group · Infertile men, including men with normal weight, overweight, and obesity | 500 mg | 150 days | — |
| Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D 1998 · Vit D3 group · Postmenopausal women | 500 mg | 1 year | — |
| Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D 1998 · HRT + Vit D3 group · Postmenopausal women | 500 mg | 1 year | — |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · B-vitamin supplementation · Older German adults, mean age 67 years | 456 mg | 1 year | — |
| Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents 2008 · Calcium carbonate, 800 mg group · Men and women aged 70 years or older living in nursing homes who completed the vitamin D intervention; calcium intervention participants had received vitamin D | 800 mg | 2 weeks | — |
| Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents 2008 · Calcium carbonate, 1,600 mg group · Men and women aged 70 years or older living in nursing homes who completed the vitamin D intervention; calcium intervention participants had received vitamin D | 1.6 g | 2 weeks | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 150 mg | — | 870 |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · control · Women planning pregnancy; generally healthy, recruited before conception | 150 mg | — | 859 |
| Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis 2010 · Placebo group · Postmenopausal women with osteoporosis and prevalent fractures | 1 g | 548 days | 544 |
| Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis 2010 · Teriparatide 20 μg group · Postmenopausal women with osteoporosis and prevalent fractures | 1 g | 548 days | 541 |
| Effect of calcium supplementation on bone resorption in pregnancy and the early postpartum: a randomized controlled trial in Mexican women 2014 · Calcium group · Pregnant women enrolled in the first trimester in Mexico City; no stated diagnosed condition | 1.2 g | — | 334 |
| Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men 2022 · Vitamin D and calcium group · Infertile men; age not stated | 500 mg | 150 days | 151 |
| Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism 2020 · high dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml | 1 g | 1 year | 129 |
| Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism 2020 · low dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml | 1 g | 1 year | 128 |
| Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis 2007 · PTH group · Postmenopausal women with low bone mineral density and osteoporosis | 500 mg | 1 year | 119 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group B · Patients after total thyroidectomy | 1.5 g | — | 111 |
| Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy 2005 · Group A · Patients after total thyroidectomy | 1.5 g | — | 104 |
| Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study 2005 · calcium + vitamin D group · Ambulatory women older than 65 years with vitamin D insufficiency (25-hydroxyvitamin D level ≤12 ng/mL) | 1 g | 1 year | 95 |
| A Combined Nutrition and Exercise Intervention Influences Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover of Healthy Chinese Middle-Aged and Older Adults 2020 · intervention group · Chinese men and women aged 50 years or older, apparently healthy and community-dwelling | 1.01 g | 24 weeks | 80 |
| Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover 2004 · Calcitonin group · Women older than 65 with high bone turnover, at high risk of osteoporosis | 500 mg | 26 weeks | 75 |
| Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study 2013 · D+ group · Adults with primary hyperparathyroidism after parathyroidectomy | 1 g | 1 year | 75 |
| Consumption of a calcium and vitamin D-fortified food product does not affect iron status during initial military training: a randomised, double-blind, placebo-controlled trial 2016 · Ca/vitamin D group · Young adult male and female volunteers enrolled in US Army basic combat training | 2 g | 9 weeks | 75 |
| Effects of vitamin D supplementation on salivary immune responses during Marine Corps basic training 2019 · Vitamin D3 + calcium group · Male and female US Marine Corps recruits entering basic training; ages and vitamin D status not specified | 2 g | 12 weeks | 73 |
| Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial 2014 · 1200 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months | 200 mg | 26 weeks | 70 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · mid-dose · Postmenopausal Chinese women aged 48–62 years | 500 mg | 1 year | 68 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · high dose · Postmenopausal Chinese women aged 48–62 years | 500 mg | 1 year | 68 |
| Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial 2004 · mid-dose · Postmenopausal Chinese women aged 48 to 62 years | 500 mg | 1 year | 68 |
| Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial 2004 · high-dose · Postmenopausal Chinese women aged 48 to 62 years | 500 mg | 1 year | 68 |
| Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial 2007 · 40 mg isoflavones · Postmenopausal Chinese women aged 48 to 62 years | 500 mg | 1 year | 68 |
| Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial 2007 · 80 mg isoflavones · Postmenopausal Chinese women aged 48 to 62 years | 500 mg | 1 year | 68 |
| Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study 2011 · calcium carbonate (control group) · Women aged over 65 years with densitometric osteoporosis of the lumbar spine or femoral neck | 1 g | 3 years | 65 |
| Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis 2007 · PTH/alendronate combination group · Postmenopausal women with low bone mineral density and osteoporosis | 500 mg | 1 year | 59 |
| Plasma levels of adrenaline, noradrenaline, dopamine, serotonin, and cortisol in sarcopenia: comparison with non-sarcopenic individuals and the impact of resistance exercise and nutrition interventions 2025 · Combined exercise and nutritional intervention (sarcopenic participants; early versus delayed intervention trial) · Adults older than 65 years with sarcopenia | 600 mg | 12 weeks | 57 |
| Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study 2011 · OHC (treatment group) · Women aged over 65 years with densitometric osteoporosis of the lumbar spine or femoral neck | 1.66 g | 3 years | 55 |
| Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method 2005 · CaCO(3) + cholecalciferol · Healthy younger women and older women and men; median ages 30 and 66, respectively | 1.2 g | 4 weeks | 53 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · ALN add TPTD · Postmenopausal women with osteoporosis previously treated with alendronate | 500 mg | 26 weeks | 52 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · ALN switch TPTD · Postmenopausal women with osteoporosis previously treated with alendronate | 500 mg | 26 weeks | 50 |
| Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial 2017 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes; age and sex not specified | 340 mg | 12 weeks | 50 |
| Once daily calcium (1000 mg) and vitamin D (1000 IU) supplementation during military training prevents increases in biochemical markers of bone resorption but does not affect tibial microarchitecture in Army recruits 2022 · Ca + D fortified food bar · Male and female Army recruits undergoing basic combat training; mean age 21.8 years | 1 g | 8 weeks | 50 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · RLX switch TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene | 500 mg | 26 weeks | 49 |
| Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate 2003 · Calcitriol pulse therapy (crossover) with calcium carbonate · Adults with chronic hemodialysis; age and sex not reported | 4.5 g | 26 weeks | 48 |
| Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] 2004 · Control group · Postmenopausal women aged 45–65 with active rheumatoid arthritis | 500 mg | 2 years | 47 |
| Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate 2008 · RLX add TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene | 500 mg | 26 weeks | 47 |
| Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease 2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission | 500 mg | 1 year | 43 |
| Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] 2004 · HRT group · Postmenopausal women aged 45–65 with active rheumatoid arthritis | 500 mg | 2 years | 41 |
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study 2009 · Group 1 · Postmenopausal women with osteoporosis | 1 g | 1 year | 41 |
| The effects of Acanthopanax senticosus extract on bone turnover and bone mineral density in Korean postmenopausal women 2009 · treatment group · Postmenopausal women younger than 65 years with osteopenia or osteoporosis | 500 mg | 26 weeks | 41 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 23.0 years | 600 mg | 1 year | 41 |
| The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes 2014 · vitamin D group · Adults aged 30–69 with vitamin D-deficient type 2 diabetes | 200 mg | 24 weeks | 40 |
| Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products 2009 · dairy intervention group (IG) · Post-menopausal women | 1.2 g | 150 days | 39 |
| Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin 2011 · First group · Postmenopausal women with osteoporosis | 600 mg | 26 weeks | 37 |
| Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D 2014 · MMN-VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.4 years | 600 mg | 1 year | 37 |
| Consumption of vitamin D-and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture 2012 · treated · Healthy postmenopausal women aged 56.6 ± 3.9 years with low spontaneous calcium and vitamin D intake | 400 mg | 6 weeks | 36 |
| Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial 2021 · group B · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet | 500 mg | 6 weeks | 36 |
| Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin 2011 · Second group · Postmenopausal women with osteoporosis | 600 mg | 26 weeks | 34 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · low VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D <10 ng/mL | 600 mg | 26 weeks | 34 |
| Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial 2021 · group A · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet | 1 g | 6 weeks | 34 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 3 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 1 g | 1 year | 33 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 6 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 1 g | 1 year | 33 |
| Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial 2008 · ch-OSA 12 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy | 1 g | 1 year | 33 |
| The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD 2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified | 1 g | 12 weeks | 33 |
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans 2012 · LPC37 plus CaP · Healthy, moderately hypercholesterolemic men and women | 1 g | 4 weeks | 32 |
| Between-meal risedronate does not alter bone turnover in nursing home residents 2006 · Risedronate group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline | 630 mg | 12 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/HK · Postmenopausal women aged 50–65 years | 1 g | 12 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/LK · Postmenopausal women aged 50–65 years | 1 g | 12 weeks | 31 |
| Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers 2018 · D + Ca · Adults, mean age 68.4 years; no specific condition stated | 800 mg | 1 year | 31 |
| A pilot intervention to increase calcium intake in female collegiate athletes 2004 · treatment group · Female collegiate athletes with regular menstrual cycles; age not reported | 1 g | 16 weeks | 30 |
| Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D 2014 · vitamin D-fortified doogh (DD) · Adults aged 30–50 of both sexes with type 2 diabetes | 300 mg | 12 weeks | 30 |
| Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D 2014 · calcium-vitamin D-fortified doogh (CDD) · Adults aged 30–50 of both sexes with type 2 diabetes | 500 mg | 12 weeks | 30 |
| Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial 2014 · calcium-vitamin D group · Adults aged over 30 with type 2 diabetes and insufficient 25-hydroxyvitamin D | 1 g | 8 weeks | 30 |
| The effects of vitamin D plus calcium supplementation on metabolic profiles, biomarkers of inflammation, oxidative stress and pregnancy outcomes in pregnant women at risk for pre-eclampsia 2016 · vitamin D3 plus calcium · Pregnant women at risk for pre-eclampsia, from 20 to 32 weeks of gestation | 1 g | 12 weeks | 30 |
| The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome | 1 g | 8 weeks | 30 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · LD/HK · Postmenopausal women aged 50–65 years | 1 g | 12 weeks | 30 |
| Between-meal risedronate does not alter bone turnover in nursing home residents 2006 · Placebo group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline | 630 mg | 12 weeks | 29 |
| Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women 2013 · vitamin D- and calcium-fortified yogurt (FY) · Institutionalized women, mean age 85.5 years, at high risk for vitamin D deficiency and osteoporotic fracture | 800 mg | 8 weeks | 29 |
| Effects of calcium-vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial 2014 · calcium-vitamin D group · Pregnant women aged 18–40 years with gestational diabetes at 24–28 weeks' gestation | 1 g | 6 weeks | 28 |
| The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome 2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome | 1 g | 8 weeks | 28 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 600 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 500 mg | 16 weeks | 28 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D arm · Participants; age, sex, and health condition not specified | 800 mg | 1 year | 27 |
| Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia 2020 · Group B (control) · Postmenopausal women with osteopenia | 1.25 g | 90 days | 27 |
| Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial 2015 · Group C · Overweight, vitamin D-deficient women aged 18–40 years with PCOS | 1 g | 8 weeks | 26 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 1200 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 500 mg | 16 weeks | 26 |
| Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial 2022 · 4000 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline. | 500 mg | 16 weeks | 26 |
| Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women 2000 · calcium carbonate plus calcitriol · Thai postmenopausal women with osteoporosis, more than 10 years postmenopausal | 750 mg | 90 days | 25 |
| Impact of supplementary high calcium milk with additional magnesium on parathyroid hormone and biochemical markers of bone turnover in postmenopausal women 2002 · milk group · Healthy postmenopausal women | 1.2 g | 4 weeks | 25 |
| A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis 2010 · Treatment group · Patients with multiple sclerosis; age and sex not specified | 1.2 g | 52 weeks | 25 |
| Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis 2011 · treated patients · Patients with multiple sclerosis; age and sex ranges not reported | 1.2 g | 1 year | 25 |
| Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China 2020 · high VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥10 ng/mL | 600 mg | 26 weeks | 25 |
| The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes 2021 · Ca+D-yogurt drink (CDY) · Adults aged 30–60 years with confirmed type 2 diabetes | 500 mg | 12 weeks | 25 |
| Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial 2012 · calcium-vitamin D supplements · Pregnant women aged 18–35 in the third trimester, primigravida, with singleton pregnancies and at risk for pre-eclampsia | 500 mg | 9 weeks | 24 |
| Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia 2020 · Group A · Postmenopausal women with osteopenia | 3.6 g | 90 days | 24 |
| Alfacalcidol (alpha D3) and calcium in osteoporosis 1994 · treatment group · Postmenopausal women with osteoporosis; mean age 67 years | 1 g | 3 years | 24 |
| Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover 2004 · Calcium and vitamin D control group · Women older than 65 with high bone turnover, at high risk of osteoporosis | 500 mg | 26 weeks | 23 |
| Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 2004 · No-alendronate group (controls) · HIV-infected men and women on stable HAART with osteopenia or osteoporosis | 1 g | 52 weeks | 23 |
| Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial 2009 · 2.0 g elemental calcium plus 800 IU vitamin D3 · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months | 2 g | 26 weeks | 23 |
| Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial 2009 · calcium plus vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months | 2 g | 26 weeks | 23 |
| Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients 2010 · calcium plus vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months | 2 g | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients 2011 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months | 2 g | 180 days | 23 |
| Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial 2011 · 2.0 g elemental calcium plus 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma | 2 g | 26 weeks | 23 |
| A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients 2012 · 2.0 g elemental calcium plus 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months | 2 g | 26 weeks | 23 |
| Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial 2015 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes | 2 g | 26 weeks | 23 |
| Consequences of a high phosphorus intake on mineral metabolism and bone remodeling in dependence of calcium intake in healthy subjects - a randomized placebo-controlled human intervention study 2016 · P1000/Ca1000 · Healthy omnivorous adults aged 18–60 years, men and women | 1 g | 8 weeks | 22 |
| Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption 2003 · HCSM with 65.5 mg magnesium · Healthy postmenopausal women | 1.2 g | 1 day | 21 |
| Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption 2003 · HCSM with 172 mg magnesium · Healthy postmenopausal women | 1.2 g | 1 day | 21 |
| Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture 2011 · Soft plain cheese consumption period · Institutionalized women aged 65 years or older with vitamin D insufficiency and low calcium intake | 302 mg | 6 weeks | 21 |
| Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis 1996 · Low-calcium mineral water · 21 patients with idiopathic calcium nephrolithiasis; age and sex not reported | 1 mmol | 30 days | 21 |
| Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis 1996 · Intermediate-calcium mineral water · 21 patients with idiopathic calcium nephrolithiasis; age and sex not reported | 6 mmol | 30 days | 21 |
| Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis 1996 · High-calcium, alkaline mineral water · 21 patients with idiopathic calcium nephrolithiasis; age and sex not reported | 20 mmol | 30 days | 21 |
| The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study 2009 · Group 2 (control group) · Postmenopausal women with osteoporosis | 1 g | 1 year | 20 |
| Calcium and vitamin-D supplementation on bone structural properties in peripubertal female identical twins: a randomised controlled trial 2011 · calcium-supplemented group · Peripubertal girls aged 9 to 13 years | 800 mg | 26 weeks | 20 |
| Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study 2018 · K citrate group · Postmenopausal women with osteopenia, more than 5 years post-menopause | 500 mg | 26 weeks | 20 |
| Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study 2018 · Placebo group with background supplements · Postmenopausal women with osteopenia, more than 5 years post-menopause | 500 mg | 26 weeks | 20 |
| Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D 1996 · three tablets containing 1000 mg CaCO3 plus 5 micrograms (200 IU) vitamin D/d · Healthy women aged 28–59 years | 1 g | 3 days | 20 |
| Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement 1998 · Ref2 (Study 2) · Healthy male volunteers; age not stated | 3.24 g | 1 day | 20 |
| Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement 1998 · Test 2 (Study 2) · Healthy male volunteers; age not stated | 1.25 g | 1 day | 20 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 1 g | 6 weeks | 19 |
| Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 2004 · Alendronate-treatment group · HIV-infected men and women on stable HAART with osteopenia or osteoporosis | 1 g | 52 weeks | 18 |
| Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement 1998 · Test 1 (Study 1) · Healthy male volunteers; age not stated | 1.25 g | 1 day | 18 |
| Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women 2013 · potassium citrate 60 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause. | 630 mg | 26 weeks | 17 |
| Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women 2013 · potassium citrate 90 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause. | 630 mg | 26 weeks | 17 |
| Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients 2018 · Calcium + Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women | 1.2 g | 1 year | 17 |
| Temporal Change in Biomarkers of Bone Turnover Following Late Evening Ingestion of a Calcium-Fortified, Milk-Based Protein Matrix in Postmenopausal Women with Osteopenia 2019 · milk-based protein matrix (MBPM) · Postmenopausal women aged 50–70 with osteopenia | 875 mg | 1 day | 16 |
| Effects of physical form of β-lactoglobulin and calcium ingestion on GLP-1 secretion, gastric emptying and energy intake in humans: a randomised crossover trial 2024 · NATIVE + MINERALS · Metabolically healthy men and women aged 18–65 years with BMI 18.5–25.0 kg/m² | 2.5 g | 1 day | 15 |
| Effects of physical form of β-lactoglobulin and calcium ingestion on GLP-1 secretion, gastric emptying and energy intake in humans: a randomised crossover trial 2024 · AGGREG + MINERALS · Metabolically healthy men and women aged 18–65 years with BMI 18.5–25.0 kg/m² | 2.5 g | 1 day | 15 |
| Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women 2008 · calcium and vitamin D group · Postmenopausal women with osteoporosis | 1 g | 90 days | 13 |
| Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome 2006 · supplementation group · Adults with Down's syndrome living in an institution | 1 g | 1 year | 12 |
| [Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3] 1995 · 1-alpha(OH) vitamin D3 group · Postmenopausal women with osteoporosis | 500 mg | 26 weeks | 12 |
| Fermentation of calcium-fortified soya milk does not appear to enhance acute calcium absorption in osteopenic post-menopausal women 2011 · fermented and fortified soya milk · 12 osteopenic post-menopausal women; mean age 54.8 years | 44 mg | 1 day | 12 |
| Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa 2006 · calcium plus vitamin D treatment group · Adults with adenomatous polyps; age and sex not stated | 4.5 g | 26 weeks | 11 |
| Systemic vitamin D supplementation and local bone formation after maxillary sinus augmentation - a randomized, double-blind, placebo-controlled clinical investigation 2016 · vitamin D3 + calcium group · Adults undergoing maxillary sinus augmentation; age and sex not stated | 600 mg | 213 days | 10 |
| SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? 2015 · Calcium citrate group (Group 1 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–55 | 1.2 g | 60 days | 10 |
| SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? 2015 · Calcium carbonate group (Group 2 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–68 | 1.2 g | 60 days | 10 |
| A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial 2020 · Aquamin · Adults aged 20–66, male or nonpregnant female, in general good health but at increased risk for colon cancer | 800 mg | 90 days | 10 |
| Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD 1994 · intravenous group · Hemodialysis patients with end-stage renal disease and severe hyperparathyroidism; age and sex not reported | 2.5 g | 36 weeks | 10 |
| Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD 1994 · pulse oral group · Hemodialysis patients with end-stage renal disease and severe hyperparathyroidism; age and sex not reported | 2.5 g | 36 weeks | 9 |
| A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis 1993 · Study group: 2.5 mEq/L calcium dialysate with oral calcitriol · Patients on peritoneal dialysis | 900 mg | 8 weeks | 9 |
| The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects 1994 · Zinc with calcium carbonate · Healthy female university subjects | 600 mg | 1 day | 9 |
| The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects 1994 · Zinc with calcium citrate · Healthy female university subjects | 600 mg | 1 day | 9 |
| Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease 2013 · Calcium carbonate · Men and women aged 35 years or older with stage 3–4 chronic kidney disease, GFR <45 mL/min, and serum PTH at least the mid-normal range; all analyzed participants were overweight and had hypertension | 1.5 g | 3 weeks | 8 |
| Tibial bone responses to 6-month calcium and vitamin D supplementation in young male jockeys: A randomised controlled trial 2015 · Supplemented group · Apprentice male jockeys, mean age 20.2 ± 3.2 years, engaged in caloric restriction and high volumes of physical activity | 800 mg | 26 weeks | 8 |
| The effect of calcium and vitamin D supplementation on bone health of male Jockeys 2017 · calcium and vitamin D group · Apprentice male jockeys; mean age 20.18 ± 3.23 years | 800 mg | 26 weeks | 8 |
| Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion 2001 · Two doses of Orocal D3 at a 6-hour interval · Healthy male volunteers; age not stated | 1 g | 1 day | — |
| Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion 2001 · One morning dose of Cacit vitamin D3 · Healthy male volunteers; age not stated | 1 g | 1 day | — |
| Alendronate prevents further bone loss in renal transplant recipients 2001 · Group A · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier | 500 mg | 1 year | — |
| Alendronate prevents further bone loss in renal transplant recipients 2001 · Group B · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier | 500 mg | 1 year | — |
| Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion 2002 · Two doses of Orocal D3 · Healthy volunteers; age and sex not specified | 1 g | 1 day | — |
| Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion 2002 · Single morning dose of Cacit D3 · Healthy volunteers; age and sex not specified | 1 g | 1 day | — |
| Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels 2002 · calcium-vitamin D (CaD) group · postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL | 500 mg | 90 days | — |
| Comparisons of oral calcium, high dose vitamin D and a combination of these in the treatment of nutritional rickets in children 2002 · Vitamin D plus calcium group · Infants aged 6–30 months with nutritional rickets | 3 g | 4 weeks | — |
| Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women 2004 · calcium citrate · Older postmenopausal women | 1 g | 12 weeks | — |
| Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women 2004 · calcium carbonate · Older postmenopausal women | 1 g | 12 weeks | — |
| Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women 2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine | 563 mg | 8 weeks | — |
| Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk 2004 · placebo · Postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk 2004 · raloxifene 60 mg/day · Postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk 2004 · raloxifene 120 mg/day · Postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women 2004 · High calcium, weight-loss group · Overweight postmenopausal women aged 52–75 years assigned to weight loss and high calcium intake | 1 g | 6 weeks | — |
| Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women 2004 · High calcium, weight-maintenance group · Overweight postmenopausal women aged 52–75 years assigned to weight maintenance and high calcium intake | 1 g | 6 weeks | — |
| Stone forming risk of calcium citrate supplementation in healthy postmenopausal women 2004 · calcium citrate and potassium citrate · Postmenopausal women without kidney stones | 800 mg | 2 weeks | — |
| The hypoglycemic effects of soy isoflavones on postmenopausal women 2004 · isoflavone group · Postmenopausal Taiwanese women | 300 mg | 26 weeks | — |
| Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial 2005 · group A · Postmenopausal women aged 49–71 years; healthy | 1.2 g | 26 weeks | — |
| Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial 2005 · group B · Postmenopausal women aged 49–71 years; healthy | 900 mg | 26 weeks | — |
| Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake 2005 · High-calcium mineral water plus vitamin D · Postmenopausal women with dietary calcium intake below 700 mg/day; mean age 70.1 years | 596 mg | 26 weeks | — |
| Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women 2005 · combined treatment · postmenopausal women | 800 mg | 2 weeks | — |
| Dietary acid-base balance, bone resorption, and calcium excretion 2006 · Cereal (acidogenic) diet group · Healthy older men and women | 600 mg | 60 days | — |
| Dietary acid-base balance, bone resorption, and calcium excretion 2006 · Fruit and vegetable (alkalinogenic) diet group · Healthy older men and women | 600 mg | 60 days | — |
| Effect of calcium, vitamins K1 and D3 on bone in galactosemia 2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia | 750 mg | 2 years | — |
| Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women 2006 · High calcium skim milk with added phylloquinone · Premenopausal women aged 20 to 35 years | 1 g | 16 weeks | — |
| The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults 2007 · calcium and vitamin D supplementation · Caucasian adults aged 65 years or older without diabetes; baseline fasting glucose was normal or impaired | 500 mg | 3 years | — |
| Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine 1992 · Group II · Postmenopausal women with osteoporosis and at least one vertebral crush fracture | 500 mg | 2 years | — |
| Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide 2007 · Placebo · Adults with osteoporosis or low bone mass: postmenopausal women and men | 1 g | 1 year | — |
| Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide 2007 · TPTD 20 microg/d · Adults with osteoporosis or low bone mass: postmenopausal women and men | 1 g | 1 year | — |
| Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide 2007 · TPTD 40 microg/d · Adults with osteoporosis or low bone mass: postmenopausal women and men | 1 g | 1 year | — |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · calcium · White postmenopausal women, 6 months to 6 years after menopause | 1.7 g | 60 days | — |
| Biochemical short-term changes produced by hormonal replacement therapy 1991 · cyclic estrogen-progestin plus calcium · White postmenopausal women, 6 months to 6 years after menopause | 1.7 g | 60 days | — |
| Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss 2008 · Placebo group · Postmenopausal Korean women aged 50–65 with moderate bone loss | 600 mg | 12 weeks | — |
| Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss 2008 · Alendronate group · Postmenopausal Korean women aged 50–65 with moderate bone loss | 600 mg | 12 weeks | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · placebo · Men and women aged 50 and older; described as healthy older adults | 600 mg | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 600 mg | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · sodium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 600 mg | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium chloride group · Men and women aged 50 and older; described as healthy older adults | 600 mg | 90 days | — |
| The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD 2009 · calcium-vitamin D(3) fixed combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease | 1.2 g | 26 weeks | — |
| The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD 2009 · calcium plus vitamin D(3) separate combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease | 1.2 g | 26 weeks | — |
| Effect of dairy and non-dairy calcium on fecal fat excretion in lactose digester and maldigester obese adults 2010 · Nondairy high-calcium diet · Healthy adults aged 21–50 with BMI 29–35, including men and women | 1 g | 6 weeks | — |
| Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial 2010 · calcium plus vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp | 2 g | 26 weeks | — |
| Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D 2010 · group 1 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L | 1 g | 8 weeks | — |
| Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D 2010 · group 2 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L | 1 g | 8 weeks | — |
| The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design 2010 · vitamin D3 and calcium · Healthy men and women aged 20–80 years | 1.2 g | 90 days | — |
| Vitamin D supplementation and bone mass accrual in underprivileged adolescent Indian girls 2010 · Ergocalciferol intervention group · Post-menarcheal underprivileged girls aged 14–15 years in Pune, India | 250 mg | — | — |
| Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial 2011 · vitamin D-fortified yogurt drink (DY) · people with type 2 diabetes; age and sex not stated | 300 mg | 12 weeks | — |
| Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial 2011 · vitamin D + calcium-fortified yogurt drink (DCY) · people with type 2 diabetes; age and sex not stated | 500 mg | 12 weeks | — |
| Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness 2012 · ibandronate group · Postmenopausal women with chronic critical illness | 1.25 g | 11 days | — |
| Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness 2012 · placebo group · Postmenopausal women with chronic critical illness | 1.25 g | 11 days | — |
| Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial 2011 · PRT + fortified milk supplement · Healthy men aged 50–79 years | 1 g | 548 days | — |
| Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial 2011 · Fortified milk supplement · Healthy men aged 50–79 years | 1 g | 548 days | — |
| [Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes] 2011 · group II · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis | 440 mg | 1 year | — |
| Superior calcium bioavailability of effervescent potassium calcium citrate over tablet formulation of calcium citrate after Roux-en-Y gastric bypass 2013 · PCC · Patients who had undergone Roux-en-Y gastric bypass; age and sex not reported | 400 mg | 1 day | — |
| Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes 2012 · vitamin D-fortified doogh (DD) · Adults aged 30–60 of both sexes with type 2 diabetes | 300 mg | 12 weeks | — |
| Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes 2012 · calcium + vitamin D3-fortified doogh (CDD) · Adults aged 30–60 of both sexes with type 2 diabetes | 500 mg | 12 weeks | — |
| Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone 2012 · alfacalcidol group · Children receiving long-term glucocorticoids | 400 mg | 1 year | — |
| Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone 2012 · menatetrenone group · Children receiving long-term glucocorticoids | 400 mg | 1 year | — |
| Management of nutritional rickets in Indian children: a randomized controlled trial 2013 · combination therapy · Children aged 6 months to 5 years with nutritional rickets | 75 mg/kg | 12 weeks | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group B · Healthy adults older than 54 years | 456 mg | 1 year | — |
| Enhanced effect of zinc and calcium supplementation on bone status in growth hormone-deficient children treated with growth hormone: a pilot randomized controlled trial 2013 · Group A · Prepubertal children with growth hormone deficiency, mean age 8.7 ± 2.8 years; 18 boys across the study | 500 mg | 1 year | — |
| Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial 2013 · vitamin D-fortified doogh (DD) · Men and women aged 30–60 years with type 2 diabetes | 300 mg | 12 weeks | — |
| Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial 2013 · calcium- and vitamin D-fortified doogh (CDD) · Men and women aged 30–60 years with type 2 diabetes | 500 mg | 12 weeks | — |
| Effect of soy isoflavone supplementation on vascular endothelial function and oxidative stress in postmenopausal women: a community randomized controlled trial 2013 · intervention group · Indonesian postmenopausal women aged 47 to 60 years | 500 mg | 1 year | — |
| Calcium and vitamin d supplementation in postmenopausal women 2013 · vitamin D3 and calcium · healthy postmenopausal white women | 1.2 g | 26 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaDEA · Children aged approximately 8 years | 700 mg | 12 weeks | — |
| Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study 2014 · intervention group (IG) · Steroid-naïve pre-pubertal children with new-onset nephrotic syndrome treated with glucocorticoids; boys and girls | 500 mg | 12 weeks | — |
| Effect of supplemental vitamin D and calcium on serum sclerostin levels 2014 · vitamin D and calcium group · Men and women aged 65 years and older, described as healthy | 500 mg | 2 years | — |
| MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial 2015 · MgCaCO3 group · Adults with peritoneal dialysis | 1.14 g | 90 days | — |
| Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial 2014 · Ca+Vit D · Men and women undergoing Army initial military training (basic combat training); ages and health conditions not specified | 2 g | 9 weeks | — |
| Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial 2014 · joint calcium-vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated | 1 g | 8 weeks | — |
| Calcium supplementation increases blood creatinine concentration in a randomized controlled trial 2014 · Calcium plus vitamin D · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male | 1.2 g | 5 years | — |
| Effect of soy isoflavone supplementation on endothelial dysfunction and oxidative stress in equol-producing postmenopausal women 2015 · Intervention group · Postmenopausal Indonesian women aged 47–60 years, stratified by equol-producer status | 500 mg | 26 weeks | — |
| Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial 2015 · Low-dose KHCO3 group · Healthy ambulatory men and postmenopausal women aged 60 years and older | 600 mg | 12 weeks | — |
| Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial 2015 · High-dose KHCO3 group · Healthy ambulatory men and postmenopausal women aged 60 years and older | 600 mg | 12 weeks | — |
| Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density 2016 · Alendronate (ALN) arm · HIV-infected men and women aged 25 years or older with low bone mineral density | 1 g | 48 weeks | — |
| Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density 2016 · Placebo arm · HIV-infected men and women aged 25 years or older with low bone mineral density | 1 g | 48 weeks | — |
| A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes 2015 · Group 3 (CDD) · Women and men aged 30–50 years with type 2 diabetes | 500 mg | 12 weeks | — |
| Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients 2017 · 1,200 mg/day elemental calcium plus 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas | 1.2 g | 1 year | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group B · Adults older than 54 years; no specific condition stated | 456 mg | 1 year | — |
| Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial 2017 · Calcium + vitamin D alone · Postmenopausal women aged 50–79 in the WHI hormone therapy trials | 1 g | 5 years | — |
| Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial 2017 · Calcium + vitamin D plus hormone therapy · Postmenopausal women aged 50–79 in the WHI hormone therapy trials | 1 g | 5 years | — |
| Effects of Vitamin D Supplementation on Semen Quality, Reproductive Hormones, and Live Birth Rate: A Randomized Clinical Trial 2018 · active group · Infertile men with serum 25-hydroxyvitamin-D levels ≤50 nmol/L | 500 mg | 150 days | — |
| High phosphorus intake and gut-related parameters - results of a randomized placebo-controlled human intervention study 2018 · P1000/Ca1000 · Healthy omnivorous men and women aged 18–60 years | 1 g | 8 weeks | — |
| Safety of calcium and vitamin D supplements, a randomized controlled trial 2018 · CaCO3 1200 mg/day with 10 000 IU vitamin D3/day · Healthy, white postmenopausal women | 1.2 g | 1 year | — |
| Safety of calcium and vitamin D supplements, a randomized controlled trial 2018 · CaCO3 1200 mg/day with 600 IU vitamin D3/day · Healthy, white postmenopausal women | 1.2 g | 1 year | — |
| Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial 2019 · vitamin D3 plus calcium group · People with sporadic colorectal adenomas; age and sex not specified | 1.2 g | 1 year | — |
| Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients 2019 · calcium plus vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms | 1.2 g | 1 year | — |
| Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial 2021 · calcium plus vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma | 1.2 g | 1 year | — |
| Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial 2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy | 800 mg | 1 year | — |
| Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial 2023 · vitamin D plus calcium group · Chinese adults with prediabetes; the reported disposition-index result was for vitamin D-insufficient individuals | 500 mg | 24 weeks | — |
| Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention 2023 · Early intervention group · Adults aged 65 years and older with sarcopenia | 600 mg | 12 weeks | — |
| Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention 2023 · Delayed intervention group · Adults aged 65 years and older with sarcopenia | 600 mg | 12 weeks | — |
| Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis 1994 · phosphate/placebo · Postmenopausal women with vertebral compression fractures | 500 mg | 104 weeks | — |
| Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis 1994 · phosphate/etidronate · Postmenopausal women with vertebral compression fractures | 500 mg | 104 weeks | — |
| Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men 1993 · High-calcium diet · Healthy men with moderate hypercholesterolemia | 500 mg | — | — |
| Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps 1996 · Low-dose fiber, low-dose calcium group · Adults with a history of resected colon adenomas | 250 mg | 39 weeks | — |
| Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps 1996 · High-dose fiber, low-dose calcium group · Adults with a history of resected colon adenomas | 250 mg | 39 weeks | — |
| Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps 1996 · Low-dose fiber, high-dose calcium group · Adults with a history of resected colon adenomas | 1.5 g | 39 weeks | — |
| Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps 1996 · High-dose fiber, high-dose calcium group · Adults with a history of resected colon adenomas | 1.5 g | 39 weeks | — |
| Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study 1996 · MgCO3 plus half the usual dose of CaCO3 · Chronic hemodialysis patients | 1.2 g | — | — |
| Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients 1996 · calcium acetate group · Patients receiving regular hemodialysis with uremia | 5.04 g | 1 year | — |
| Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients 1996 · calcium carbonate group · Patients receiving regular hemodialysis with uremia | 2.71 g | 1 year | — |
| Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3 1998 · cholecalciferol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism | 1 g | 26 weeks | — |
| Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3 1998 · calcitriol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism | 500 mg | 26 weeks | — |
| Low dose estrogen and calcium have an additive effect on bone resorption in older women 1999 · Calcium plus vitamin D (Ca+D) · Healthy women over 70 years of age | 1.5 g | 12 weeks | — |
| Low dose estrogen and calcium have an additive effect on bone resorption in older women 1999 · Combination Ca+D and E2 · Healthy women over 70 years of age | 1.5 g | 12 weeks | — |
| Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults 2020 · One-serving WP-MND group during the open-label extension · Adults aged 65 years or older with sarcopenia who continued from the RCT | 500 mg | 13 weeks | 133 |
| Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers 2018 · D + Ca + B · Adults, mean age 68.4 years; no specific condition stated | 800 mg | 1 year | 32 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · Tablets · Postmenopausal women aged 50–65 years | 2 g | 12 weeks | 30 |
| A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome 2017 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS) | 800 mg | 12 weeks | 30 |
| The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes 2019 · Magnesium-zinc-calcium-vitamin D group · Women aged 18–40 with gestational diabetes mellitus, at 24–28 weeks’ gestation at diagnosis | 800 mg | 6 weeks | 30 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified | 800 mg | 1 year | 25 |
| Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants 2009 · cinacalcet group · Healthy men and postmenopausal women aged 45–70 years | 1.2 g | 11 days | 9 |
| Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants 2009 · placebo group · Healthy men and postmenopausal women aged 45–70 years | 1.2 g | 11 days | 8 |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 0.15 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 0.4 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 1.0 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 2.5 mg daily sCT · Healthy postmenopausal women aged 55–85 years | 1 g | 90 days | — |
| Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover 2004 · 1.0 mg intermittent sCT (every other day) · Healthy postmenopausal women aged 55–85 years | 1 g | 90 days | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group A · Healthy adults older than 54 years | 456 mg | 1 year | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), premenopausal women · Premenopausal women, mean age 41 years; no specific condition stated | 1 g | 12 weeks | — |
| Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women 2016 · Intervention (Int), postmenopausal women · Postmenopausal women, mean age 59 years; no specific condition stated | 1.2 g | 12 weeks | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group A · Adults older than 54 years; no specific condition stated | 456 mg | 1 year | — |
| A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya 2017 · standard regimen · Pregnant women enrolled between 16 and 30 weeks of gestation | 1.5 g | 8 weeks | — |
| A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya 2017 · low-dose regimen · Pregnant women enrolled between 16 and 30 weeks of gestation | 1 g | 8 weeks | — |
| Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate 2001 · placebo group · Postmenopausal women with osteoporosis | 500 mg | 3 years | 180 |
| Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis 2005 · All patients (alendronate, calcitonin, and placebo groups) · Postmenopausal women with osteoporosis | 1 g | 26 weeks | 135 |
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 · placebo · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate | 600 mg | 1 year | 88 |
| Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy 1993 · calcium supplementation · Postmenopausal women with osteoporosis | 500 mg | 3 years | 52 |
| The interactive effect of improvement of vitamin D status and VDR FokI variants on oxidative stress in type 2 diabetic subjects: a randomized controlled trial 2015 · plain doogh (PD) · people with type 2 diabetes; age and sex not stated | 300 mg | 12 weeks | 50 |
| Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial 2025 · Randomized trial, placebo group · Infertile men; mean age approximately 34 years | 400 mg | 160 days | 49 |
| Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial 2014 · calcium group · Adults aged over 30 with type 2 diabetes and insufficient 25-hydroxyvitamin D | 1 g | 8 weeks | 29 |
| Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome 2015 · 1000 mg/d calcium + vitamin D placebo · Overweight and obese vitamin D deficient women diagnosed with PCOS | 1 g | 8 weeks | 26 |
| Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial 2017 · placebo group · Postmenopausal women aged 50–72 years with osteopenia | 500 mg | 26 weeks | 25 |
| [Effect of hormone replacement therapy on hemorheology in postmenopausal women] 2001 · Group C · Healthy postmenopausal women | 600 mg | 26 weeks | 20 |
| Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial 2005 · Placebo group (calcium supplementation) · Older residents of residential care, mean age 83.4 years, with serum 25-hydroxyvitamin D levels of 25–90 nmol/L | 600 mg | 2 years | — |
| Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial 2007 · Placebo group · Postmenopausal women with osteoporosis and low bone mineral density at the hip or lumbar spine | 700 mg | 548 days | — |
| Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals 2009 · calcium · Community-dwelling women and men, mean age 77 years, with serum 25-hydroxyvitamin D below 78 nmol/l | 1 g | 1 year | — |
| Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial 2014 · calcium carbonate · Healthy non-Hispanic white adults aged 45–75 years | 1.2 g | 1 year | — |
| Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial 2014 · vitamin D3 and calcium carbonate · Healthy non-Hispanic white adults aged 45–75 years | 1.2 g | 1 year | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Caloric restriction-only group (CR) · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 1 g | 20 weeks | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Moderate-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 1 g | 20 weeks | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Vigorous-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 1 g | 20 weeks | — |
| Body mass index, calcium supplementation and risk of colorectal adenomas 2019 · VCPPS calcium carbonate plus vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified | 1.2 g | 1303 days | — |
| Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia 2022 · Group B · Postmenopausal women with osteopenia | 500 mg | 1 year | — |
| Nutritional quality of calorie restricted diets in the CALERIE™ 1 trial 2022 · Tufts 10% CR · Healthy adults without obesity, ages 24–60, assigned to 10% calorie restriction | 500 mg | 1 year | — |
| Nutritional quality of calorie restricted diets in the CALERIE™ 1 trial 2022 · Tufts 30% CR · Healthy adults without obesity, ages 24–60, assigned to 30% calorie restriction | 500 mg | 1 year | — |
| Increased calcium intake from skimmed milk in energy-restricted diets reduces glycation markers in adults with type 2 diabetes and overweight: A secondary analysis of a randomized clinical trial 2024 · low calcium · Adults with type 2 diabetes, overweight, and habitual calcium intake below 600 mg/day | 6.4 mg | 12 weeks | — |
| Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis 1996 · placebo · postmenopausal women with osteoporosis | 500 mg | 3 years | — |
| Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial 1998 · Control group · Postmenopausal women with osteoporosis, at least one prevalent vertebral fracture, and low bone mineral density; mean age 68.4 years | 750 mg | 1 year | — |